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Inflammatory bowel disease (IBD) is a chronic, relapsing and remitting inflammatory condition 
of the gastrointestinal tract. The diagnosis and monitoring of IBD is reliant on endoscopic 
techniques which are invasive and do not provide quantification. Molecular imaging 
approaches such as immuno-PET have superior sensitivity and provide quantitative 
information of the entire body. Immuno-PET combines the superior target selectivity provided 
by antibodies with the sensitivity of PET. This thesis outlines the development of two novel 
radiolabelled antibody tracers against intestinal inflammation in a preclinical model of IBD and 
one novel tracer against intestinal fibrosis in a model of chronic murine IBD.  Symptom flare 
in IBD typically corresponds with an increased activation of innate immune pathways. We 
aimed to compare immuno-PET of the innate immune mediators IL-1β and CD11b against 
standard 18F-FDG and MRI to detect colonic inflammation. For visualising intestinal 
inflammation, 89Zr-α-IL-1β and 89Zr-α-CD11b immuno-PET detected colonic inflammation, as 
did 18F-FDG, and all PET tracers were more sensitive than MRI. While 18F-FDG volumes of 
interest correlated with colitis severity and a strong trend was observed with 89Zr-α-IL-1β, no 
correlation was observed for 89Zr-α-CD11b or MRI. 89Zr-α-IL-1β was distributed mainly to the 
gastrointestinal tract, while 89Zr-α-CD11b was distributed in more tissue types. Intestinal 
fibrosis is one of the most common complications of IBD, with severe fibrosis leading to 
stricture and stenosis in approximately 30% of patients. Currently, intestinal fibrosis is 
diagnosed and monitored using endoscopies and MRI. Fibrosis is characterised by the 
excessive deposition of extracellular matrix (ECM) as a result of multiple periods of 
inflammation and subsequent healing, as seen in IBD and murine colitis. Matrix 
metalloproteinases (MMP) play a large role in fibrogenic pathways by regulating the 
 v 
deposition of ECM during tissue renewal. MMP-9 is found to be elevated in fibrotic tissue 
resected from IBD patients and in preclinical models of intestinal fibrosis. We aimed to 
visualise intestinal fibrosis by targeting pro-MMP-9 using f(ab’)2 antibody fragments, 
radiolabelled with zirconium-89. This was the first immuno-PET study of fibrosis in any tissue 
in a preclinical or clinical setting. In our preclinical model of chronic IBD, 89Zr-pro-MMP-9-
f(ab’)2 successfully detected intestinal fibrosis in the absence of inflammation. Furthermore, 
immuno-PET and biodistribution studies indicated that the kidneys became fibrotic after 
multiple rounds of DSS. This was further confirmed by an increase in collagen and pro-MMP-
9 levels in the kidneys, in the absence of elevated immune markers. As the mechanisms 
underlying fibrosis are similar across all organs, immuno-PET of pro-MMP-9 may be a valuable 
addition to the detection of fibrosis in all tissues. Additionally, development of these 
technologies for human subjects will provide a less invasive approach than endoscopy for 
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Chapter 1 Introduction   
 
This thesis investigates the pathogenesis of inflammation and fibrosis in inflammatory bowel 
disease (IBD) and how disease mediators can be targeted with radiolabelled antibodies to 
provide improved diagnostic imaging techniques. The mechanisms underpinning IBD and 
intestinal fibrosis have not been fully elucidated leading to a lack of effective therapeutics and 
management. Current diagnostic imaging modalities are invasive and lack specificity, 
selectivity and the option for quantification. Elucidation of IBD immune and profibrogenic 
mechanisms will provide targets for novel molecular imaging tracers.  I investigated the use 
of zirconium-89 (89Zr) labelled antibodies for the detection of intestinal inflammation and 
fibrosis in a preclinical model of IBD. This introduction will provide a broad overview of IBD, 
focusing on current diagnostic modalities and emerging radiolabelled antibody imaging 
techniques which will form the basis of this thesis.  
 
1.1 Inflammatory bowel disease  
 
IBD is a chronic idiopathic inflammatory condition of the gastrointestinal tract. The two main 
subtypes of IBD are ulcerative colitis (UC) and Crohn’s disease (CD). IBD causes symptoms such 
as gastrointestinal bleeding, diarrhoea, severe pain and cramping, with more serious cases 
leading to weight loss and malnutrition. CD commonly occurs in the colon and lower small 
intestine, but can affect the entire gastrointestinal tract, leading to multiple separate areas of 
inflammation. Ulceration in CD is typically transmural, damaging all layers of the gut 
Chapter 1 Introduction 
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and is commonly associated with fistulae, strictures and abscesses. In contrast, UC generally 
affects the sigmoid colon and rectum, forming continuous patches of inflammation which 
damage the innermost layers of the intestinal wall. Histologically, UC shows inflammatory 
changes limited to the mucosa and submucosa with cryptitis and crypt abscesses, in contrast 
to CD which presents with a thickened submucosa, transmural inflammation, fissuring 
ulceration and non-caseating granulomas (1). These conditions are debilitating to live with 
and are invisible to others. 
 
The incidence of IBD is steadily increasing, with Western diets thought to be a driving cause 
(2). Asian countries have also seen an increased incidence of IBD, which correlates with an 
increase in the consumption of Western diets. For example, in South Korea, there was a 100% 
and 136% increase in UC and CD incidence from 1991-2000, respectively (3). The rates of IBD 
in Australia have been gradually increasing, with a prevalence of IBD 308.3/100,000 in 2005 
(4, 5). Due to this, the economic burden of IBD is significantly increasing. In 2013 it was 
estimated that the total hospitalisation costs associated with IBD were close to $100 million 
per annum in Australia alone (6). Due to the severity and chronic nature of IBD, it often leads 
to losses in productivity - in 2012 productivity losses due to IBD were estimated to be over 
$380 million (6). On average IBD sufferers lose 7.2 days of work per annum, whereas CD 
sufferers can average up to 30 days loss (7). Productivity at work can often be decreased due 
to flare of IBD and ill health in addition to higher rates of mental illnesses such as depression 
and anxiety (8). Although IBD largely affects people of work age, early age onset is common 
and can disrupt the sufferer’s education due to pain, frequent toileting and discrimination by 
teachers and peers. IBD affects many aspects of life and thus requires a 
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high quality of primary and multidisciplinary care in an attempt to improve quality of life. To 
prevent long term complications and preserve future quality of life, it is essential to diagnose 
IBD within the early stages.  
 
1.2 Pathogenesis  
 
The pathogenesis of IBD is believed to be multifactorial, with environmental, genetic and 
immune factors playing a role. IBD is thought to arise due to an uncontrolled immune 
activation to otherwise innocuous stimulation, such as commensal bacteria, initiating a chain 
of inflammatory events which damage the intestinal wall, allowing for the translocation of 
bacteria and bacterial products into the mucosa, further stimulating inflammation. Healthy 
gut epithelial cells form a tight barrier against the luminal contents, with Goblet cells forming 
IgA-rich mucus and Paneth cells secreting antimicrobial peptides such as defensins and TNF-
α, which help to defend against pathogens and regulate commensal gut bacteria. Increased 
intestinal permeability is often observed in IBD patients (9). Dendritic cells sample the gut 
microenvironment and respond to pathogens and molecules secreted by the gut bacteria, 
initiating an immune response. This inflammatory activation disrupts the tight seal of the 
intestinal barrier, whilst dendritic cells continue to induce inflammation in the layers below 
the epithelial cells.  
 
The innate immune system is our first line of defence against pathogens. The gastrointestinal 
tract is constantly being bombarded with stimuli whether pathogenic or innocuous. Innate 
immunity is non-specific and provides prompt responses to stimuli through a variety of cells 
including neutrophils, dendritic cells, monocytes, macrophages and natural killer cells. 
Chapter 1 Introduction 
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Immunity at this level is largely driven by interactions with pattern recognition receptors, such 
as toll like receptors (TLRs), present on the cell surface and nucleotide-binding oligomerization 
domain-like (NOD) receptors in the cytoplasm (10). It has been suggested that innate immune 
responses and the expression and function of TLRs and NOD proteins are dysregulated in IBD. 
NOD2 mutations as seen in CD, may contribute towards disease pathogenesis through a 
dampened response to lipopolysaccharides (LPS) in the gut, decreasing the secretion of 
antibacterial agents, thus permitting pathogenic microbial invasion (11).  
 
In contrast to innate immunity, adaptive immunity is highly specific, provides long-lasting 
immunity and takes days to produce pathogen-specific immune responses which are largely 
dependent on T cells. T helper type 1 (TH1) cells are induced by IL-12 and secrete IFN-γ, in 
contrast to TH2 cells which secrete IL-4, IL-5 and IL-13. TH1 cells are crucial for the elimination 
of intracellular pathogens, whereas TH2 cells are protective against parasites and mediate 
allergic responses and TH17 cells defend against extracellular bacteria and fungi (12). 
Consequently, dysregulation of T cell immunity leading to abnormal T cell expansion and 
activation may lead to the onset of inflammation through the increased secretion of cytokines 
and chemokines which will further stimulate the innate and adaptive immune systems. 
Abnormal TH1 responses, induced by mucosal IL-18 and IL-12, are thought to be involved with 
CD with macrophage-secreted IL-12 elevated in CD patients (13, 14). Mucosal T cells from CD 
patients also secrete higher levels of IL-2 and IFN-γ than UC T cells and healthy controls (15, 
16). As such, CD is often characterised by abnormal TH1 immune responses, in contrast to UC 
which is considered to be TH2-mediated (12). TH17 cells are induced by IL-6 and TGF-β and are 
characterised by their production of IL-17A, IL-17F, IL-21 and IL-22 (17). The expression of IL-
Chapter 1 Introduction 
 5 
17A is found to be elevated in UC and CD mucosa, as well as being secreted in larger amounts 
in the lamina propria, relative to health controls. Regulatory T cells (TREG) maintain gut 
homeostasis by supressing abnormal immune responses against innocuous stimuli such as 
commensal bacteria and dietary or self-antigens. TREG cells are characterised by their 
expression of FOXP3 and secretion of the anti-inflammatory cytokines IL-10 and TGF-β. 
Proportions of TREG cells have been found to be decreased in the peripheral blood of patients 
with active IBD, compared to quiescent IBD patients and controls (18).  As such, the decrease 
in TREG anti-inflammatory and subsequent increase in proinflammatory responses, contribute 
towards IBD pathogenesis. Genome-wide association studies (GWAS) have identified multiple 
IBD susceptibility genes, including NOD2, ATGL16L1 and IRGM, which are related to autophagy 
(19).  
 
Recent evidence suggests that the microbiome plays a large role in IBD pathogenesis, which 
has led researchers to trial faecal microbiota transplantation (FMT) (20). FMTs have 
demonstrated some success in IBD treatment, increasing the chance of UC remission at 8-
weeks post FMT. Multiple studies have analysed the microbiome in UC and CD in inflamed 
and noninflamed segments and found that there is a significantly decreased microbiome 
biodiversity when compared with healthy controls (21). In the healthy gut, Firmicutes and 
Bacteroidetes phyla predominate the microbiome. In contrast, there is a relative lack of 
Firmicutes and Bacteroidetes and an overgrowth of enterobacteria in CD and reduction in 
Clostridium spp and increased Escherichia coli in UC (22).
Chapter 1 Introduction 
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1.3 Clinical significance and management   
 
Although there is no cure for IBD, the understanding of these debilitating diseases has 
significantly grown over the past decade. This has provided targets for more effective 
therapeutics that improve mucosal health, consequently inducing remission and decreasing 
the frequency and duration of inflammation. However, many of these therapeutics lack 
efficacy and often induce a myriad of side effects and as a result there remains a need to 
develop novel therapies. In some cases, patients develop tolerance to these drugs, leading to 
decreased efficacy, with a small subset of patients where all drugs fail (23). Current treatment 
of IBD in Australia involves the induction of remission by biologics, sulfasalazine, 5-
aminosalicylates (5-ASAs) given orally, rectally or both (24).   
 
Mild to moderate UC that does not respond to oral or rectal 5-ASAs may be attenuated with 
oral glucocorticoids or immunosuppressive agents (azathioprine or 6-mercaptopurine). For 
patients that continue to require or do not respond to glucocorticoids, biological agents such 
as monoclonal antibodies such as infliximab may induce remission. Once remission has been 
induced, oral and rectal 5-ASAs are effective for maintenance, particularly in distal colitis (25).  
When 5-ASAs are poorly tolerated or inefficient, thiopurines (azathioprine) can be used for 
maintenance (26). When pharmacological agents have been trailed with no success or if 
serious complications develop (e.g. perforation, toxic megacolon and uncontrollable 
bleeding), sections of gut may be surgically removed (26). Unlike CD, surgery for UC can be 
curative, with 5-20% of patients requiring the intervention; however, this can be associated 
with severe side effects such as short bowel syndrome or pouchitis, intestinal failure and the
Chapter 1 Introduction 
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 possible requirement of enteral nutrition (27). Intestinal fibrosis is a common complication of 
IBD which occurs after repeated bouts of tissue injury, extracellular matrix (ECM) remodelling 
and tissue repair, resulting in ECM protein accumulation and scar formation, leading to the 
loss of function and anatomical abnormalities of the gastrointestinal tract. Complications of 
intestinal fibrosis include stricture, fistulae and abscesses, which typically require surgical 
repair and are the most common indication for surgery in CD. Although the development of 
intestinal fibrosis can be prevented by controlling intestinal inflammation, once fibrosis has 
developed, the control of inflammation cannot reverse the fibrosis. Apart from surgical 
intervention, there are no therapies to reverse the development of intestinal fibrosis, as such 
further research is required to elucidate fibrogenic pathways in IBD.  
 
1.4 Diagnostic imaging   
 
Currently, imaging of IBD is used to differentiate UC and CD in newly diagnosed patients, 
assess and monitor the progression of GI inflammation and extrasystemic side effects and to 
monitor the progression of already diagnosed patients (28). Diagnostic tools in IBD include 
colonoscopies and or endoscopies and can include barium x-ray, magnetic resonance imaging 
(MRI) and computed tomography (CT) and clinical investigations like histology and various 
blood tests for erythrocyte sedimentation rate, faecal lactoferrin and calproctectin which can 
indicate the level of inflammation. Scope investigations are largely invasive and 
uncomfortable due to a change in diet at least 3 days prior to the procedure (low residue diet), 
overnight fasting and bowel preparation by purging the colon of its contents for 
colonoscopies. Double contrast barium enemas can be utilised in IBD; however, CT and MRI 
are largely replacing this technique. Barium contrast studies may reveal signs such as: 
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pseudopolyps, filiform polyps, loss of haustra, strictures and ulcerations but may return 
unremarkable in some patients with mild UC (29). Barium enema findings for CD may include 
cobblestone appearance of gastrointestinal tract, fistulas, abscesses, strictures and separation 
of bowel loops (29). Barium enemas should be used with caution in patients with severe colitis 
as it may induce ileus with toxic megacolon. CT and MRI may reveal thickening of the bowel 
wall which is not specifically indicative of UC or CD and are less suitable than barium x-ray for 
detection of early colitis due to lower sensitivity (29). Additionally, ultrasound with Doppler 
may reveal thickening of the mucosal layer in active mild UC or transmural thickening in severe 
UC; however, neither of these signs are indicative of UC and may arise due to other causes. 
There has been a shift from traditional contrast radiography to CT, MRI, ultrasound and 
positron emission tomography (PET), with future applications focusing on PET-CT and 
magnetic resonance colonography. The diagnosis of IBD is largely achieved by endoscopies 
and colonoscopies; however, the evaluation of the small bowel appears to remain a challenge. 
The length and many overlapping loops of the small intestine limits the utility of endoscopies. 
CD and UC can be differentiated by colonoscopy, based on the focality and pattern of 
ulceration. Biopsies are routinely obtained during scope studies for confirmation of diagnosis 
through analysis of ulceration patterns and acute or chronic inflammation (29). The use of 
wireless capsule endoscopies has been increasing for assessment of the small bowel; 
however, it must be used with caution in patients with suspected strictures as the capsule 
may require surgical removal.  
 
Currently, diagnostic imaging relies on the identification of anatomical signs for CD or UC. This 
provides minimal information on the degree of gastrointestinal inflammation present. 
Although colonoscopies are routinely performed for a range of conditions, including IBD, up
Chapter 1 Introduction 
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 to 33% of patients experience at least 1 minor temporary gastrointestinal symptom as a result 
of the procedure (30). A relatively common adverse effect, perforation of the gastrointestinal 
tract due to mechanical manipulation of the scope occurs in up to 0.3% of patients (31). 
Haemorrhage may occur as a result of colonoscopy, but most commonly occurs in 
colonoscopy with polypectomy, compared with colonoscopies without polypectomy (32).  
 
1.5 Molecular imaging and immuno-PET  
 
Molecular imaging techniques are indispensable in the diagnosis and management of many 
conditions. They have the power to characterise, visualise and measure the activity of 
biological processes. In terms of gastrointestinal exploration and imaging, colonoscopies are 
generally used for investigations of the large intestine in addition to MRIs; however, 
colonoscopies are restricted to the mucosal surface. In the small bowel, MRIs and endoscopies 
are utilised; however, it can be difficult to observe inflammation in the small intestine using 
these methods. PET is a non-invasive functional imaging modality mostly used in the detection 
of cancer. This technique relies on the use of a radiolabelled probe attaching to its target and 
on radioactive decay, releasing a positron and subsequent gamma rays, which are detected 
by the scanner. Utilising this concept, it is possible to synthesize a radiolabelled antibody 
which will track to a desired target at high sensitivity and resolution, illustrating the areas of 
inflammation in 3D. The use of radiolabelled antibodies in PET is an attractive non-invasive 
imaging modality, which remains at the forefront of molecular imaging. The past forty years 
have seen the development of multiple radiolabelled antibodies for diagnostic and 
therapeutic purposes, particularly in the detection of tumours (33). Currently (18F)-fluoro-2-
deoxy-D-glucose (FDG) PET or radiolabelled leukocyte scintigraphy is utilised for IBD.  
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FDG-PET is used as a non-invasive imaging modality to illustrate aberrant glucose uptake, 
particularly in oncology. Inflamed or cancerous tissues often have higher glycolytic rates and 
tend to accumulate FDG, allowing for the visualisation of inflammation and tumours. Due to 
this, the specificity of this tracer can be lower in comparison to tracers with a specified target. 
Radiolabelled leukocyte scintigraphy also depends on a broad set of targets. This technique 
relies on the extraction of leukocytes from the patient’s blood which are radiolabelled. In 
contrast to other techniques such as FDG-PET, the synthesis of this tracer is much more time 
consuming and there is also the risk of cross contamination between patients and staff when 
working with blood products. Consequently, the currently available imaging tracers for IBD 
lack specificity and sensitivity, often targeting non-specific processes. Immuno-PET is a largely 
non-invasive technique, as such the risk of adverse effects is reduced. In addition to imaging, 
immuno-PET also possesses the ability to quantify molecular interactions. The amount of 
radiation exposed to a patient during the procedure is small, accordingly, the risk of follow-on 
effects is limited. Additionally, the beneficial results and improvement in patient management 
and treatment outcomes outweighs the risks of the test. There is also a small risk of allergic 
reaction to the tracer in some patients, as well as infection at the site of injection. Immuno-
PET of IBD will provide functional and quantitative information by directly showing areas of 
inflammation, particularly in areas in and around current lesions or newly forming lesions, in 
addition to extramural manifestations and may reduce the need for biopsies.  
 
Creating a tracer that is based on an antibody against a target fundamental to the 
development of IBD will increase the sensitivity and specificity of gastrointestinal 
inflammation imaging. This will provide clinicians and researchers with an increased 
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understanding into the patient’s condition and treatment requirements, as well as 
differentiating between CD and UC, in addition to other conditions. This will play a key role in 
personalised medicine against IBD as patients can be imaged to evaluate the efficacy of their 
pharmacological therapies. In addition to this, this technique would greatly benefit drug 
development against IBD, with this technology being transferrable to other inflammatory 
conditions such as arthritis.  
 
1.6 PET imaging with 89Zr  
 
The use of zirconium-89 (89Zr) in radiolabelling of antibodies is relatively new, compared with 
other radionuclides such as technetium-99m. This radionuclide provides many advantages 
over other alternatives, such as a relatively long half-life of 78.4 hours and a relatively low 
average positron energy and good in vivo stability which are amongst characteristics which 
makes it suitable for immuno-PET with monoclonal antibodies (mAbs). 89Zr decays by positron 
emission (23%) and electron capture (77%) to the stable isotope of 89Y which also has suitable 
properties for immuno-PET (34). The half-life of 89Zr is well-matched with the time required 
for mAbs to circulate and bind to their targets, resulting in optimal target-to-background 
ratios. The Emax for positron emission is 897 keV and Eave of 396.9 keV could result in improved 
spatial resolution due to not having prompt photons with energies near 511 keV. 
Disadvantages of 89Zr include high energy gamma emission of 908.97 keV which limit the 
radioactive dose which can be administered to patients and its limited availability. However, 
an increase in the commercial availability of 89Zr will make this radionuclide widely available 
for research, with the possibility of developing novel clinical applications. The use and 
development of mAbs is rapidly expanding, with the US Food and Drugs Administration having 
approved over 30 for therapeutic use. 
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1.7 Production and purification of 89Zr  
 
89Zr is typically formed by cyclotron bombardment of 89Y foil, most often by 89Y(p,n,)89Zr or 
89Y(d,2n)89Zr reactions (35). These reactions are preferred over other alternatives due to its 
higher yield of 89Zr from 89Y which is naturally abundant, and the reaction can occur with high 
purity using low level energy as yttrium only has 1 stable isotope (36). However, one of the 
largest issues associated with the use of 89Zr is removing impurities and maintaining purity. 
Bombardment of 89Y as mentioned above can form many impurities, one of which is the 
radiochemical impurity 88Zr (~0.01%) which has a half-life of 83.4 days, in addition to 65Zn, 48V, 
56Co, and 156Tb which may interfere with synthesis of the immunoconjugate (37, 38). This can 
be resolved by dissolving 89Zr in hydrochloric acid and separating it from impurities by ion-
exchange chromatography, particularly by hydroxamate resin purification (37). The final 
purified 89Zr solution should be of high chemical and radiochemical purity with endotoxin 
concentrations below accepted levels (39). Using the methodology above, 89Zr can be 
produced reliably with high purity (>99.99%) and high specific activity (470 – 1195 mCi/mmol) 
(40).   
 
1.8 Conjugation of 89Zr PET tracers with DFO  
 
The combination of an intact mAb with 89Zr allows for a relatively long-lived tracer which 
would be advantageous in transportation. Ideally, the compound which will be conjugated to 
89Zr should have a residency time similar to the half-life of the radionuclide. This allows for 
imaging to continue days post-injection, allowing for longer-term observations of treatment 
efficacy. 89Zr is a residualizing isotope, meaning that free 89Zr is internalised into cells, in 
contrast to other radionuclides such as 124I, which remains internalised for a short period of 
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time before re-entering the blood stream (39). To prevent non-specific uptake, it is imperative 
that 89Zr chelators are effective for the entire duration that contrast agents remain within the 
body. Previous 89Zr chelators have lacked efficiency, allowing for cleavage of 89Zr from the 
tracer. Multiple studies investigating 89Zr biodistribution have shown that free 89Zr 
accumulates within the bones and causes degradation of the bone in mice; however, bone 
uptake is not particularly observed in humans (41, 42). Zirconium is commonly conjugated to 
antibodies by desferrioxamine (DFO). There are two commonly used synthetic strategies used 
to achieve this: firstly, by a succinic acid linkage to the amine residue of DFO and an amine 
residue of the antibody and secondly, in a two-step process involving p-isothiocyanatobenzyl-
desferrioxamine (p-NCS-Bz-DFO) (43, 44). The latter being the preferred methodology due to 
its simplicity and commercial availability.  
 
Synthesis of 89Zr-DFO-Bz-NCS complexes can 
result in high immunoreactivity, radiochemical 
purity and structural integrity (44). Due to the 
relatively simple conjugation protocol, p-NCS-Bz-
DFO allows for easier compliance to GMP 
guidelines as well as rapid and efficient 
preparation. P-NCS-Bz-DFO has been proven to 
be an efficient chelator of 89Zr with no adverse 
uptake in normal organs or accumulation within 
the bone (44). P-NCS-Bz-DFO is currently being 
widely utilised in the development of zirconium 
tracers due to its superior chelating properties. In the past ten years there has been a 
significant amount of interest in the use of 89Zr in radiopharmaceuticals, partly due to its 
 Figure 1 Schematic representation of p-NCS-Bz-DFO 
coupling with a monoclonal antibody (1) and labelling 
with 89-zirconium (2) (adapted from 45). 
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recent commercialization and increased availability. 89Zr-mAb immuno-conjugates are already 
being utilised to provide high quality PET images in both clinical and preclinical settings. As 
mentioned above, p-NCS-Bz-DFO is the most suitable chelator at present, due to its superior 
chelating properties. A streamlined and more efficient coupling method has been developed 
in contrast to initial methodology (45, 46). Firstly, the chelator p-NCS-Bz-DFO attaches to the 
mAb by binding to a lysine-NH2 group at pH 9.0 (step 1, figure 1). This product is purified by 
gel filtration prior the addition of 89Zr-oxalic acid, from which the 89Zr is complexed into the 
hexadentate ligand DFO (step 2, figure 1). The final product is purified by gel filtration. Another 
benefit of updated methodology is that there is no need to work under strict metal-free 
conditions, in contrast to other chelators such as DOTA and DTPA (45).  Labelling of the p-NCS-
Bz-DFO-mAb conjugate with 89Zr results in >85% purity. The optimal purity of the final 
immuno-conjugate product should be >95% which can be confirmed by instant thin-layer 
chromatography (ITLC), high performance liquid chromatography (HPLC) and SDS-PAGE (45).  
 
1.9 Antibody fragments  
 
Antibodies have demonstrated their supreme utility as therapeutics through their highly 
selective and effective binding, to treat a range of diseases in immunology, cardiology and 
oncology (47). As such, the knowledge and availability of antibodies have significantly 
increased in recent decades. The long biological half-life of antibodies is ideal for therapeutic 
application but for use as imaging contrasts, intact antibodies have a long half-life and can 
require days to achieve good signal-to-noise ratios (see 47 for a thorough review on antibodies 
and engineered fragments). For in vivo imaging, this leads to increased radiation exposure. 
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Ideally imaging contrasts will not have any biological activity as this can alter the mechanisms 
of interest and may lead to side effects. Additionally, tracer targets should have an increased 
expression in disease and low expression in health. An antibody’s binding properties and 
kinetics can be altered by engineering fragments through manipulations such as removing the 
fragment crystalizing (Fc) portion. This portion is not required for biological or therapeutic 
activity and its removal can improve target binding, signal-to-noise ratio and clearance. 
Retention of the fragment variable (Fv) portion is required for antigen binding. Furthermore, 
removal of the Fc portion prevents recycling through the neonatal Fc receptor pathway and 
complement, and effector cell-mediated immune interactions (47). These factors combined 
lead to rapid binding to target tissues, rapid blood clearance and improved contrast. Due to 
this, antibody fragments can be paired with isotopes that decay more rapidly, such as 18F, 
reducing radiation exposure. The route of antibody clearance can be altered by the size, 
charge and hydrophobicity/hydrophilicity of the protein as well as any conjugated moieties 
(47). Use of antibody fragments and proteins less than approximately 60 kDa, promotes renal 




IBD is a debilitating and lifelong condition which is often invisible to others. Although the 
understanding of IBD pathogenesis has increased in recent decades, there is still a lack of 
effective pharmacological therapies and imaging modalities. Molecular imaging is emerging 
as the forefront of medical imaging. PET in combination with a pathology-specific tracer has a 
multitude of advantages over conventional diagnostic imaging modalities, including providing 
temporal and spatial visualisation of a molecular probe within a biological pathway in vivo, as 
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well as quantification of tracer uptake which may indicate severity. Personalised medicine is 
becoming more prominent in clinical settings, which will only increase in the future– 
molecular imaging and personalised medicine go hand in hand. Immuno-PET in general may 
allow clinicians to assess a patient’s responsiveness to their treatment regime. This may 
increase the patient’s prognosis, sparing the patient extra exams, time and decrease 
treatment costs. Early management due to immuno-PET and tailored treatment plans will also 
decrease the development of lesions, inflammation and fibrosis, prior to the requirement of 
invasive procedures such as a colectomy. Patient’s drug dosing can be adjusted to achieve 
maximum therapeutic potential, whilst decreasing potential side effects. This technology also 
has the potential to quickly and non-invasively assess drug efficacy in vivo, while providing 
quantification into the biological pathway in question. Accordingly, I aimed to define the 
immune and epithelial barrier changes associated in DSS colitis and fibrosis. This will identify 
targets for molecular probes, which I will design and validate.  
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Chapter 2 Gut barrier, tolerance and dietary emulsifiers: a review 
 
2.1 Statement of authorship 




The gastrointestinal tract has an array of innate and adaptive mechanisms for maintaining 
homeostasis by limiting immunogenicity against the host and by mounting the appropriate 
immune responses against pathogens. This can range from innate mechanisms such the 
antibacterial properties of the gastrointestinal mucus layer, to adaptive, anti-inflammatory 
activity by regulator T cells (TREG). The intestinal epithelium and thick mucus layer are primary 
modes of defence against pathogens. The mucus itself is an active regulator of commensal 
bacterial colonisation and species diversity (1). The intestinal barrier primarily consists of 
epithelial cells in which tight junction complexes create a tight seal preventing the passage of 
the luminal contents into the mucosa. Intestinal biopsies from patients with CD, shows a 
decreased expression of the tight junction protein e-cadherin, impairing tight junction 
function (2). In addition to the physical intestinal barrier, Goblet cells, enterocytes, Paneth 
cells, neuroendocrine cells and M cells also contribute to the maintenance and homeostasis 
of the intestinal barrier (3). Accordingly, dysfunction of these cell types may contribute 
towards IBD pathology. Everything that we ingest has an interplay with our immune system, 
whether pathogenic or innocuous. This may be dietary components which are key for health, 
or more sinister stimuli such as pathogens like Salmonella. Regardless, our gastrointestinal 
immune system is being constantly bombarded with stimuli which will either be tolerated or 
deemed immunogenic by our gut. This fine balance between tolerance and immunogenicity 
is crucial in maintaining gut health and is implicated in many gastrointestinal disorders 
including inflammatory bowel disease (IBD). IBD encompasses both ulcerative colitis (UC) and 
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Crohn’s disease (CD), which are characterised by chronic remitting and relapsing inflammation 
of the gastrointestinal tract (GIT), causing gastrointestinal ulcerations, bleeding, bowel 
disturbances and pain. The pathogenesis of IBD is not fully elucidated but is believed to be 
multifactorial in nature with host immunological, genetic, environmental and bacterial factors 
involved. Typical treatment of IBD involves the use of corticosteroids, immunosuppressants 
and biological agents such as anti-TNF-a agents. Tolerance of and side effects to 
pharmacological treatments is common, as such surgery is often required. Patients with IBD 
have been found to have decreased diversity of their microbiome (4). A decrease in bacteria 
populations which have anti-inflammatory properties may contribute to intestinal pathology. 
A decrease in short chain fatty acid-producing bacterium, such as Faecalibacterium prausnitzii, 
can contribute towards pathology by modulating epithelial cell growth and TREG differentiation 
and expansion (5). Bacteria such as Escherichia coli can also modulate intestinal permeability, 
alter the microbiome composition and induce inflammation by modulating the expression of 
inflammatory genes (6). Modulation of the microbiome in active UC by faecal biota transfer 
has shown therapeutic promise (7). This review aims to assess the current understanding of 
tolerance and the maintenance of homeostasis in the gastrointestinal tract and how dietary 
emulsifiers can modulate this. 
 
2.3 Modulation of intestinal homeostasis by dietary emulsifiers 
 
The gastrointestinal tract is constantly exposed to a range of stimuli, which can be pathogenic 
or innocuous in nature. The gastrointestinal tract is home to a multitude of bacteria which can 
be beneficial to the host or can contribute towards pathologies. The disturbance of this fine 
balance between tolerance and pathogenicity of the gut microbiota can modulate the 
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host’s mucosal immunity, possibly leading to inflammatory conditions such as IBD. A primary 
defence in the intestine is the layer of mucus which protects the epithelium from the 
microbiota (8). Consequently, disturbance of this mucus layer has the potential to potentiate 
inflammatory conditions of the gut. It has been hypothesised that compounds like dietary 
emulsifiers have the potential to disturb this mucus layer by altering its physicochemical 
properties, allowing for bacterial translocation into the lamina propria and subsequent 
inflammation of the gastrointestinal tract. Emulsifiers are widely used in the Western diet and 
may partially explain the rise of inflammatory conditions of the gut in Westernised countries. 
Emulsifiers are often added to foods such as mayonnaise, ice-cream and some processed 
meats to evenly distribute fats throughout the mixture, providing a more palatable texture 
and consistency. Two commonly used emulsifier carboxymethyl cellulose (CMC) and 
polysorbate-80 (P-80) work to stabilise emulsions in beverages and food. CMC increases 
viscosity by reducing the rate of sedimentation and P-80 is a non-ionic surfactant. It has been 
shown, that the administration of relatively low concentrations of the commonly used 
emulsifiers CMC and P-80 induced low-grade intestinal inflammation in WT hosts and 
potentiated robust colitis in IL10-/- and TLR5-/- mice (9). It is speculated that this occurred 
through a shift in microbiota which favoured pro-inflammatory interactions. Changes in 
microbiota can cause gastrointestinal inflammation or can occur as a result of inflammation, 
and therefore it can be difficult to discern the extent that a substance can alter an organisms’ 
microbiota. Emulsifier-treated mice showed an average reduction of 50% in the distance 
between the epithelium and nearest bacteria (9). This microbiota encroachment was also 
associated with a reduced mucus thickness, with no change in Muc2 expression. Reduction in 
mucus thickness was not observed in germ-free mice, suggesting the CMC and P-80 act on the 
microbiota, rather than the mucus layer itself. Treatment with CMC or P-80 induced 
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significant alterations in microbiota composition in WT, IL10-/- and TLR5-/- mice. Faecal levels 
of proinflammatory flagellin and bioactive LPS were also increased in emulsifier-treated WT, 
IL10-/- and TLR5-/- mice. Additionally, it has been shown that P-80 can increase Escherichia coli 
translocation through CACO2-cl1 monolayers, M-cells and across human Peyer’s patches (10).  
 
More recent studies have supported the premise that the microbiota is an important target 
of CMC and P-80 (11). Using the ex vivo M-SHIME model it was shown that the human 
microbiota undergoes shifts in composition in response to CMC and P-80, increasing 
proinflammatory interactions (11). In mice with a pathobiont-free microbiota, there were no 
changes in microbiota composition in response to CMC and P-80. Additionally, M-SHIME 
suspensions from CMC and P-80-treated mice, when transferred into germ-free mice were 
able to produce low-grade inflammation and metabolic disease. A recent study has shown 
that acute exposure to CMC and P-80 is sufficient to alter intestinal mucus structure and 
transport properties (12). These changes result in the translocation of bacteria into the lamina 
propria, which may contribute towards the development of intestinal inflammation. CMC 
exposure induced a decrease in mucus pore size which correlates with significantly slower 
Escherichia coli speed and particle diffusion. Exposure to P-80 caused negligible changes to 
the mucus microstructure and particle diffusion but increased the movement speed of 
Escherichia coli. Both CMC and P-80 were found to alter mucus volume and thickness in rat 
intestinal tissue and mucus-producing cell cultures (12). These results suggest that dietary 
exposure to CMC may result in compaction of the intestinal mucus and the loss of some 
clumped material. In contrast, exposure to P-80 may alter microbial binding and transport in 
addition to altering the mucosal make-up through the loss of some mucosal components (12).
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Although the consumption of emulsifiers has not been linked to directly causing 
gastrointestinal conditions, it has been shown to alter homeostatic conditions of the gut, 
perhaps permitting and potentiating the development of inflammation. The Westernised diet 
is often described as a risk factor for IBD. However, it must also be considered that it is 
common to consume multiple emulsifiers and dietary additives simultaneously, thus more 
work is required into the effects of multiple emulsifiers – are these effects additive or 
synergistic? Additionally, the concentration of dietary additives such as emulsifiers are not 
well reported or regulated as they are generally regarded as safe (GRAS) for consumption.  
 
2.4 Innate lymphoid cells  
 
Innate lymphoid cells (ILCs) are relatively recently discovered players in the field of mucosal 
immunology and inflammation. Although their functions are not entirely known, it has 
become apparent that they play a significant role in immune responses, particularly in chronic 
inflammation by mediating the transition from innate to adaptive immune responses and in 
tissue repair (13, 14). Although ILCs make up a small proportion of immune cells throughout 
the body, their strategic positioning in the epithelial layers, amongst others, enables them to 
be highly efficient in maintaining gastrointestinal homeostasis. Currently, three subtypes of 
ILCs are described, which are based on cytokine secretion, extracellular markers and 
transcription factors (table 1).


















Table 1. Innate lymphoid cell subtypes and characteristics (13, 14).  
 
ILCs do not express T or B cell antigen receptors, nor do they express lymphoid differentiation 
lineage markers (13). ILCs are crucial for maintaining the fine balance between homeostasis 
and autoimmune inflammation, suggesting that they play a key role in autoimmune, allergic 
and inflammatory conditions, accordingly an understanding into their roles and functions may 
provide novel targets for much needed therapeutics. ILCs have been found to be crucial in the 
maintenance and repair of various tissues throughout the body, such as the intestinal 
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epithelium, which is crucial in the control of inflammation and homeostasis. The analysis of 
ILC populations in healthy control intestinal biopsies revealed that NKp44+ ILC3s are most 
dominant of the ILCs throughout the ileum, caecum and colon, with the lowest proportions in 
the ileum (15). ILC1s were most frequent in the ileum and ILC2s were in low proportions 
throughout the entire gastrointestinal tract. Proportions of NKp44+ ILC3s were significantly 
decreased in inflamed active UC and CD biopsies, relative to health. This reduction is observed 
in newly diagnosed and chronic IBD patients. Interestingly, this reduction correlated with the 
local endoscopic disease severity in both UC and CD patients. This reduction of NKp44+ ILC3s 
has severe consequences for maintaining epithelial barrier integrity and homeostasis, as 
discussed further below. This decrease in NKp44+ ILC3s correlated with an increase in ILC1 
and ILC2 proportions in CD and UC at the time of diagnosis, respectively. However, in patients 
with chronic UC or CD both proportions of ILC1 and ILC2 were increased. Changes in ILC 
composition primarily occurred in inflamed tissue only and correlated with endoscopic 
damage scores. There were no changes to the proportions of ILCs in the noninflamed mucosa 
or peripheral blood of IBD patients, compared to healthy controls. 
 
Group 1 innate lymphoid cells  
Deriving from natural killer cell progenitors, T-bet+ group 1 ILCs secrete IFN-g and TNF-a in 
response to IL-12, IL-15 and IL-18 (16, 17). Although deriving from the same progenitor, group 
1 ILCs differ from NK cells as they lack the cellular markers CD16, CD56 and CD94 (16). 
Currently, there are three distinct subsets of ILC1s, which includes natural killer cells (NK cells), 
intraepithelial CD127- CD103+ ILC1 and CD127+ ILC1 (18). CD127- CD103+ ILC1 are cytotoxic 
and typically reside in the intestinal epithelium, in contrast to CD127+ ILC1 which 
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are not cytotoxic and mostly reside in the lamina propria (19). In health, ILC1s are potent 
stimulators of mononuclear phagocytes and are key for immunity against intracellular 
pathogens such as Toxoplasma gondii through their inherent secretion of TNF-a and IFN-g 
(20). Group 1 ILCs have been found to accumulate in the inflamed intestine of patients with 
CD and out of the three subsets, group 1 ILCs were the most frequent, suggesting a role for 
this subset in CD (16). RORgt+T-betdim ILC3 cells can differentiate into IFN-g-producing RORgt- 
T-betHi ILC1 cells when cultured with IL-2 and Il-12 (16). Previous studies have suggested that 
both human and mouse ILC3s can upregulate T-bet and downregulate RORgt (16). 
Additionally, the differentiation of ILC1 to ILC3 can be induced by IL-23 and is accelerated by 
IL-1b and retinoic acid (18). This is supported by an increase in RORgt and decreased levels of 
T-bet. Furthermore, retinoic acid has been shown to upregulate RORgt (21). This multi-
directional differentiation from ILC1 to ILC3 and vice versa is mediated by a subset of dendritic 
cells (16). Intestinal resections from patients with CD were found to have a higher proportion 
of CD14+ dendritic cells which promote the differentiation of ILC3 to CD127+ ILC1 (18). 
Conversely, CD14- dendritic cells can promote the reverse differentiation of CD127+ ILC1 to 
ILC3. This may explain the increased proportion of ILC1s in the inflamed intestine of CD 
patients. This coincides with a previous study which indicated that IFN-g and IFN-g producing 
cells, such as ILC1s, were significantly increased in the intestine of patients with active CD (22). 
Interestingly, fontolizumab, an anti-IFN-g antibody was not found to be efficacious in treating 
CD (23). Experiments with DSS-treated human immune system mice indicate that proportions 
of CD127+ ILC1s increase as a result of acute inflammation, rather than as a side-effect of 
chronic intestinal inflammation (16). This is thought to occur through the inflammation-
induced differentiation of NKp44+ ILC3s, which are a predominant subset in homeostatic 
conditions into ILC1 (16).
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This differentiation is driven by IL-12 secreted by phagocytes which influx into the 
gastrointestinal tract during inflammation (16, 24, 25).  
 
Group 2 innate lymphoid cells  
ILC2s are highly responsive to epithelial cell secreted cytokines such as IL-25 and IL-33 which 
are released following breaking of the intestinal barrier (26). They are capable of secreting 
type 2 cytokines such as IL-5, IL-13, IL-4 and IL-9 and originate from common lymphoid 
progenitors via common helper innate lymphoid cell progenitors, like ILC3s. These cells are 
dependent on GATA-3 for their development and function and are crucial for immune 
responses to helminths through their stimulation of eosinophilia and development of goblet 
cell hyperplasia (26). In health, ILC2s can produce factors required for epithelial barrier repair 
such as amphiregulin (27). They are predominantly located in non-lymphoid tissues such as 
those in the gastrointestinal tract, lungs and skin (26). ILC2s exist in very small proportions in 
the human colon and accordingly aren’t speculated to play a large role in gastrointestinal 
inflammation, particularly if not due to parasites (28). Interestingly, some intestinal biopsies 
from patients with CD have been found to have increased numbers of ILC2s, with no change 
found in UC (21, 29). They have also been found to be protective in murine DSS colitis, 
suggesting that they may be involved in maintenance of the intestinal epithelial barrier (30). 
Recently it has been shown that T-bet regulates intestinal ILC2 functions (31). To date, T-bet 
has been understood to be critical for the function of ILC1s and NCR+ ILC3s and the depletion 
of T-bet prevents the development of these subsets. Additionally, the depletion of T-bet leads 
to dysregulated ILC3 responses, causing microbiota-dependent colitis. Accordingly, in the 
innate immune system, T-bet is considered to inhibit pathogenic immune responses. The 
selective depletion of T-bet in ILCs causes increased activity and expansion of ILC2s
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which is beneficial for mucosal immunity, particularly in the defence against Trichinella spiralis 
and inflammatory colitis (31). This T-bet-dependent regulation of intestinal ILCs potentially 
occurs through IL-7 receptor signalling. This mechanism is crucial for maintaining the fine 
balance between pathogenic and protective immune responses, which may play a role in IBD. 
T-bet transcriptionally represses the Il7ra gene in ILCs. In a T-bet deficient environment, 
increased IL-7Ra expression in ILCs causes increased activation of STAT-5 on stimulation with 
IL-7 (31). This can occur in normal GATA-3 levels, further suggesting that T-bet acts directly as 
a transcriptional repressor of IL-7Ra. It has been previously shown that increased IL-7 
sensitivity, independent of retinoic acid signalling is associated with higher ILC2 proliferation 
and accumulation (32). Adding to this, it has been found that T-cell plasticity and lineage 
stability can be influenced by interactions between the retinoic acid receptor-a and T-bet (31). 
STAT-5 stimulation may stabilise the expression of GATA-3 in ILCs, increasing the proportion 
of ILC2s, which is observed in T-bet deficient animals. It is suspected that human ILC3s also 
comprise of multiple subtypes, but their similarity to murine subset is yet to be determined.  
 
Group 3 innate lymphoid cells  
Group 3 innate lymphoid cells are characterised by their expression of RORgt and the secretion 
of IL-17A, IL-17F, IL-22 and GM-CSF (33). Multiple subsets of ILC3s exist in both humans and 
mice and are defined by their localisation in different tissues and transcriptional, 
developmental and functional differences (1, 34). ILC3s are constitutively present throughout 
the murine and human gastrointestinal tract, however their densities throughout these 
organs differs.
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They are the most abundant ILC subset at intestinal mucosal surfaces, such as the ileum and 
colon (16, 28). Distribution of ILC subsets is dictated by IL-7 expression as IL-7 stimulation 
promotes RORgt expression, which in turn promotes ILC3 proliferation (19). In mice, there are 
at least 2 ILC3 subsets: the lymphoid tissue inducer (LTi)-like ILC3 and NCR+ILC3 cells. LTi-like 
ILC3s are characterised by the expression of c-kit, CCR6 and their localisation within lymphoid 
tissues. Conversely, NCR+ ILC3 lack LTi markers such as CCR6 and instead express NKp46, the 
transcription factor T-bet and reside in the lamina propria of the small intestine. In health, 
ILC3s are extremely responsive to different environmental stimuli in various tissues including 
cytokine and cell surface receptor dependant mediated mechanisms to maintain homeostasis 
of the gut immune system. Crucial to IBD, ILC3s maintain gut barrier function and integrity, 
whilst balancing immunogenic and tolerance mechanisms against the microbiota. When 
immunogenic bacterial antigens have been sensed, ILC3s are stimulated by IL-23 or IL-1b 
secreted by CX3CR1+ mononuclear cells and dendritic cells (19). This stimulates the ILC3s to 
secrete their main effector cytokines IL-22, IL-17 and GM-CSF.  
 
Recent studies suggest that LTi-like ILC3 tend to be polarised towards maintaining 
homeostatic functions and regulating adaptive immunity, in contrast to NCR+ILC3s which are 
involved in inflammatory processes through the T-bet-dependent secretion of IFN-g. 
NCR+ILC3s predominantly reside within the small intestine and are seldom present in lymph 
tissues. This is maintained through their expression of CXCR6, which retains the cells within 
the intestinal lamina propria (35). In contrast, LTi-like ILC3 reside within the lymph tissue, 
which includes Peyer’s patches and mesenteric lymph nodes and aggregate around cells of 
the adaptive immune system such as CD4+ T cells and B cells (36). ILC3 are a main source of 
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IL-22 during homeostasis. Both NCR+ILC3 and LTi-like ILC3 can produce IL-22 when stimulated 
by myeloid cell-derived signals such as IL-1b (37).  
 
 In mice, TH17 cells are also a source of IL-22, but this does not translate to humans where 
TH22 and TH1 subsets produce majority of IL-22. IL-22 is in the IL-10 family of cytokines which 
also includes, IL-10, IL-19, IL-20, IL-24, IL-26, IL-28 and IL-29 (38). IL-22 is crucial for mucosal 
host defence against extracellular pathogens such as bacteria and also for tissue repair and 
acts on only non-hematopoietic stromal cells such as epithelial cells (39). IL-22 target tissues 
include the small intestine, colon, liver, lung, kidney, skin and pancreas (40). Dependent on 
location, IL-22 secretion can be pathogenic due to its pro-inflammatory properties. This is 
amplified when IL-22 is secreted with other proinflammatory cytokines such as IL-17, which 
can lead to abnormal epithelial proliferation and differentiation as seen with many 
inflammatory conditions (39). To prevent this, IL-22 and IL-17 secretion are highly and 
independently regulated. Both IL-22 and IL-17 regulation is dependent on RORgt and STAT3 
expression but independent regulation of IL-22 comes from other factors such as c-Maf (39). 
ILC3 secretion of IL-22 is regulated by the aryl hydrocarbon receptor (Ahr), which stimulated 
by endogenous and xenobiotic ligands (41). 
 
In the absence of ILC3s, epithelial maintenance is decreased, leading to increased pathology 
and severe damage to the intestinal crypts (42). Loss of ILC3-secreted IL-22 leads to the 
translocation of commensal bacteria into the peripheral organs, which allows bacteria to 
reside closely within the epithelium or within lymphoid tissues (43). This suggests that IL-22 is 
crucial for the maintenance of the intestinal barrier. IL-22 producing ILC3 within cryptopatches 
can maintain epithelial barrier homeostasis through the maintenance of crypt 
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stem cells which can differentiate to intestinal epithelial cells and other epithelial and 
enteroendocrine cell subsets (42). To ensure and maintain a closely sealed barrier, crypt stem 
cells continuously proliferate and replenish all intestinal epithelial cells within days. It has been 
found that the restoration of proliferating crypt cells and epithelial phosphorylation of Stat3 
after tissue damage occurs, is dependent on Thy1+ cells (42). In response to tissue damage, 
Thy1+ cells are essential for the generation of IL-22 and GM-CSF, working to restore intestinal 
homeostasis.  
 
2.5 Innate lymphoid cell migration  
 
It has been shown that ILCs migrate into the intestine using CCR9 and a4b7 and that ILC1s and 
ILC3s in both the small intestine and colon highly express a4b7 (44). All ILC subsets require 
CCR9 to migrate into the small intestine, whereas a4b7 serves as a general gut migration 
marker. Interestingly, 30-50% of ILC1s and ILC3s within the mesenteric lymph nodes (MLN) 
express CCR9 and a4b7, but these markers are not required for migration into the MLN, 
suggesting that the MLN are a site for the generation of ILCs, but not an endpoint (44). CCR7 
is highly expressed on ILC1s and ILC3s in the MLN and may play a role in the bidirectional 
migration between the MLN and intestine (44). The accumulation of homing receptor 
deficient ILCs in the spleen suggests that migration into the spleen occurs passively without 
specific homing receptors. Furthermore, the migration of ILC1s and ILC3s but not ILC2s is 
regulated by mucosal dendritic cells and retinoic acid (44). Retinoic acid secreted by dendritic 
cells within gut-lymphoid tissues can induce upregulation of gut homing receptors on ILC1 and 
ILC3, thus causing migration between organs (44). It has been shown that retinoic acid plays 
a role in the upregulation of both CCR9 and a4b7 on ILC1 and ILC3 (44). However, it is 
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still not known whether retinoic acid regulates all ILC subsets in the same manner. It has been 
observed that ILC3s are the most sensitive to retinoic acid-induced homing receptor switching 
from CCR7 to CCR9 and a4b7, as with ILC1s, but ILC2s did not respond at all (44). Interestingly, 
regardless of organ, all ILC2s were found to express CCR9, including in the spleen (45) and 
intestinal ILC2s do not highly express a4b7 (44). Upregulation of gut homing receptors appears 
to occur in the periphery for ILC1 and ILC3, in contrast to ILC2 which occurs in the bone 
marrow. Vitamin A levels can alter ILC distribution, causing abhorrent mucosal immunology 
through a decreased secretion of anti-microbial peptides and IL-22 (44). However, ILC 
migration mechanisms are not fully elucidated so it is likely that non-retinoic acid-based 
pathways may be involved.  
 
2.6 Regulatory T cells  
 
Regulatory T cells (TREG) powerfully modulate mucosal immunity throughout the 
gastrointestinal tract by exerting anti-inflammatory effects. They are crucial for restraining 
immune responses against self and innocuous antigens, whilst permitting antipathogen and 
antitumor activity (46). To operate effectively, TREG cells must interact with both the adaptive 
and innate immune systems, which depends on their proximity to their targets and their ability 
to migrate to specific tissues. Loss of these cells can promote intestinal inflammation. TREG 
cells are constitutive within secondary lymphoid tissues and can be also found within most 
non-lymphoid tissues, even during homeostatic conditions. TREG cells can secrete suppressive 
messengers such as TGF-b, IL-10 and IL-35. Expansion of TREG cells from CD4+ T cells is induced 
by IL-2 and TGF-b (47). Forkhead box P3 (FOXP3) expression of CD4+ cells is characteristic of 
TREG cells (46). Stimulation of T cell receptors on TREG cells in secondary 
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lymphoid organs can promote the homing of TREG cells (48), however little is understood about 
TREG priming and migration to the gut. TREG cells can migrate to other tissues by various homing 
and chemokine receptors (See 46 for a thorough review). Currently it is thought that a large 
proportion of peripheral TREG (p TREG) cells differentiate in the mesenteric lymph nodes, where 
they upregulate gut-homing receptors such as a4b7 and CCR9 (49). Both thymus-derived TREG 
cells (tTREG) and pTREG are present in the gastrointestinal tract, but it is currently thought that 
pTREGs are responsible for tolerance to microbial and dietary factors (50). Furthermore, pTREGs 
have been found to prevent aberrant TH1 immunity to food antigens (51).  
 
TREG cells have been implicated in the onset and development of UC and CD (52). Evidence 
suggests that an altered balance between anti-inflammatory TREG cells and proinflammatory 
effector cells in the intestinal microenvironment can contribute to the pathogenesis of IBD 
(53). This allows the mucosal immune system to mount a response against the host. TREG 
subset phenotype and function in inflamed gastrointestinal tissue of patients with IBD are 
drastically different from TREG cells obtained from peripheral lymphoid tissue of healthy 
controls (54). Patients with IBD have decreased peripheral TREG cells but increased peripheral 
TH17 cells. Also, mRNA expression of FOXP3, IL-17A, IL-1b and IL-6 are elevated in the mucosa 
of patients with IBD. Interestingly, it has recently been shown that patients with IBD with 
active endoscopic disease, the intestine has increased proportions of CD4+ T cells, TREG and 
Tcentral memory cells, compared with healthy controls and endoscopic inactive IBD (55). 
Proportions intestinal of CD8+ and CD103+ T cells were decreased in active IBD. The 
composition of T cell subsets in patients with active endoscopic disease was maintained 
between the initial and follow up visit, suggesting that this composition maintains consistency 
over time. T lymphocyte composition returned to the levels of healthy controls when IBD 
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patients were in endoscopic inactive disease. These proportions of lymphocyte subsets also 
correlates with endoscopic disease activity. There was no variation in lymphocyte subsets 
between the ileum and colon, suggesting that it is more so based on disease and not restricted 
to one location (55). Patients with CD that had a higher baseline proportion of TREGs were 
associated with disease with more strictures, penetrations and or abdominal surgeries. 
Interestingly, CD patients with a lower baseline of TREG proportions usually experienced milder 
colitis and treatment with steroids was the strongest treatment used. It is difficult to explain 
the purpose of this increase in TREG populations in active IBD; however, this expansion may be 
in an effort to dampen inflammation.  
 
2.7 T-helper cell subset 17  
 
T-helper cell 17 (TH17) is subset of effector memory T cells characterised by the secretion of 
IL-17 that have been implicated in the pathogenesis of CD and UC (56-58). TH17 cells are 
distinct from TH1 and TH2 cells and are crucial for the clearance of pathogens and homeostasis 
of the intestinal mucosa. Loss of this subset can permit the translocation of bacteria into the 
intestine, causing chronic inflammation. It has been shown that TH17 cells which induce TH1 
cells are critical for the pathogenesis of colitis (59). This occurs primarily through the secretion 
of IFN-g by TH1-like cells which derive from TH17 precursors. T-bet is required for the transition 
from TH17 precursor cells to TH1-like cells (60, 61). TH17 cells secrete IL-17A, IL-17F, IL-21, IL-
22, IL-26, IL-8, IL-10, TNF-a, CXCL8, CCL20 and GM-CSF (62). IL-17A and IL-17F are crucial for 
the defence against extracellular pathogens. TREG cells are the anti-inflammatory counterparts 
of TH17 cells and are crucial for maintaining the balance between tolerance and 
immunogenicity. Interestingly, secukinumab, a monoclonal antibody against IL-17A, failed in 
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the treatment of IBD, suggesting that IBD is not a typical TH17-mediated autoimmune disorder 
(63). Binding of IL-17 to its receptor stimulates the recruitment of ACT1, subsequently 
activating TNF receptor-associated factor 6, activating NF-κB and MAPK pathways (64). This 
leads to the recruitment, activation and migration of granulocytes, but also stimulates 
epithelial cells, endothelial cells and fibroblasts. Macrophages can also be stimulated to 
produce proinflammatory mediators such as IL-6, TNF-a and IL-1b (64, 65). Differentiation of 
TH17 cells is induced by cytokines such as IL-1b, IL-6 and IL-21. The TREG- TH17 balance can be 
modulated by environmental cues such as all-trans retinoic acid which promotes TREG 
differentiation and inhibits TH17 differentiation (66). Studies in germ-free mice have shown a 
decreased capacity for differentiation between TH17 and TREG cells, suggesting that the 
microbiota can modulate these cell populations (67, 68). The Clositridia species have been 
found to be a prominent regulator of intestinal homeostasis and T cell plasticity. 
Transplantation of human or murine faecal Clostridium mixture induces strong polarisation 
towards TREG cells (68, 69). It has been shown that the epithelial adhesion of microbes such as 
Citrobacter rodentium causes the induction of TH17 cells by segmented filamentous bacteria 
(SFB) and enterohemorrhagic Escherichia coli (EHEC) (70). In contrast, adhesion-defective SFB 
and EHEC were not able to trigger these TH17 responses. 20 different bacterial strains were 
isolated from faecal samples of a patient with UC were able to cause the induction of TH17 
cells in the mouse colon and bind to the epithelium (70). However, the authors suggest that 
only 3 of these strains are found to be significantly elevated in the microbiomes of CD and UC 
patients. Consequently, it is believed that the intestinal immune system evokes TH17 
responses through the recognition of microbes themselves, rather than microbial 
secretions/components or metabolites. Adhesion of microbes to the epithelium 
Chapter 2 Gut barrier, tolerance and dietary emulsifiers 
 41 
correlated with an increase in intestinal IgA+ cells, thus TH17 and IgA+ cells may play a role in 
the control of epithelial cell-adhering microbes (70).  
 
2.8 Mechanisms in the maintenance of intestinal homeostasis and tolerance 
 
Recently it was found that the transcriptional repressor Hypermethylated in cancer 1 (HIC1) 
was involved in the retinoic acid-dependant regulation of intestinal homeostasis by ILCs (71). 
Additionally, HIC1 has also been found to regulate intestinal T-cell function during 
inflammation and homeostasis (72). Mice that were fed a diet deficient of vitamin A lacked 
HIC1-positive cells in the intestine (72). These cells were found to over-secrete IL-17A, which 
led to a failure to mount an intestinal immune response. The expression of HIC1 on ILCs occurs 
in a vitamin A-dependant manner. Without HIC1, proportions of IL-22-producing RORgt+T-bet+ 
ILC3s decreased, leading to the increased risk of Citrobacter rodentium infection. There were 
no HIC1-dependant changes to the proportions of ILC2s and CD4+ ILC3s (lymphoid tissue 
inducing-cells, LTi). Additionally, a loss of HIC1 did not disturb the development of ILC 
progenitor cells in the bone marrow, suggesting that HIC1 regulates ILC function and 
development in the periphery. The authors hypothesised that retinoic acid induces the 
expression of HIC1, promoting cellular quiescence in the intestine, through Myc-dependant 
mechanisms. Tolerance of Citrobacter rodentium is mediated by IL-22, ILC3s being one of the 
largest sources, consequently, HIC1 is crucial for immunity to Citrobacter rodentium (71). In 
addition to this, it has been shown that retinoic acid receptor-a (RARa) signalling is essential 
in maintaining intestinal homeostasis and in the development of the intestinal immune system 
(73). RARa signalling in the intestinal epithelia influences the cellular composition of the 
intestinal barrier which plays a large role in intestinal immune homeostasis and defence 
against bacterial infections (73). A RARa underdeveloped immune system also has difficulty 
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in clearing Citrobacter rodentium infection. ILC3 are sensitive to modulation by dietary stimuli 
(1). Their ability to react to dietary stimuli suggests that ILC3 have a role in host tolerance of 
food-derived antigens. It has been shown that commensal bacteria can regulate vitamin A 
metabolism and storage, which is crucial for the maintenance of intestinal epithelial cells (74). 
As briefly discussed previously, retinoic acid can modulate transcriptional programs in a 
concentration-dependant manner, which can encourage protective or pathogenic immune 
responses in the gastrointestinal tract. Recent studies have shown that Clostridia species can 
modulate gut levels of retinoic acid by supressing intestinal epithelial cell expression of retinol 
dehydrogenase 7 (Rdh7), which catalyses the oxidation of retinol to retinaldehyde. This 
mechanism is key for the maintenance of tolerance, whilst preventing bacterial colonisation 
of the gut by enteric pathogens. Partial depletion of the gut bacteria by oral antibiotic 
administration in mice caused a significant increase in Rdh7, compared with untreated control 
mice but did not reach the same level as germ-free mice (74). This correlated with an increased 
concentration of retinoic acid and decreased retinol in the intestine, compared to control 
mice. Vancomycin-induced dysbiosis in mice caused a significant increase in the expression of 
Rdh7, which correlated with significantly higher amounts of gut retinoic acid. This data 
suggests that symbiotic bacterial colonies supress Rdh7 expression and retinoic acid secretion 
in the gut, whereas dysbiotic microbiomes do not (74).  
 
 In addition to vitamin A, dietary metabolites such as vitamin D and aryl hydrocarbon receptor 
ligands can modulate ILC3 populations and intestinal tolerance (1). Vitamin D deficiency has 
been indicated as a risk factor for inflammatory bowel diseases, with a correlation between 
vitamin D levels and disease activity (75). When ILC3 were stimulated with IL-23 and IL-1b, 
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vitamin D receptors were upregulated (76). Stimulation of gut ILC3 with vitamin D3 caused a 
downregulation of the IL-23 pathway, leading to suppressed IL-22, IL-17F and GM-CSF, but 
upregulated genes involved in the IL-1b pathway as well as IL-6 and IL-8. GM-CSF is crucial for 
tolerance to dietary antigens by supporting the tolerogenic activity of intestinal mononuclear 
phagocyte populations which can modulate intestinal TREG populations (77) Vitamin D3-
induced changes in ILC3 subsets did not alter cell proliferation, viability or phenotype. Aryl 
hydrocarbon receptors (Ahr) are known to interact with dietary and endogenous bacterial 
metabolites and xenobiotic environmental toxins (78). Ahr are essential for the maintenance 
and function of ILC3 and the secretion of IL-22 (41). It has been shown that IL-22-dependant 
signalling between ILC3 and epithelial cells can modulate the composition of the microbiota 
in mice, altering tolerance to pathogenic and commensal species (43). ILC3-secreted IL-22 is 
also key for restricting bacterial translocation and in the defence against opportunistic 
pathogens (19). Mice that are deficient in IL-22 or ILC3s showed decreased barrier integrity, 
which decreases their capacity to prevent the translocation of commensal bacteria. Under a 
deficit of IL-2, ILC3s can inhibit commensal-specific T cells through the MHCII receptor (79). 
Due to their expression of B cell activating factors such as CD40L, BAFF and APRIL, ILC3s are 
able to promote B cell-mediated defence against commensals (80). Furthermore, through 
lymphotoxin-dependent pathways ILC3s are able to stimulate the secretion of T cell-
dependent and independent IgA and IgG antibodies (80). These IgA and IgG antibodies 
contribute towards maintaining intestinal homeostasis by modulating the size, composition 
and anatomical containment of the commensal microbiota (81). The modulation of ILCs by toll 
like receptors (TLRs) is still largely unknown. However, it has been shown that human LTi-like 
ILCs can be stimulated by TLR2 ligands to express IL-5, IL-13 and IL-22 in a NK-κB-dependent 
manner (82). The IL-23 receptor has been found as a susceptibility allele in IBD 
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and as such is suspected to be involved in the pathogenesis (83). IL-23-driven intestinal 
pathology was initially thought to be due to TH17 cells, but it is now understood that ILCs also 
play a role (84). Stimulation of colonic leukocytes with IL-23 induced an increase in the 
production of IL-17 and IFN-g, which was solely secreted by Thy1+ SCA-1+ RORgt+ IL-23R+ ILCs 
(83). This subtype of ILCs is found to be increased in the inflamed colon.  
 
 Ahr -/- mice were found to have increased IL-17 secretion by CD4+ T cells in the small intestine, 
enhancing TH17 responses (41). The authors suggest that Ahr is required to suppress TH17 
responses under homeostatic conditions in the gut. This increase of IL-17 by CD4+ T cells in 
Ahr -/- mice seems to arise from an increase in RORgt expression. Microbiota such as 
segmented filamentous bacteria can promote TH17 cell differentiation through the induction 
of RORgt expression in CD4+ T cells (85). Ahr -/- mice were found to have a significant increase 
in faecal segmented filamentous bacteria, which correlates with previous studies showing that 
segmented filamentous bacteria can induce TH17 responses in the gut (86). This suggests that 
expansion of gut segmented filamentous bacteria in Ahr -/- mice plays a role in increased TH17 
responses. It has also been shown that a depletion of ILCs leads to an increase in segmented 
filamentous bacteria in Rag -/- mice, suggesting that ILCs play role in the maintenance of levels 
of commensal bacteria during homeostasis (41). Mice deficient in Ahr also spontaneously 
developed intestinal pathology, showing signs of thickening and fibrosis of the intestine, 
without displaying weight loss or diarrhoea. These studies suggest that the Ahr-IL-22 axis in 
ILC3s works to maintain intestinal homeostasis through the suppression of TH17 responses 
(41).
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In addition to this, Ahr signalling has also been shown to modulate ILC2 function (87). Out of 
the ILC subsets, Ahr is most highly expressed on ILC2s and controls the accessibility of 
chromatin at the Ahr locus by positive feedback. Ahr stimulation supresses the transcription 
factor Gfi1-mediated expression of IL-33 receptor ST2 on ILC2. This also decreases secretion 
of the ILC2 effector molecules IL-5, IL-13 and amphiregulin. Removal of Ahr increases the 
capacity for anti-helminth immunity in the gut, but pharmacological or genetic stimulation of 
Ahr suppresses ILC2 function but enhances ILC3 immunity against Citrobacter rodentium 
infection. This suggests that through modulation of the Ahr pathway, the host is able to 
regulate the gut ILC2-ILC3 balance to mount the appropriate immune response against various 
pathogens (87).  
 
2.9 Conclusion  
 
Everything that we ingest has the potential to modulate our mucosal immunity and intestinal 
barrier. Additives such as emulsifiers and thickeners are commonly used in an array of foods 
and have been shown to contribute towards intestinal pathology. It is crucial to build our 
understanding of how dietary elements such as emulsifiers and other food additives affect our 
intestinal tolerance and microbiome and how they may contribute towards disease. The 
mechanisms underpinning IBD are highly complex and interwoven, but our understanding of 
these debilitating diseases continues to improve. Understanding of these mechanisms is 
crucial for the development of novel therapeutics to improve patient care. New therapies 
must be developed as current therapies lack efficacy and may decrease in efficacy over time 
and frequently cause debilitating side effects. It is evident that the interplay between the 
intestinal immune system and the microbiota can contribute towards pathology. Future 
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therapies should be personalised based on an individual’s aberrant inflammatory responses 
or microbiota and may even include dietary interventions.  
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The gastrointestinal tract has an array of innate and adaptive defences and tolerogenic 
mechanisms to regulate and maintain the fine balance and control of gastrointestinal 
homeostasis and mucosal immunity. Dietary emulsifiers are detergent-like compounds added 
to foods to evenly distribute fats throughout the mixture creating a more palatable texture 
and consistency. The use of emulsifiers is particularly high in Westernised diets and can be 
found in foods such as mayonnaise, ice-cream and even some processed meats. 
Carboxymethyl cellulose (CMC) is a commonly used emulsifier which stabilises emulsions in 
beverages and foods by reducing the rate of sedimentation. It has been shown that dietary 
emulsifiers can disturb the mucus layer of the gut by altering its physicochemical properties. 
This allows bacterial translocation into the lamina propria, promoting inflammation (1).   
 
It has previously been demonstrated that emulsifier-treated mice show increased intestinal 
bacterial encroachment which correlated with reduced mucus thickness but did not change 
mucin 2 (MUC2) expression, which is required for maintenance of the insoluble mucus 
membrane (2). The administration of relatively low concentrations (1% w/v) of CMC incudes 
low-grade intestinal inflammation in WT hosts and promotes robust colitis in IL-10-/- and TLR5-
/- mice (2). Faecal levels of proinflammatory flagellin and bioactive LPS were also increased in 
emulsifier-treated WT, IL-10-/- and TLR5 -/- mice. Additionally, emulsifiers altered host-
microbiome interactions resulting in polarisation of the microbiota that favours mucolytic and 
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pro-inflammatory activity, promoting intestinal inflammation and leading to the 
manifestation of colitis.  
 
Although the consumption of dietary emulsifiers has not directly been shown to cause 
inflammatory conditions of the gastrointestinal tract, it has been demonstrated that they have 
the potential to alter homeostatic conditions of the gut, promoting the development of 
inflammation. The effects of emulsifier treatment on metabolism and microbiome have been 
well characterised, however, changes to the mucosal immune profile have not been 
determined. Innate lymphoid cells (ILCs) are crucial for the maintenance of intestinal 
homeostasis and the mucosal barrier by responding to effector cytokines in the immediate 
microenvironment, as well as exogenous or endogenous danger patterns (3). Group 3 ILCs 
predominate the gastrointestinal tract and are dependent on RORγT expression and secrete 
IL-17, IL-22 and colony stimulating factor 2. Although considered to be innate, ILCs can 
produce and secrete cytokines that are typically regarded as CD4+ TH cells (3). TREGULATORY cells 
(TREG), typified by their expression of forkhead box P3 (FOXP3) and secretion of suppressive IL-
10 and TGF-β, are crucial for the maintenance of immune tolerance in the gastrointestinal 
tract through their secretion of regulatory cytokines, modulation of antigen-presenting cell 
functions and the alteration in cellular metabolism (4). Furthermore, CD4+ T cells can migrate 
into effector sites of the gut epithelium during inflammation through the expression of α4β7 
integrin and mucosal addressin cell adhesion molecular-1 (5). We aimed to analyse the CMC-
induced changes in innate and adaptive immune regulation and intestinal barrier properties 
in WT healthy control and DSS colitis mice.




Mouse treatments  
Colitis was induced in group-housed male SPF mice with 2% dextran sodium sulfate (DSS) in 
drinking water, as previously described (6). Emulsifier treated mice received daily oral gavage 
of 100 μL 1% carboxymethylcellulose sodium (CMC) for 21 days. The DSS emulsifier group 
completed a course of DSS colitis to coincide with the completion of CMC administration. 
Healthy control mice received no treatments. See figure 1 for a summary of mouse 
treatments.  
Figure 1. Summary of mouse treatments.  
 
Colon histopathological analysis 
Following euthanasia, a 1 cm section of distal colon was dissected and stored in 4% buffered 
formalin at 4°C prior to embedding in paraffin. 5 μm thick sections were stained with 
hematoxylin and eosin (H&E) using standard protocols and 20x images were scored from 
inflammatory and epithelial changes as previously described (7).
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Ussing Chamber studies  
Segments of distal colon were mounted into 0.1 cm2 aperture slides in 5 mL baths with 
oxygenated glucose-fortified Ringers solution for analysis by Ussing chamber as previously 
described (6, 8). 
 
PCR 
mRNA extracted from segments of distal colon was analysed for the expression of sodium-
potassium adenosine triphosphate (Na-K-ATPase) and sodium-potassium-chloride 
cotransporter (NKCC1), relative to the housekeeper EEF2 by quantitative RT-PCR as previously 
described (7). 
 
Flow cytometry  
Colon lamina propria mononuclear cells (LPMCs) were isolated enzymatically as previously 
described (6, 7). Splenocytes and mesenteric lymph node (MLN) cells were isolated by flushing 
with PBS, followed by filtration and centrifugation.  
 
Prior to staining for innate lymphoid cells, single cell LPMC suspensions were cultured with 10 
nm/ml IL-23 and GolgiPlug, overnight. 0.5 x 106 Fc blocked LPMC, MLN cells or splenocytes 
were stained with the extracellular anti-mouse monoclonal antibodies (BD Biosciences) for T 
cells CD45-BV605 (30-F11), CD4-BUV737 (GK-1.5), CD326-BV510 (G8.8), CD25-PE-Cy7 (PC61), 
CD49d-AF647 (R1-2), B7-BB515 (FIB504), CD29-PE (HM β 1-1), CD103-BV786 (M290) and for 
ILC3s CD45-BV605 (30-F11), CD326-BV510 (G8.8), Ly-6G/Ly-6C-BV510 (RB6-8C5), CD11b-
BUV737 (M1/70), CD3-BUV737 (145-2C11), B220-BUV737 (RA36B2), TER-119-BV650 (TER-
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119), NK-1.1-BUV395 (PK136) and FCεRIa-PE-Cy7 (MAR-1, BioLegend) (lineage negative: 
CD326, Ly6G/Ly-6C, CD11b, CD3, B220, FCεRIa, TER119). Cells were stained with intracellular 
anti-mouse monoclonal antibodies following fix/permeation (BD Biosciences): FOXP3-
PECF594 (MF23) for TREG and IFN-γ-AF488 (XMG 1.2), IL-17A-AF647 (TC11-18H10), RORγT-PE 
(Q31-378), T-bet-BV786 (04-46) and GATA3-BV421 (L50-823) for ILC3, following standard 
protocols. 50,000 events per test were analysed using a FACS-Fortessa (BD Biosciences) and 
proportions of live (FVS700, BD Biosciences) singlets were determined using FlowJo as 
described previously (6, 7).  
 
MLN and bone marrow cell stimulations  
Bone marrow cells were isolated by flushing of the femur with PBS, followed by filtration and 
centrifugation. MLN cells and splenocytes were plated at 1 x 105 cells per 200 µL in complete 
media in 96-well U-bottom plates. MLNs were cultured in the presence of CD3/CD28 beads 
(1:4, cell:bead) for 96 hours. Bone marrow cells were cultured in the presence of 1µg/mL 
lipopolysaccharide (LPS). Cultures were centrifuged, the supernatant was collected and stored 
at -80°C until multiplex immunoassay analysis. 
 
Innate and adaptive cytokine concentrations  
Colonic proteins were extracted from a 1 cm segment of distal colon as previously described 
(6, 7). A Milliplex bead-based multiplex immunoassay was used to quantify the colonic 
concentrations of G-CSF, GM-CSF, IFN-γ, IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, IL-
12p40, IL-12p70, IL-13, IL-15, IL-17, IP-10, KC, MCP-1, MIP-1a, MIP-1b, MIP-2, RANTES and 
TNF-α, as per the manufacturer’s instructions. LPS stimulated bone marrow supernatants 
were assessed for the innate cytokines IL-1β, IL-6, IL-10, CXCL2, CXCL10, CCL2, CCL3 and TNF-
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α, as per the manufacturer’s instructions. CD3/CD28 stimulated MLN cells were assessed for 
the adaptive cytokines IFN-γ, IL-10, IL-13, IL-17, IL-2, IL-4, IL-5 and TNF-α, as per the 
manufacturer’s instructions. Plates were read and analysed using a Luminex MAGPIC with 
xPONENT software. Concentrations were normalised to total protein content as determined 
by a BCA assay, as previously described (6, 7). Limits of detection were CXCL10 (48.0 pg/ml), 
CCL2 (17.1 pg/ml), CCL3 (10.0 pg/ml), CXCL2 (16.7 pg/ml), G-CSF (72.2 pg/ml), GM-CSF (14.8 
pg/ml), IFN-γ (35.2 pg/ml), IL-1a (32.8 pg/ml), IL-1β (18.2 pg/ml), IL-2 (8.3 pg/ml), IL-4 (7.5 
pg/ml), IL-5 (8.5 pg/ml), IL-6 (21.0 pg/ml), IL-7 (26.2 pg/ml), IL-9 (439.0 pg/ml), IL-10 (23.1 
pg/ml), IL-12p40 (192.6 pg/ml), IL-12p70 (11.4 pg/ml), IL-13 (61.4 pg/ml), IL-15 (154.2 pg/ml), 
IL-17 (16.5 pg/ml), CXCL10 (26.9 pg/ml), CXCL1 (26.0 pg/ml), CCL2 (14.7 pg/ml), CCL3 (17.2 
pg/ml), CCL4 (113.9 pg/ml), CCL5 (73.8 pg/ml) and TNF-α (44.4 pg/ml). 
 
Statistical analysis  
All data has been expressed as mean ± SEM in all cases. The significance of the results was 
determined by one-way ANOVA with a Bonferroni post-hoc. Differences where P<0.05 were 
deemed statistically significant. Multiple comparisons were only made for groups of interest: 
control vs emulsifier, control vs DSS colitis, DSS colitis vs emulsifier and DSS colitis and 








Macro and microscopic inflammatory changes  
CMC treatment increased DSS induced colitis weight loss, at end point (P<0.001), with no 
change in microscopic damage score (P>0.05) (figure 2). DSS colitis induced significant weight 
loss at end point (P<0.001), colon contraction (P<0.001) and histological microscopic damage 
score (P<0.001), relative to controls. Administration of CMC had no significant effect on colon 
length or weight loss, (P>0.05), but induced histological microscopic damage, compared to 
















Figure 2. CMC treatment exacerbates DSS colitis. A) CMC treatment worsens DSS colitis weight 
loss (N=15/group). B) Colon length is decreased in DSS colitis, which did not change with CMC 
treatment (N=15/group). Ci) CMC treatment increases colonic microscopic damage scores, but 
not to the same extent as DSS colitis (N=6/group). Cii) Representative images of colon histology. 
# is CMC vs DSS, * is CMC vs CMC+DSS, $ is DSS vs CMC+DSS. *P0.05, **P<0.01, ***P<0.001. 
Scale bar = 200 !m. 
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Epithelial barrier properties 
DSS colitis induced a significant decrease in TEER and short circuit current, relative to controls 
(P<0.01) (figure 3). This effect on TEER was abolished in the presence of CMC (P<0.01), with 
no change in short circuit current (P>0.05). DSS colitis significantly decreased forskolin 
(P<0.001) and carbachol (P<0.05) induced epithelial short circuit changes, relative to health. 
DSS colitis induced a decrease in the colonic expression of Na-K-ATPase, which was abolished 
in the presence of CMC (P<0.01). CMC treatment had no effect on TEER, baseline short circuit 
current or secretagogue-evoked changes to short circuit current, Na-K-ATPase or NKCC1 
expression, relative to controls (P>0.05). 
Figure 3. Epithelial responsiveness. A) Baseline TEER (N=6/group). B) Baseline short circuit current 
(N=6/group). C) Carbachol-evoked changes in short circuit current (N=6/group). D) Forskolin-evoked 
changes in short circuit current (N=6/group). E) Colonic expression of Na-K-ATPase (N=6/group). F) 
Colonic expression of NKCC1 (N=6/group). *P<0.05, **P<0.01, ***P<0.001.  
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Innate and adaptive mediators  
DSS colitis induced increased secretion of colonic CCL2, CCL5 and CXCL10 (P<0.05, P<0.05, 
P<0.01), which were unchanged in the presence of CMC (P>0.05) (figure 4). However, CXCL1 
was significantly increased in DSS colitis in the presence of CMC (P<0.01). CMC treatment did 
not induced changes in colonic chemokine secretion, relative to controls (P>0.05).
Figure 4. Colonic concentrations of innate chemokines. N=6/group. *P<0.05, **P<0.01, ***P<0.001.  
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DSS colitis induced significant increases in colonic IL-1α (P<0.05), which was unchanged with 
CMC treatment (P>0.05) (figure 5). DSS colitis when treated with CMC resulted in significant 
increases in IL-1β (P<0.01), IL-6 (P<0.01), IL-12p40 (P<0.05), IL-12p70 (P<0.05), G-CSF 
(P<0.001) and GM-CSF (P<0.05). CMC treatment increased colonic secretion of IL-12p40 
(P<0.001), with no changes in other innate cytokines, relative to controls (P>0.05).DSS colitis 
in the presence of CMC increased colonic secretion of IL-13 (P<0.001) but did not alter the 
secretion of adaptive cytokines in controls (P>0.05) (figure 6).
Figure 5. Colonic concentrations of innate cytokines. N=6/group. *P<0.05, **P<0.01, ***P<0.001.  



















CD3/CD28 stimulated MLN cell cytokine secretion 
DSS colitis induced CD3/CD28 stimulated MLN cells to secrete increased IFN-γ (P<0.01), IL-2 
(P<0.05), IL-5 (P<0.01), IL-10 (P<0.001) and IL-13 (P<0.05), relative to controls (figure 7). CMC-
treated DSS colitis resulted in the increased secretion of IL-2 (P<0.05), IL-4 (P<0.05), IL-17 
(P<0.001) and TNF-α (P<0.01) from CD3/CD28 stimulated MLN cells, compared to DSS colitis. 
CMC treatment did not alter the cytokine secretion of CD3/CD28 stimulated MLN cells 
(P>0.05). 
Figure 6. Colonic concentrations of adaptive cytokines. N=6/group. *P<0.05, **P<0.01, ***P<0.001.  



















LPS stimulated bone marrow cell cytokine and chemokine secretion  
DSS colitis induced LPS-stimulated bone marrow cells to secrete increased IL-1β (P<0.01), IL-
10 (P<0.001), CCL3 (P<0.001), CXCL2 (P<0.05) and CXCL10 (P<0.001), relative to controls 
(figure 8). CMC-treated DSS colitis resulted in the decreased LPS stimulated bone marrow 
secretion of IL-1β (P<0.05), IL-10 (P<0.001) and CXCL10 (P<0.001), but increased CCL3 
(P<0.001), CXCL2 (P<0.05) and TNF-α (P<0.05), relative to DSS colitis. CMC-treatment 
decreased the secretion of IL-1β (P<0.05), IL-6 (P<0.01), CCL3 (P<0.001) and CXCL2 (P<0.05) 
from LPS stimulated bone marrow cells, relative to controls .
Figure 7. CD3/CD28 stimulated MLN cytokine secretion. N=6/group. *P<0.05, **P<0.01, ***P<0.001.  






DSS colitis increased proportions of colonic TREG cells (P<0.001), which was abolished when 
treated with CMC (P<0.001). CMC treatment did not induce changes in TREG populations in 
controls (P>0.05). DSS colitis did not alter the percentage of CD4+ T helper cells expressing the 
integrins α4β7, α4β1 or αEβ7, when compared to controls (P>0.05); however, expression of α4β7 
was increased when treated with CMC (P<0.05). CMC treatment induced increased expression 
of α4β7 (P<0.05), α4β1 (P<0.01) and αEβ7 (P<0.001), relative to controls. DSS colitis decreased 
colonic proportions of ILC3s, relative to controls (P<0.001), which was abolished in the 
presence of CMC (P<0.01). CMC treatment decreased colonic ILC3 proportions, relative to 
controls (P<0.001). 
Figure 8. LPS stimulated bone marrow cytokine secretion. N=6/group. *P<0.05, **P<0.01, ***P<0.001.  






Figure 9. Proportions of CD4+ LPMCs expressing integrin α4β7 (Ai), α4β1 (Aii) or αEβ7 (Aiii). B) 
Proportions of colonic ILC3s. C) Colonic proportions of TREG cells. N=6/group. *P<0.05, **P<0.01, 
***P<0.001.  




We aimed to elucidate the immune and epithelial barrier changes induced by CMC 
administration in DSS colitis and healthy controls. Our findings demonstrate that CMC 
administration alone is not sufficient to induce profound innate or adaptive immune 
activation or changes to intestinal epithelial permeability. Treatment of WT mice with CMC 
prior to and during DSS colitis induces a more severe and prolonged disease course, with 
amplified innate and adaptive immune responses, without changes to intestinal epithelial 
permeability. This suggests that dietary additives such as CMC may have the potential to 
provide an environment which promotes intestinal inflammation in human IBD, but not 
necessarily initiate inflammation in health. Our results support previous studies examining the 
effects of CMC to the microbiota and intestine, contributing to intestinal inflammation (1,2). 
 
CMC treatment induces a more severe DSS colitis course 
Despite no robust induction of innate or adaptive immune mechanisms, mice pre-treated with 
CMC lost more body weight at a faster rate during DSS colitis compared to DSS alone. Just 
after 3 days of treatment with DSS, CMC-pre-treated mice showed a steep decline in 
percentage original body weight, which persisted until the completion of the treatment 
course. Typically, we observe these changes and other symptoms of colitis 3-4 days later in 
mice treated with DSS only (6). This suggests that CMC increases the susceptibility of DSS 
colitis in mice, supporting previous studies which showed CMC-induced degradation of the 
intestinal mucus barrier promotes of inflammation.
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CMC administration does not alter epithelial barrier properties in control or DSS colitis mice  
Although CMC can alter properties of the intestinal mucus layer, leading to increased exposure 
of the intestinal contents such as the microbiota to the intestine, it is not known how this 
alters epithelial barrier function. Our findings demonstrate that CMC administration in control 
or DSS colitis mice does not alter the secretory capacity of the colonic epithelium, including 
the transcellular movement of Cl-. Baseline ion transport and secretagogue-provoked Cl- 
secretion were not altered by CMC treatment, despite an induction in innate and adaptive 
immune responses in CMC-treated DSS group relative to DSS colitis alone. However, DSS colitis 
alone reduced baseline ISC and carbachol-provoked change in ISC relative to health, indicating 
that DSS treatment induces changes in intestinal epithelial barrier function. These results 
suggest that DSS colitis leads to a saturated reduction in epithelial barrier permeability, 
restricting deficits in epithelial Cl- secretion which may be induced by CMC administration in 
DSS despite an increase in immune activation. Carbachol-provoked changes in ISC are largely 
due to activity by Na-K-ATPase and NKCC1. Epithelial sodium channels (ENaC), sodium-
hydrogen antiporter 3 (NHE), Na-K-ATPase and NKCC have been shown to be downregulated 
in colonic biopsies from active IBD patients and in acute TNBS colitis (9-11). However, the 
effect we observed is unlikely to be caused by ENaC and NHE as they were blocked by 
amiloride in our study. Interestingly, the changes in carbachol-provoked Cl- secretion were not 
due to changes in the expression of Na-K-ATPase or NKCC in our study. In fact, administration 
of CMC in DSS colitis preserved the expression of Na-K-ATPase, relative to DSS colitis alone. 
Further investigations into the mechanisms of CMC-induced epithelial barrier function in DSS 
colitis are required as increased Cl- secretion induces diarrhoea, which is a common symptom 
of IBD.
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Induction of innate and adaptive immune mechanisms in CMC-treated DSS colitis 
Our results indicate induction of innate and adaptive immune responses in CMC-treated DSS 
colitis, relative to DSS colitis alone. This was characterised by striking increases in the secretion 
of colonic IL-1β and IL-6.  Increased secretion of IL-1β and IL-6 may be due to the amplified 
attraction of macrophages via CXCL1. Interestingly, IL-6 secretion can be increased in response 
to microbial PAMPs, suggesting an increased translocation of the microbiota or microbial 
secreted products into the lamina propria (12). Colonic IL-13 secretion was also significantly 
increased, as DSS colitis classically produces a TH2-like immune response (13).  LPS stimulated 
bone marrow cell secretion also revealed polarisation of innate immune responses through 
the increased secretion of CCL3, CXCL2 and TNF-α in CMC-treated DSS colitis, relative to DSS 
colitis. This suggests that immature bone marrow cells in CMC-treated DSS colitis are more 
primed to attract innate immune cells, despite not migrating from the bone marrow 
microenvironment. Interestingly, CD3/CD28 stimulated MLN cells show enhanced TH1, TH2 
and TH17 immune activation through the increased secretion of IL-2, IL-4 and IL-17 in CMC-
treated DSS colitis, relative to DSS colitis. DSS colitis has previously been described as a TH1-
TH17-mediated acute inflammatory response which shifts to a predominant TH2-mediated 
inflammatory response in chronic disease, which may explain the mixed TH responses that we 
observed (13). Alternatively, these mixed immune responses may be due to asynchronous 
stimulation from CMC-induced breaks in the mucosal barrier, subsequent bacterial 
translocation into the lamina propria and DSS colitis. CMC-treatment abolished the increase 
in TREG cells that was seen in DSS colitis perhaps due to the gradual exposure of luminal 
antigens due to CMC-induced break in mucus barrier. 
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There was also a greater induction of T helper cells in CMC-treated DSS colitis, shown by the 
increased migration of α4β7+ T helper cells to the colon. Interestingly, there was also an 
increase in T helper cell migration to the colon as a result of CMC-treatment, which was not 
accompanied by an increase in adaptive cytokine secretion. The increase in gut-homing T 
helper cells in response to CMC treatment in controls may indicate early adaptive immune 
activation brought on by retinoic acid secretion by activated dendritic cells (14). This may 
occur due to CMC-induced alterations to the mucosal barrier, as shown in previous studies 
(1). 
 
ILC3 populations were significantly decreased in the lamina propria in CMC-treated mice, 
relative to controls, suggesting a loss of tolerance and dysregulation of intestinal homeostasis. 
ILC3s are crucial for the maintenance of intestinal homeostasis and oral tolerance, particularly 
through their secretion of IL-22 which acts on non-hematopoietic cells, including intestinal 
epithelial cells to maintain crypt stem cells, promote the differentiation of mucus-producing 
goblet cells as well as stimulating Paneth cells to secrete antimicrobial peptides (15). Loss of 
beneficial ILC3 functions as well as dysregulation of ILC3 mechanisms have been reported in 
murine and human IBD, which results in an inflammatory phenotype, exacerbating disease 
(16). Interestingly, the loss of ILC3s in the lamina propria was slightly conserved in CMC-
treated DSS colitis when compared to DSS colitis alone.  
 
In summary, our results indicate that the commonly used dietary emulsifier CMC exacerbates 
DSS colitis but does not induce significant immune activation or intestinal damage in healthy 
controls. This suggests that dietary additives such as CMC may have the potential to provide 
an environment which promotes intestinal inflammation in human IBD, but not necessarily 
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initiate inflammation in health. Our results support previous studies examining the effects of 
CMC to the microbiota and intestine, contributing to intestinal inflammation (1, 2). A 
limitation of this study may be that although Bonferroni corrections were applied within each 
test, due to the number of tests performed in this study, it may be prudent to adjust the P-
value cut off to <0.001 (***) to account for the overall risk of statistical error when comparing 
between groups. Furthermore, concentrations of emulsifiers used in food products are not 
reported, therefore a limitation of this study may be the emulsifier dosing amount and timing 
used which may or may not represent typical human consumption. 
 
In recent decades there has been a steady increase in the consumption of the Westernised 
diet and food additives such as emulsifiers, many of which were not strenuously tested when 
approved for use and were given GRAS status. As multiple food additives are frequently and 
concurrently consumed, further research is required as to whether food additives such as CMC 
have an additive or synergistic effect. Furthermore, human clinical trials on dietary emulsifiers 
and other food additives are required to fully understand their physiological effects and 
impacts on the microbiome.   
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Chapter 4 Advances in imaging specific mediators of inflammatory 
bowel disease: a review  
 
4.1 Statement of authorship




Inflammatory bowel disease (IBD) is characterised by chronic remitting and relapsing 
inflammation of the lower gastrointestinal tract. The aetiology underlying IBD remains 
unknown, but it is thought to involve a hypersensitive immune response to environmental 
antigens, including the microbiota. Diagnosis and monitoring of IBD is heavily reliant on 
endoscopy, which is invasive and does not provide information regarding specific mediators. 
This review describes recent developments in imaging of IBD with a focus on positron emission 
tomography (PET) and single-photon emission computed tomography (SPECT) of 
inflammatory mediators, and how these developments may be applied to the microbiota. 
 
4.3 Introduction  
 
Inflammatory bowel disease (IBD) is an inflammatory disorder of the gastrointestinal (GI) tract 
that impacts substantially on quality of life. The causes of inflammation in IBD remain 
unknown but are thought to involve a hypersensitive immune response to the intestinal 
microbiota. IBD is commonly associated with dysbiosis, but it remains unknown whether 
dysbiosis is a cause or consequence of inflammation. Diagnosing and monitoring IBD is heavily 
reliant on endoscopy, which is an invasive technique that requires bowel preparation and 
typically, also anaesthesia.
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Although generally well tolerated, endoscopy noticeably impacts on patient quality of life and 
does not provide any direct information regarding the role that specific mediators contribute 
toward inflammation. Therefore, new technologies are required that are sensitive enough to 
grade disease severity, are non- or only minimally invasive, and can be optimised for the 
detection of specific mediators. Recent developments in positron emission tomography (PET), 
particularly with the use of antibody-conjugated tracers, have demonstrated success in 
cancers, but have only recently been adapted to IBD. This review summarises the current 
advances of these technologies in IBD, how they have been used to detect specific mediators 
of inflammation, and their potential to image microbiota. 
 
4.4 Inflammatory bowel disease 
 
IBD is a collection of debilitating idiopathic diseases characterised by chronic inflammation of 
the lower gastrointestinal tract that have a remitting and relapsing disease course. The 
cause(s) of IBD remain unknown; however, they are thought to involve aberrant immune 
responses to environmental stimuli in people with a complex genetic predisposition. The 
global prevalence of IBD is estimated to be 0.3% and is widely regarded as increasing (1). The 
relatively recent increase in the incidence of IBD is perplexing and highlights the likely 
importance of yet-to-be-determined environmental factors in its aetiology. IBD is typically 
diagnosed in adolescence and early adulthood; however, it can also occur in the very young 
paediatric population, and approximately 25% of paediatric cases present prior to reaching 10 
years of age (2,3). It is currently unclear whether the mechanisms underlying IBD differ 
between the very young paediatric and late adolescent populations. However, it is probable 
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that yet-to-be-characterised genetic factors feature more prominently in the very young, as 
the length of time of exposure to environmental factors is unlikely to be long enough to 
sensitize the developing immune system. IBD is a chronic disease in paediatric and adult 
populations; however, the paediatric population is particularly vulnerable to the 
consequences of IBD, including impacts on growth and development, bone health, and 
psychosocial function and development (2). 
 
There are two major subtypes of IBD: Crohn’s disease (CD) and ulcerative colitis (UC), which 
can typically be distinguished by pathological and histological differences. Inflammation in UC 
is typically restricted to the mucosal layer of the colon and progresses in a contiguous manner. 
CD differs in that it is characterised by transmural skip lesions that can occur anywhere in the 
GI tract but are typically located in the ileum with and without involvement of the colon. The 
initiating factors and inflammatory aspects are likely to differ between CD and UC given the 
distinctions between their pathology but are only poorly understood relative to what is known 
regarding how inflammation is perpetuated. This increased understanding has led to the 
relatively recent development of biologic drugs targeting specific immune mechanisms, most 
prominently the cytokines TNF-α, interleukin (IL)-12 and -23, and integrins involved in the 
migration of immune cells into the GI tract, including α4β7 (4). These treatments and other 
nonspecific immune suppressants can be beneficial in IBD; however, treatment gaps remain 
due to intolerance, incomplete efficacy, and side effects of current therapies, leading to a 
disease course characterised by variable periods of remission and relapse. Prognostic 
indicators of relapse in IBD are only poor, and therefore patients are required to undertake 
constant surveillance, typically via endoscopy. Severe persistent or relapsing symptoms also 
lead to fibrosis and stricture in >30% of CD and approximately 5% of UC patients (5). 
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Intestinal fibrosis and stricture occurs as a result of excessive deposition of extracellular matrix 
proteins that accumulate following tissue remodeling and lead to serious complications, 
including obstructions (6). No drugs are currently clinically available to treat fibrosis and 
stricture, and therefore these cases often lead to surgery, which can be curative for UC 
(withstanding complications), but is not curative for CD (7). This high rate of surgery highlights 
the ongoing need for a deeper understanding of the mechanisms involved in initiating and 
perpetuating inflammation in IBD. 
 
4.5 Imaging IBD: current approaches  
 
Treatments for IBD depend on clinical severity, which is typically assessed by endoscopy. The 
gastrointestinal mucosa is directly imaged by endoscopy for assessment of disease stage and 
monitoring, and when forceps are attached, which allows for the collection of biopsy material 
for analysis of pathology and mechanistic studies. Endoscopy can differentiate between UC 
and CD in the majority of cases (8). However, endoscopic approaches have limitations, as the 
quality of results is operator-dependent, and it may not be sensitive enough for assessment 
of clinical severity in some cases. Furthermore, endoscopic imaging is restricted to the 
superficial mucosal layers of the intestine and therefore provides no information regarding 
inflammatory damage to the deeper layers of the intestinal wall, the degree of muscle 
thickness, or the diameter of the lumen. Finally, a major limitation of endoscopy is the 
difficulty in reaching the small intestine, due to the distance needed to be covered and the 
complexities of intestinal anatomy with its multiple loops and folds. These limitations are 
particularly relevant to the paediatric population, who are sensitive to perforation of the 
intestinal wall and risks associated with sedation (9).
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A number of novel imaging technologies are emerging that complement or may even replace 
endoscopy as the gold standard for clinical diagnosis, as recently reviewed in detail (10,11). 
Chromoendography involves the application of dyes onto the mucosa, improving endoscopic 
characterization of lesions and neoplasia, and has the potential to correlate with histological 
damage, although the latter remains controversial (12). Confocal laser endomicroscopy and 
endocytoscopy combine high-resolution microscopic imaging with endoscopy, and again, are 
primarily used to detect colonic dysplasia and neoplasia (13). Wireless capsule technologies 
may circumvent the limitations that endoscopy has in accessing difficult-to-reach areas of the 
small intestine. While these capsules provide high-resolution imaging, they have similar 
limitations to standard endoscopy regarding assessment of inflammatory damage to the 
deeper layers of the colon wall and may also require surgery for removal when stricture occurs 
(14,15). 
 
Less invasive imaging technologies include barium X-rays, ultrasound, magnetic resonance 
imaging (MRI), computed tomography (CT), PET, and single photon emission computed 
tomography (SPECT). Barium X-rays provide excellent visualisation of the bowel and can reveal 
thickening of the bowel wall, but are not recommended in patients with severe inflammation 
due to the risk of complications such as toxic megacolon, and while they have been 
traditionally used to assess stricture location and severity, this is largely being replaced by CT 
and MRI (2). Ultrasound, MRI, CT, PET, and SPECT are minimally invasive relative to endoscopy 
and offer the additional benefits of visualizing planes through the colon wall and 
extraintestinal manifestations. Bowel ultrasound has some attractions as a non-invasive 
diagnostic tool for IBD, including relative inexpensiveness, high accuracy in CD, and ease of 
use.
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It has recently been used to reveal ulcer location and severity in adult CD, and ultrasound and 
MRI are currently the preferred tools for assessment of paediatric perianal abscesses and 
fistulas (16,17,18). However, ultrasound is highly operator-dependent and its accuracy is 
sensitive to anatomical location, as it is reduced for detecting ulcers in the jejunum and rectum 
(17,18). MRI is currently the imaging technique of choice for follow-up of CD patients due to 
its lack of ionising radiation. Notably, MRI can differentiate between normal and pathological 
sections of the bowel by analysis of changes in bowel wall thickness (19). Recent 
developments with MRI and CT include using them to assess fibrosis and stricture. 
Gadolinium-contrasted MRI has recently been shown to reliably predict severe fibrosis in CD 
and, interestingly, also revealed that areas of fibrosis often coexist with inflammation within 
the same intestinal segment (20). A recent comprehensive review of the use of PET/SPECT for 
IBD diagnosis, prognosis, and follow-up indicated that 2-deoxy-2-(18F)fluoro-D-glucose (18F-
FDG) coupled with CT has the highest accuracy for detecting inflammation in IBD (11). 18F-FDG 
is a radiolabelled glucose analogue that detects tissue glucose metabolism and has been the 
tracer of choice for PET studies for decades; however, radiolabelled leukocytes are also 
typically used to assess GI inflammation. Indeed, SPECT of technetium-99m (99mTc)-leukocytes 
was shown nearly two decades ago to accurately assess the extent and severity of disease for 
people with severe UC, correlating with endoscopic and histological findings (21). However, 
limitations with radiolabelled leukocytes exist, including a relatively extensive protocol 
required for working up the cells, risks of cross-contamination, and importantly, the 
nonspecific nature of the tracer. Only limited information exists regarding the use of PET, 
SPECT, or CT for paediatric IBD, although the combination of 18F-FDG PET/CT has been 
suggested to be the most reliable due to its improved anatomical mapping (22). 
Importantly, 18F-FDG dosing and imaging protocols are yet to be standardised for PET of 
paediatric patients, highlighting the need for more studies in this area.
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Nonetheless, the potential benefits of PET/CT in the paediatric IBD population were 
highlighted in the first published case, where scans in a 12-year-old child revealed diffuse 
heterologous uptake of 18F-FDG in the gut wall, particularly in the stomach (23). CT confirmed 
that the uptake was focal, and endoscopy revealed ulceration of the gastric wall, with an 
ensuing diagnosis of gastric and intestinal CD. It is important to note that while these 
technological advances are welcome for IBD management, none of them currently target 
specific mediators. This highlights the need for the development of new imaging technologies 
that are highly sensitive, quantitative, and able to provide longitudinal data in real time, but 
are also only minimally invasive. 
 
4.6 Imaging inflammatory mechanisms in IBD: which targets to choose? 
 
4.6.1 Immune targets  
 
Inflammation is central to IBD; however, much remains to be understood regarding the causes 
of inflammation in humans. It is currently thought that inflammation in IBD is driven by a loss 
of immune tolerance to autologous proteins in the colon wall and foreign antigens in the 
lumen, including the microbiota. This initiates a cascade of cytokines and chemokines which 
cause an influx of immune cells, as comprehensively reviewed elsewhere (24,25). Immune 
cells are attracted to sites of inflammation by chemokines and also by upregulated expression 
of “gut-homing” integrins on the cell surface, including α4β7 (26). Subsequent inflammatory 
lesions and damage to the epithelial wall and deeper layers of intestinal tissue result in the 
production of damage-related mediators during active disease, which progresses 
Chapter 4 Imaging inflammatory mediators 
 91 
toward mediators related to tissue-remodeling and wound healing as disease improves 
toward remission, but also toward mediators associated with fibrosis after repeated or 
extended periods of inflammation. The immunological basis for the differences in 
pathophysiology of UC and CD are not clear, and while it is suggested that CD is driven by a 
TH1/TH17-type immune response and UC is mediated by a TH2-type immune response (↑ IL-
5, IL-13) that is atypical as IL-4 is not involved, much of the evidence for this generalization 
results from animal models. Furthermore, while there is evidence supporting a genetic 
predisposition, large-cohort IBD human studies indicate this is clearly complicated and 
contains loci that coexist in both CD and UC, but also other loci that are not shared (27,28). 
Environmental factors are thought to contribute to IBD; however, evidence for or against 
these are heavily biased toward animal studies and are yet to be definitively determined in 
humans. The best evidence supporting an aggravating role for specific immune mediators in 
IBD is the success of several biologic medications targeting the cytokines TNF-α and IL-12/23 
and the gut-homing integrin α4β7. This success is tempered by the lack of efficacy of therapies 
directed against IL-17, IFN-γ, and IL-13, amongst others (29). However, as failure of biologics 
in the clinic can be related more to toxicity and side effects than to a lack of involvement of 
their target, tracers directed to these cytokines may still prove to be valuable for imaging. 
With this in mind, new immune modulators are currently undergoing clinical trials, including 
those targeting specific cytokines such as IL-6, inhibitors of intracellular pathways including 
Janus kinases (JAK), and mediators related to tissue remodeling and fibrosis, such as matrix 
metalloproteases (MMP) (29). 
 
Recent advances in two-photon laser scanning microscopy have enabled in vivo imaging of 
deep visceral tissues and immune cells in particular, indicative of the potential for this 
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technique to provide preclinical evidence prior to relatively expensive immuno-PET studies. 
Two-photon laser scanning microscopy was instrumental in identifying goblet cell-associated 
passage (GAPs) as the major mechanism for delivering luminal antigens to dendritic cells in 
the small intestine in health (30). Interestingly, GAPs only appear in the colon following the 
disruption of microbe-sensing pathways, highlighting a potential role in IBD (31). We have 
recently applied two-photon laser scanning microscopy to investigate immune cell migration 
in the trinitro benzene sulphonic acid (TNBS) model of colitis, demonstrating in vivo that not 
only are immune cells in very close apposition to nerves within the colon wall, but also that 
myeloid cell infiltration is increased in TNBS colitis (32). This technique can be easily combined 
with reporter mice and promises to increase the understanding of the mechanisms involved 
in immune cell migration from blood vessels into the lower GI tract in IBD. 
 
4.6.2 Microbiota  
 
Recent improvements in high-throughput “omics” technology have also revealed the 
involvement of the microbiome in IBD. The general consensus indicates that active IBD is 
characterised by an overall loss of diversity coupled with a dysbiotic phenotype primarily 
depicted by elevated Proteobacteria and decreased Firmicutes, although inconsistencies 
between studies remain (33,34,35). Functionally, the major classes of bacteria affected relate 
to the production of short-chain fatty acids (e.g., Faecalibacerium prausnitzii), bacteria with 
mucolytic activity (e.g., Ruminococcous torques), and sulfate-reducing species 
including Desulfovibrio (36,37,38). While this dysbiotic composition may contribute to disease 
progression through dysregulated epithelial barrier function and aberrant immune 
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signalling, it is currently contentious whether dysbiosis itself causes IBD or simply reflects the 
disease course (39). 
 
Uncovering the compositional shifts in the microbiome has undoubtedly increased our 
understanding of its role in disease initiation, progression, and relapse. However, techniques 
such as 16S pyrosequencing are inherently limited by the variations that exist in aspects of 
their methodology, including inconsistent or incomplete reference libraries, the unknown 
impact of batched analyses, non-standardised statistical analyses, and an inability to 
adequately appreciate the heterogeneity in the microbiome (40). This is further confounded 
by the fact that the annotation is based on putative association of the 16S rRNA gene, with a 
taxon defined as an operational taxonomic unit (OTU) (41,42). Although whole-genome 
shotgun sequencing has enhanced our ability to define species taxa with more accuracy, it 
remains an expensive alternative to 16S and requires significantly greater data analysis (40). 
As such, conclusions regarding the functional implications of compositional shifts remain 
difficult to draw, relying on metagenomic inference using phylogenetic investigation of 
communities by reconstruction of unobserved states (PICRUSt). Nonetheless, changes in 
microbiota composition offer the intriguing potential to image microbiota as markers of 
disease severity in IBD. 
 
4.7 PET and SPECT of specific mediators in IBD 
 
PET of radioisotope-labelled antibodies is currently being used in multiple clinical trials in 
cancer to tailor personalised therapies based on specifically targeted diagnostic tests (43,44). 
However, immuno-PET of IBD is currently limited to preclinical studies. When deciding which 
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inflammatory mediators to image in IBD, it is firstly important to understand which immune 
processes are likely to be involved in the model of choice, and secondly to understand what 
the information will provide regarding the initiating, perpetuating, and resolving phases of 
colitis. 
 
4.8 Imaging colitis in animal models  
 
Animal models of colitis have significantly improved our understanding of how inflammation 
develops and perpetuates, highlighting roles for both the innate and adaptive arms of the 
immune response. There are currently numerous animal models of IBD, including colitis that 
develops due to primary genetic defects, adoptive transfer of activated immune cells, or is 
chemically induced (45). Importantly, most of these models progress directly from acute 
through to fulminant colitis and therefore are not useful for investigating pathways involved 
in the resolution of inflammation and tissue remodeling. Nuclear imaging of colitis has so far 
relied upon two models of chemically induced colitis: the TNBS model and the dextran sulfate 
sodium (DSS) model. TNBS is administered by enema and inflammation is therefore restricted 
to the colon. TNBS is a hapten; it is not directly toxic, but instead binds to autologous proteins 
and luminal microbiota, turning them immunogenic. The colitis that develops is transmural, 
involves an IL-12-driven TH1/TH17-type response, and is therefore considered to model 
aspects of inflammation associated with CD (46). DSS differs as it is directly toxic to epithelial 
cells and, when administered by the oral route in drinking water, results in a colitis that takes 
longer to develop than TNBS. DSS colitis is considered to model aspects of inflammation 
associated with UC as the colitis results from direct damage to the epithelial layer and is not 
as deep as that which occurs with the TNBS model. While animal models are useful for 
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emphasizing the importance of specific mediators and mechanisms, it is important to note 
that findings from animal models can be difficult to translate to human IBD. This is common 
with most chronic diseases that have a remitting and relapsing course due to the involvement 
of multiple and overlapping pathways that are intertwined with disease stage as inflammation 
progresses and regresses, highlighting the requirement for extensive validation in human 
subjects. 
 
4.9 PET and SPECT of immune mediators in colitis  
 
Cell-secreted immune mediators are generally classified as chemokines or cytokines, with 
chemokines mediating cell attraction and cytokines mediating immune responses. Table 
1 provides an overview of PET/SPECT studies of immune mediators in human IBD and animal 
models of colitis. The first study investigating whether radiolabelled antibodies are efficacious 
for imaging colitis was disappointing, as uptake of 111In-labelled IgG was substantially lower 
than 111In-labelled leukocytes, the gold standard at the time, and also the newly 
developed 111In-labelled liposomes in TNBS-colitic rabbits (47). While imaging of liposomes 
and leukocytes enabled grading of inflammation, the contrast provided from IgG labelling was 
not sufficient for this to occur. This result was not surprising given the large abundance of IgG 
in circulating blood and its relative non-selectivity for colitis. Interleukin (IL)-8, more recently 
renamed CXCL8, is a chemokine produced by innate immune cells, but also cells in other 
tissues, including epithelial cells and endothelial cells. IL-8 is primarily involved in attracting 
neutrophils to inflammatory sites, but also attracts other granulocytes, including mast cells. 
Colonic inflammation in TNBS-treated rabbits was detected more readily with 99mTc-labelled 
IL-8 than 99mTc-labelled granulocytes (48). Furthermore, the severity of inflammation was also 
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able to be graded with 99mTc-IL-8, but not with 99mTc-granulocytes. More recently, IL-8 was 
labelled with 99mTc for SPECT studies and was found to have higher sensitivity for detecting 
inflammation than endoscopy in a large clinical study of people with IBD, although specificity 
was lower than for endoscopy (49).  
TNF-α is a cytokine that is secreted by a range of immune cells from both the innate and 
adaptive arms of the immune response and is produced in large amounts in many 
autoimmune diseases, including IBD. Neutralising TNF-α with antibodies, for example 
infliximab, has proven success in treating IBD (50,51). In preclinical studies, 99mTc-labelled 
infliximab was able to discriminate between moderate and severe colonic inflammation in 
TNBS-treated rats (52). However, enthusiasm for infliximab as a tracer in preclinical studies 
was hampered by high background uptake in healthy control rats. This study is of importance 
as it not only revealed TNF-α mediated inflammation, but it also demonstrated target 
specificity of a clinically useful drug for IBD. This is also particularly significant given the 
increased development of biologics, particularly antibody-based therapies, but also the 
relatively recent expansion of personalised medicine and theragnostic approaches toward 
treating disease.
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4.10 Imaging immune cells in colitis  
 
The DSS colitis model is the most commonly used model to image immune cells in colitis. Table 
1 provides an overview of PET/SPECT studies of immune cells in human IBD and animal models 
of colitis. The integrins α4 and β7 form a heterodimer (α4β7) which specifically directs the 
migration, or homing, of immune cells to the gastrointestinal tract via interactions with its 
ligand, the addressin MAdDCAM-1 (26). Targeting this pathway has proved successful in IBD 
with the recent development of vedolizumab, a monoclonal antibody that blocks α4β7 (56). 
Uptake of 64Cu-labelled β7 antibodies is increased in DSS-colitic mice relative to healthy 
controls and also to 64Cu-labelled IgG isotype negative control, indicating the potential for 
β7 as a tracer for human IBD (53). However, high levels of background were also observed in 
nontarget organs including the small intestine and stomach, prompting the development of 
antibody fragments. In the same model, uptake of 64Cu-labelled β7 antibody fragments was 
superior to both whole 64Cu-labelled β7 antibodies and 64Cu-labelled α4β7, suggesting that 
antibody fragments may provide enhanced signalling of inflammation in IBD compared to 
whole antibodies (54). The concept of increased sensitivity with small antibodies has recently 
been validated in cancer biology and in inflammation. 18F-labelled antibody fragments 
directed against the antigen-presenting complex major histocompatibility complex (MHC)II 
were much more sensitive than standard 18F-FDG in detecting xenoplanted tumours, even 
detecting tumours when growth was neither palpable nor visible (57). Furthermore, 18F-
labelled antibody fragments directed against CD11b detected complete Freund’s adjuvant 
(CFA)-induced inflammation in the mouse paw much earlier than standard 18F-FDG (57). Most 
recently, 89Zr-labelled antibody fragments against the THELPER marker CD4 were observed to 
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have higher uptake in the colon of DSS mice compared to healthy controls (55). However, 
uptake was also increased in the spleen and lymph nodes, highlighting the intrinsic difficulties 
in imaging immune cells during inflammation, as they generally migrate to and from 
inflammatory sites and lymph nodes, incorporating blood vessels and lymphatics 
 
4.11 Imaging the microbiota in colitis   
 
As our understanding of microbiota–host interactions grows, it is necessary to move beyond 
current genomics technology and compositional descriptions. This remains a daunting task 
when imaging specific microbiota in the gut, as it is limited by the diversity of tissue types that 
need to be maintained, which is of particular importance when considering the sensitivity of 
the mucous layer to standard fixation methods and the heterogeneity within gut 
microenvironments. As such, it is critical that a robust protocol including mucous-preserving 
sample preparation, image segmentation, and quantitative analysis tools be developed. A 
framework satisfying these criteria was recently developed by Earle et al. (58), where high-
resolution quantification of the spatial organisation of the gut microbiome revealed that 
changes in the proximity of microbes to the epithelium are sufficient to induce increased 
expression of key inflammatory markers, despite negligible shifts in microbiota composition. 
Most recently, chemical imaging techniques exploiting a blinking surface enhanced Raman 
spectroscopy (SERS) have been used to visualise bacteria in vitro with exquisite resolution, 
and have demonstrated the ability to differentiate between the chemical signatures of 
different bacteria (59). MRI, CT, fluorescence/bioluminescence imaging, and PET have also 
been applied to investigate the activity of bacteria in vivo; however, these typically only 
provide indirect information about bacterial activity by inference from immune function 
(60,61).
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Recent advances exploiting the bacterial uptake of carbohydrates have proven successful for 
the selective in vivo imaging of bacteria independently of host factors and secondary 
pathologies (61,62). Furthermore, specific bacteria have also been labelled with iron oxide 
nanoparticles for MRI to track bacteria longitudinally during infection (60). These 
developments highlight the potential to image specific bacteria during inflammation but are 
yet to be applied to IBD. 
 
4.12 Limitations of radiolabelled antibodies  
 
Despite the evidence outlined above supporting the potential use of radiolabelled antibodies 
or immune mediators for in vivo diagnostic imaging, several issues remain that currently limit 
enthusiasm for widespread use. The primary limitation is economy-based, as specialised 
equipment is required for the manufacture and detection of radiolabels. These costs are high, 
but may be mitigated by improved clinical outcomes, including early detection, and the 
potential development of personalised medicines to improve clinical responses and reduce 
side effects. Scientific challenges also exist, particularly with relation to the relatively long half-
life of antibodies and the time required for them to move through the circulatory system to 
the site of inflammation and clear after studies have been performed. These issues relate to 
the increased risk of cancer due to radiation exposure, particularly as IBD patients already 
have a higher risk of colon cancer. However, PET is considered safe and the effective dose of 
whole-body 18F-FDG was approximately 7 mSv, much less that the 16 mSv used for a routine 
abdominal–pelvic CT with contrast (63,64). Notable efforts are underway to reduce circulation 
time by using pretargeted methods, as explained in more detail below. The relatively large 
structure of antibodies may lead to difficulties in penetration of the site of 
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inflammation, although this may be mitigated by altering the structure of the antibody, also 
explained in more detail below. A limitation also relates to the single mode of PET detection, 
as only a single mediator can be imaged. This is problematic in terms of detailed studies of 
immune cell subsets, as they are typically identified by flow cytometry techniques requiring 
multiple targets. Furthermore, mediators must be accessible to antibodies and are therefore 
restricted to soluble cytokines and chemokines or markers located on the outer surface of the 
cell membrane. While intracellular cytoplasmic cytokines and nuclear transcription factors 
such as FOXP3 (TREG) and ROR-γ (TH17) are increasingly being used to characterise immune cell 
subsets, antibody penetration inside immune cells typically requires cell permeabilization, 
which is not possible in vivo.  
 
4.13 Future directions of imaging IBD 
 
Remarkable progress has been achieved in recent years toward understanding the 
mechanisms underlying IBD. This has resulted in a number of specific biologics for treatment, 
but they are yet to be applied to diagnosis or surveillance. The complex immunological 
mechanisms of IBD indicate that there are multiple markers that could potentially be used for 
diagnostic imaging and drug bioavailability. Imaging specific sites of inflammation should be 
achievable relatively easily; however, determining markers that differentiate between IBD and 
other gastrointestinal diseases, such as cancer, is more problematic and requires extensive 
preclinical validation. 
 
Intact antibodies are increasingly being used as therapeutics; however, their utility as imaging 
agents is reduced by their extended half-life, as the duration of time required to reach a 
sufficient signal-to-noise ratio is long.
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Furthermore, extended half-lives may also lead to other harmful biological activity and side 
effects, potentially altering the biological function being imaged; however, in theory, this risk 
is minor as concentrations are typically much lower for imaging than for treatment. Recent 
developments in antibody engineering include a shift from whole IgG antibodies to fragments, 
enhancing their physical properties and leading to enhanced efficacy as extensively reviewed 
in (65). Enzymatic cleavage or restructuring of the antibody attenuates problems associated 
with half-life by decreasing clearance times. Furthermore, decreasing the amount of time 
required to reach a suitable signal also permits the use of short-lived isotopes, reducing 
radiation exposure. 
 
Pretargeting strategies have also emerged as a means of improving efficacy whilst reducing 
radiation dose; for example, by using a novel biorthogonal inverse electron demand Diels–
Alder reaction between a 64Cu-labelled radioligand and a site-specific immunoconjugate (66). 
This occurs in four steps: (a) injection of the modified antibody, (b) accumulation of the 
antibody at its target site and clearance from the blood, (c) injection of the radioligand 24 h 
later, and (d) the in vivo click ligation between the immunoconjugate and radioligand and 
subsequent excretion of excess radioligand. The target was able to be delineated four hours 
post-injection of the radioligand in tumour tissue, with image contrast improved over time 
and an ideal signal-to-noise ratio at 24 h. This pretargeting approach and similar approaches 
may expedite the clinical translation of future immunoconjugates for imaging. 
 
A tantalizing approach is the potential to image different bacterial species; however, this is 
again currently limited by the lack of knowledge of functional roles for specific microbiota in 
IBD and the limited ability of PET to simultaneously label multiple targets. Additionally, it may 
be useful to perform simultaneous PET-MR which would combine the strengths and 
Chapter 4 Imaging inflammatory mediators 
 102 
weaknesses of each technique. MRI biomarkers of intestinal inflammation can include 
anatomical signs but also intestinal motility indices, small bowel water content and whole gut 
transit time (67). Cine sequence MRI can be used to identify bowel segments with abnormal 
motility, such as increased or decreased peristaltic activity which may indicate early signs of 
inflammation such as in CD (67). Furthermore, imaging of microbiota in general currently 
requires models where the bacteria can be isolated, labelled, and readministered. Future 
developments including the ability to use multiple labels, but also advances in the 
identification of bacterial species of interest and anaerobic culturing of microbiota, would be 
a welcome addition to preclinical models of IBD in the first instance before clinical studies are 
warranted. Furthermore, the potential to exploit factors that are selectively produced by 
bacteria and differentiate between active and quiescent states may provide intriguing 
insights. Bacterial toxins may be the ideal sensor as they are typically only secreted during 
disease, are readily identifiable by antibodies, and are relatively easily attached to various 
detection technologies. However, biosensing technology remains limited in its ability to 
provide insight into the spatial organisation of the microbiome, and as such, the ideal 
microbial analysis tool remains elusive and current investigations must combine genomic, 
visual, and activity-based measures. 
 
4.14 Summary  
 
Imaging has a critical role in the diagnosis and management of IBD patients, where endoscopic 
studies are currently the gold standard. However, there is a clear need for new technologies 
that are less invasive than endoscopy, but more penetrative at both the local level within the 
intestinal wall and more broadly along the entire intestinal length. These factors are most 
relevant for paediatrics IBD, where risks of adverse outcomes are increased, and also in small 
intestinal inflammation and fibrosis, which is generally not accessible by endoscopy. 
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Animal studies indicate that PET and SPECT of immune cells and/or mediators are potentially 
useful for IBD management and diagnosis. The potential targets for PET/SPECT of immune 
mediators and cells in active IBD are numerous; however, options for imaging of microbiota 
are currently limited by the lack of understanding of the role that specific microbiota 
contribute toward IBD. Translation of these technologies into human studies in IBD is currently 
non-existent, yet applicability in other diseases such as cancer is encouraging. Imaging of 
currently available biologics should be relatively achievable in the short term, while longer-
term goals include the development of tracers with deep tissue penetration and short half-
lives. Concurrent research into the immune mechanisms underlying IBD should deliver targets 
that offer insight into disease mechanisms, for example in paediatrics IBD, and can 
differentiate between diseases and/or disease states, for example between active 
inflammation and fibrosis in UC and CD. In conclusion, the future for the development of 
imaging techniques in IBD is bright, and further refinement will clearly lead to benefits in the 
diagnosis and management of IBD patients.  
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Chapter 5 Immuno-PET of innate immune markers CD11b and IL-1β 
detect inflammation in murine colitis. 
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5.2 Abstract   
 
Inflammatory bowel disease (IBD) is a chronic relapsing and remitting inflammatory disease 
of the gastrointestinal tract. The diagnosis and monitoring of IBD are reliant on endoscopy, 
which is invasive and does not provide information on specific mediators. Symptom flare in 
IBD is associated with increased activation of innate immune pathways. Immuno-PET 
approaches have previously demonstrated the ability to detect colitis; however, a direct 
comparison of antibodies targeted to innate immune mediators and cells has not been done. 
We aimed to compare immuno-PET of antibodies to IL-1β and CD11b against standard 18F-
FDG and MRI approaches to detect colonic inflammation. Methods: Colonic concentrations of 
IL-1β and myeloperoxidase were determined by ELISA, and colonic infiltration by CD11b-
positive CD3-negative innate immune cells was determined by flow cytometry and compared 
between healthy and dextran sodium sulphate–treated colitic mice. PET of 89Zr-α-IL-1β, 89Zr-
α-CD11b, and 18F-FDG was compared by volume-of-interest analysis and with MRI by region-
of-interest analysis. Imaging results were confirmed by ex vivo biodistribution analysis. 
Results: Colonic inflammation was associated with impaired colonic epithelial barrier 
permeability, increased colonic IL-1β and myeloperoxidase concentrations, and increased 
CD11b-positive CD3-negative innate immune cell infiltration into the colon. 89Zr-α-IL-1β and 
89Zr-α-CD11b immuno-PET detected colonic inflammation, as did 18F-FDG, and all PET tracers 
were more sensitive than MRI.
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Although 18F-FDG volumes of interest correlated with colitis severity and a strong trend was 
observed with 89Zr-α-IL-1β, no correlation was observed for 89Zr-α-CD11b or MRI. 89Zr-α-IL-
1β was distributed mainly to the gastrointestinal tract, whereas 89Zr-α-CD11b was distributed 
to more tissue types. Conclusion: Immuno-PET using antibodies directed to innate immune 
markers detected colonic inflammation, with 89Zr-α-IL-1β providing a more tissue-specific 
signal than 89Zr-α-CD11b. Development of these technologies for human subjects will 
potentially provide a less invasive approach than endoscopy for diagnosing and monitoring 
IBD.  
 
5.3 Introduction  
 
Inflammatory bowel disease (IBD) is a collection of chronic idiopathic inflammatory diseases 
of the gastrointestinal tract, including Crohn disease and ulcerative colitis (1). IBD substantially 
affects quality of life, and although treatable, significant gaps remain because of incomplete 
efficacy, lack of tolerance, and side effects, leading to variable periods of remission and 
relapse (2). Patients with IBD require constant surveillance because prognostic indicators of 
symptom flare remain poor and patients with long-standing disease have an increased risk of 
developing colon cancer (2,3). The diagnosis and management of IBD are currently heavily 
reliant on endoscopy, which is generally well tolerated but is invasive, is restricted to imaging 
of the superficial mucosal surface, cannot easily reach all areas of the small intestine, and does 
not provide immediate information on specific mediators or mechanisms.
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Therefore, new technologies are required for imaging IBD that are less invasive than 
endoscopy and can provide information on specific pathologic processes in real time. Clinical 
studies support the use of PET, SPECT, and MRI for detecting inflammation in the 
gastrointestinal tract, satisfying the criteria for reduced invasiveness and real-time 
information (4,5). However, current clinical PET, SPECT, and MRI approaches in IBD are 
restricted to using radiolabelled autologous leukocytes and 18F-FDG in PET and SPECT and 
using gadolinium contrast in MRI, none of which provides information on specific mediators. 
This lack of detail is of increasing importance because of the increase in use of target-specific 
biologics, particularly antibodies, and the emergence of personalised medicine.  
Monoclonal antibodies have exquisite selectivity for their target, and their applicability to 
immuno-PET has been appreciated for decades, particularly in the cancer field (6–8). 
However, the use of immuno-PET in IBD is currently limited to preclinical studies, in which T-
cell infiltration into the colon of colitic animals has been demonstrated either directly by 
imaging the THELPER cell marker CD4 (9) or indirectly by targeting the gut-homing integrin 
α4β7 (10). In contrast, immuno-PET of immune mediators is yet to be reported; however, 
direct labelling of the neutrophil-attracting chemokine CXCL8 (also known as IL-8) (11,12) and 
antibody-directed imaging of TNF-α (13) have shown some efficacy for SPECT in both colitic 
animals and human IBD.  
Activation of the innate immune system is intimately linked to inflammation in IBD, most 
obviously illustrated by the clinical utility of detection of the neutrophil-secreted mediators 
calprotectin and lactoferrin in stool (3). IL-1β is an inducible cytokine that has a key role in
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innate immune responses and is predominantly secreted by neutrophils, monocytes, 
macrophages, and dendritic cells, whereas CD11b is a pan-myeloid innate immune marker 
predominantly expressed on these same cell types. Here, we aimed to compare the ability of 
PET of 89Zr-conjugated antibodies against IL-1β and CD11b with the ability of standard (18F- 
FDG) PET and MRI to detect inflammation in colitic mice.  
 
5.4 Materials and methods  
 
All experiments were approved by the Animal Ethics Committee of the South Australian Health 
and Medical Research Institute (SAHMRI) and the University of Adelaide.  
 
Mice  
Male C57BL/6jSah mice aged 10–14 week (20–30 g) were bred and group-housed in a specific 
pathogen-free environment at SAHMRI. Animals had ad libitum access to food and water. 
Experiments were conducted with only male mice to eliminate the potential confounding 
effects of the oestrous cycle. Mice were humanely euthanised via CO2 inhalation and cervical 
dislocation to remove tissues. 
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DSS Colitis Model  
Colitis was induced by replacing normal drinking water with 2% (w/v) dextran sodium sulphate 
(DSS) (molecular mass, 40–50 kDa; Alfa Aesar) for 5 d, followed by an additional 3 d of normal 
drinking water. Mice were assessed daily for signs of acute colitis, including a decrease in body 
weight and diarrhoea. Healthy mice were age and weight matched. Colon length was 
measured on excised colons dissected free from surrounding tissue from the tip of the anus 
to the distal end of the cecum.  
 
Ussing Chamber Studies  
Distal colon segments were mounted into 0.1 cm2 aperture sliders bathed in 5 mL baths with 
oxygenated glucose-fortified Ringers solution for Ussing chamber analysis (Physiologic 
Instruments) as previously described (14). Briefly, voltage-clamped tissues were equilibrated 
for 20 minutes before baseline transepithelial electrical resistance (V cm2) and short circuit 
current (mA/cm2) were averaged over 10 minutes.  
 
Myeloperoxidase Activity  
Myeloperoxidase activity in the distal colon was determined as previously described (15,16). 
Briefly, phosphate-buffered saline–washed tissue segments were homogenised in 0.5% 
hexadecyl-trimethylammonium bromide (Sigma-Aldrich) and reacted with o-dianisidine 
hydrochloride (Sigma-Aldrich). Absorbance at 450 nm was averaged over 5 minutes at 30-s 
intervals.
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Myeloperoxidase activity is expressed as units/mg of tissue, with 1 unit of myeloperoxidase 
activity defined as the amount of myeloperoxidase required to degrade 1 mmol of peroxide 
per minute at 25°C.  
 
IL-1β ELISA  
Proteins were extracted from the distal colon as previously described (14,15). Briefly, colon 
segments were homogenised for 5 minutes in cell extraction buffer (ThermoFisher Scientific) 
supplemented with protease inhibitor cocktail (Sigma-Aldrich), 1 mM phenyl-methanesulfonyl 
fluoride (Sigma-Aldrich), and 50 mM ethylenediaminetetraacetic acid at 1 mL/50 mg of tissue. 
The lysate was incubated (1 h, 4°C, with rotation), sonicated (2 minutes), and centrifuged 
(14,000 rpm, 15 minutes, 4°C). Supernatant was collected and stored at -80°C until analysis. 
IL-1β concentrations were determined by OptEIA IL-1β ELISA (BD Biosciences) as previously 
described (14,15). The limit of sensitivity was less than 4 pg/mL. Concentrations were 
normalised to total protein concentration as determined by a bicinchoninic acid assay (Abcam) 
as previously described (15).  
 
Flow Cytometry  
Colon lamina propria mononuclear cells (LPMCs) were isolated enzymatically, essentially as 
previously described (14,15). Briefly, the colon was excised free of fat and blood vessels, 
flushed with cold phosphate-buffered saline, roughly chopped, and incubated in 4-(2- 
hydroxyethyl)-1-piperazineethanesulfonic acid buffered Hanks balanced salt solution 
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supplemented with 1 mM ethylenediaminetetraacetic and 1 mM dithiothreitol (20 minutes, 
37°C, gentle shaking). Tissue segments were filtered (100 mM), and the remaining tissue was 
minced and incubated (20 minutes, 37°C, gentle shaking) in complete RPMI 1640 (Gibco) 
supplemented with foetal calf serum, GlutaMAX (Life Technologies Corp.), 
penicillin/streptomycin, collagenase D (1 mg/mL), DNAse1 (0.5 mg/mL), and dispase (3 
mg/mL) (all from Sigma-Aldrich) before being strained (40 mM) and resuspended over a 40/80 
Percoll gradient and the interphase LPMC layer collected and pelleted for LPMCs. Viability was 
determined (trypan blue), and only preparations with at least 80% viability were investigated 
further. Fc-blocked LPMCs (0.5 · 106) were stained with the antimouse monoclonal antibodies 
CD45-BV605 (30-F11), CD3-BUV395 (145-2C11), and CD11b-APC- Cy7 (M1/70) (all from BD 
Biosciences). Per test, 20,000 events were analysed using a FACS-Fortessa (BD Biosciences), 
and proportions of live (FVS700; BD Biosciences) singlets were determined using FlowJo (Tree 
Star), as described previously (14,15).  
 
Antibody–Chelator Conjugation and Radiolabelling  
89Zr-oxalate was produced via proton irradiation of 89Y target on a PETtrace 880 cyclotron 
(GE Healthcare) and purified on Aleco (Comecer) as previously described (17). Monoclonal α-
CD11b (M1/ 70) and α-IL-1β (B122) (BD Biosciences) were conjugated to 89Zr with NCS-Bz-
DFO (Macrocyclics) linkage as previously described (18,19). Competitive blocking assays 
determined the specificity of 89Zr-conjugated antibodies, whereby 0.5 · 106 healthy mouse 
splenocytes were incubated with 1.25 mg of 89Zr-labelled α-IL-1β or α-CD11b for 20 minutes 
at 37°C, in the presence or absence of 50 mg of unlabelled α-IL-1β or α-CD11b added for 20 
minutes beforehand.
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Cells were pelleted and counted using a Hidex γ-counter for accumulation of 89Zr. All counts 
were background- and decay-corrected. 18F-FDG (phosphate buffer) was produced by the 
Molecular Imaging and Therapy Research Unit of SAHMRI on a FASTLab synthesiser (GE 
Healthcare).  
 
Ex Vivo Biodistribution Studies  
Immediately after post-imaging culling, organs of interest were dissected, weighed, and 
counted for 89Zr accumulation as outlined above for blocking experiments.  
 
Statistical Analysis  
Data are expressed as mean 6 SEM in all cases. The significance of results was determined by 
unpaired t testing except for weight loss data, for which a 2-way ANOVA with Bonferroni post 
hoc testing was used. The strength and significance of correlations were determined by 




A 3 to 5 MBq quantity of 89Zr-α-IL-1β (37.5 mg) and 89Zr-α-CD11b (85 mg) in 100–200 mL of 
saline was administered intravenously (tail vein) 24 h before imaging, and a 10 to 15 MBq 
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quantity of 18F-FDG in 100–200 mL of saline was administered intravenously 30 minutes 
before imaging. Some mice underwent MRI first. The mice were anesthetised with isoflurane 
(2%), and a T2-weighted rapid- acquisition-with-refocused-echoes (RARE) spin-echo sequence 
was acquired with a benchtop MRI system (Bruker Icon 1T; Bruker Physik GmbH) (repetition 
time, 84 ms; echo time, 4,314 ms; number of excitations, 1; RARE factor, 8; field of view, 80x80 
mm; slice thickness, 2 mm; scan time, 2 minutes). ITK snap (www.itksnap.org) was used for 
consequent segmentation of the scans (20). PET experiments were performed over 15 
minutes using a submillimeter-resolution (0.7 mm) Albira PET-SPECT small-animal scanner 
(Bruker Biospin GmbH). Manually drawn volumes of interest in the area of interest were 
applied to analyze average and total radiotracer accumulation using the PMOD imaging suite 
(PMOD Technologies).  
 
5.5 Results  
 
DSS Colitis Association with Body Weight Loss, Colon Shortening, and Impaired Epithelial 
Permeability  
Body weight was reduced in the DSS-treated group 4 d after treatment began (P<0.01, Figure 
1A) and was further reduced by about 10% 8 d after treatment began (P<0.001, Figure 1A). By 
day 8, DSS-treated mice also had approximately 15% shorter colons (P<0.001, Figure 1B), an 
approximately 35% reduction in epithelial resistance (P<0.01, Figure 1C), and an 
approximately 60% reduction in short-circuit current (P<0.01, Figure 1C), indicative of colonic 
inflammation and damage to the epithelial barrier. 












Increase in Colonic Innate Immune Infiltration in DSS Colitis  
DSS-treated mice had an approximately 7.5-fold increase in colonic myeloperoxidase activity 
(P<0.001, Figure 2A) and an approximately 2.5-fold increase in colonic IL-1β concentration 
(P<0.01, Figure 2B), indicating that innate immune mediators are increased in colitic mice. The 
proportion of CD11b colonic LPMCs was increased about 6-fold in DSS-treated mice (P <0.001, 
Figure 2C), indicative of an infiltration by innate myeloid cells, including neutrophils, 
monocytes, macrophages, and dendritic cells. 












Immuno-PET Detection of Colonic Innate Immune Activation in Colitis  
89Zr was successfully conjugated to α-IL-1β and α-CD11b as demonstrated by outcompeting 
binding in the presence of excess unlabelled antibody (89Zr-α-IL-1β: 8,135 ± 1,510 counts per 
minutes (cpm) hot vs. 3,026 ± 337 cpm cold, P<0.05, n =3; 89Zr-α-CD11b: 61,535 ± 8,355 cpm 
hot vs. 34,811 ± 4,081 cpm cold, n=3, P<0.05). PET imaging revealed that in DSS colitic mice, 
distal colonic uptake of 89Zr-α-IL-1β was increased about 3-fold (P<0.001, Figure 3A, 
Supplemental Videos 1 and 2; supplemental materials are available at
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 http://jnm.snmjournals.org), 89Zr-α-CD11b was increased about 5-fold (P<0.05, Figure 3B, 
Supplemental Videos 3 and 4), and 18F-FDG was increased about 3.5-fold (P<0.01, Figure 3C, 
Supplemental Videos 5 and 6). A robust positive correlation (R2 = 0.70, P<0.05) was observed 
between colonic uptake of 18F-FDG and percentage body weight loss (Figure 3C), with a 
strong trend toward a similar effect observed for 89Zr-α-IL-1β (R2 =0.54, P=0.09, Figure 3A) 
but not for 89Zr-α-CD11b (Figure 3B).
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Biodistribution of 89Zr-α-IL-1β and 89Zr-α-CD11b  
Ex vivo analysis indicated that uptake of 89Zr-α-
IL-1β and 89Zr-α-CD11b was increased 
throughout the gastrointestinal tract in DSS-
treated mice relative to control mice but also in 
some extragastrointestinal sites. Specifically, 
uptake of 89Zr-α-IL-1β was increased about 3-
fold in the colon (P <0.05), 5-fold in the cecum 
(P<0.01), 1.5-fold in the small intestine (P<0.05), 
and 1.75-fold in the stomach (P<0.05), whereas 
uptake in the spleen was also increased about 
1.75-fold (P<0.05) (Figure 4A). Uptake was 
similar between DSS-treated and control mice in 
all other tissues investigated. Uptake of 89Zr-α-
CD11b was more discrete in the gastrointestinal 
tract, with increases observed only in the colon 
(26-fold, P<0.05) and small intestine (20-fold, P<0.05) and a trend toward an increase in the 
cecum (21-fold, P=0.083) (Figure 4B). However, increased uptake of 89Zr-α-CD11b was 
observed in more sites outside the gastrointestinal tract than 89Zr-α-IL-1β, including 
approximately 6-fold in the spleen (P<0.05) but also approximately 7-fold in the liver (P<0.05) 
and 8-fold in the bone marrow (P<0.05). Notably, trends toward increased uptake of 89Zr-α-
CD11b were observed across most other tissues, including the cecum, tail, and stomach; 
however, uptake was generally more variable for 89Zr-α-CD11b than for 89Zr-α-IL-1β, limiting 
the significance of these observations.  
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MRI Detection of Colonic Inflammation in Colitic Mice  
MRI analysis of colonic inflammation revealed an approximately 2-fold increase in the T2 
signal intensity ratio in DSS colitis relative to control (P<0.01, Figure 5, Supplemental Videos 7 
and 8), but this analysis did not correlate with percentage body weight loss (Figure 5).  
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5.6 Discussion  
 
We demonstrate for the first time, to our knowledge, that immuno-PET directed against 
innate immune cells and mediators is applicable for detection of colitis. The sensitivity of 89Zr-
labelled α-IL-1β and α-CD11b immuno-PET for detecting colonic inflammation was similar to 
that of 18F-FDG, and all PET approaches were more sensitive than MRI. Furthermore, uptake 
of 89Zr-α-IL-1β was restricted to the gastrointestinal tract and spleen, whereas 89Zr-α-CD11b 
was distributed over a broader range of tissue types. Our comparison demonstrates the strong 
potential that immuno-PET of innate immune mediators has for diagnosing and monitoring 
IBD.  
 
Activation of the innate immune system is a hallmark of inflammation in IBD both in humans 
and in animal models (3,21). DSS is directly toxic to epithelial cells, and we confirm that 
epithelial damage in DSS colitis is associated with increased colonic infiltration of CD11b-
expressing cells and increased colonic concentrations of innate immune cell–secreted IL-1β 
(22), both of which we were reliably able to detect by PET of 89Zr-conjugated monoclonal 
antibodies. Previous immuno-PET studies have identified increased infiltration of T cells in DSS 
colitis, either by directly labelling of the THELPER marker CD4 or by labelling of the gut-homing 
integrin complex α4β7, which is upregulated on T cells in IBD (9,10,23). However, we believe 
our study to be the first to describe the potential that radiolabelled antibodies against innate 
immune markers have for PET in IBD diagnosis and monitoring. 
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We observed a striking difference in the biodistribution of 89Zr-α-IL-1β and 89Zr-α-CD11b, 
with 89Zr-α-IL-1β being restricted to the gastrointestinal tract and spleen whereas 89Zr-α-
CD11b was observed in a broad range of tissues. Furthermore, 89Zr-α-IL-1β also correlated 
with colitis severity whereas 89Zr-α-CD11b did not. These findings are likely to relate to 
immunologic processes underlying innate immune activation in colitis. Innate immune cells 
migrate from induction sites in lymphatic tissue through the bloodstream into sites of 
inflammation, where they mature and secrete cytokines, including IL-1β, before clearing from 
tissue by the lymphatics or dying (24). CD11b is expressed on innate cell subsets that promote 
inflammation, such as M1 macrophages and most neutrophil subsets, but also on innate 
immune cells that promote tolerance, wound healing, and immune suppression, including M2 
macrophages, dendritic cells, and CXCL4-expressing neutrophil subsets (25,26). These cells 
express CD11b at all stages of maturity, and imaging CD11b is therefore likely to detect sites 
of inflammation but also migration between tissues and lymph nodes, including the bone 
marrow and, particularly in mice, the spleen. Furthermore, whereas CD11b expression is high 
on myeloid innate immune cells, it is also expressed on other immune cells, including T- and 
B-cell subsets, which may contribute toward the signal we observed in our imaging (27). The 
expression of individual markers on multiple cell types is common; for example, CD4 is 
expressed on macrophages in addition to THELPER cells, and complex flow cytometry using 
multiple markers is typically required to conclusively characterise individual immune cell 
subsets. For IBD, this is particularly relevant to the ever expanding THELPER cell subsets and 
innate lymphoid cells, which rely on staining of cytoplasmic cytokines or nuclear transcription 
factors for their characterisation (28). Definitively identifying these subsets for in vivo imaging 
is difficult in live cells because antibodies are typically too large to passively enter cells. 
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In contrast, IL-1β has 2 favourable characteristics for immuno-PET. First, it is inducible rather 
than constitutive and therefore is secreted only by activated cells, which, in colitis, are 
predominately located at sites of inflammation. Second, proteolytic processing of IL-1β into 
its mature form typically occurs within the cell, and it is secreted as a mature functional 
protein (29). This is somewhat an anomaly for cytokines but is beneficial for immuno-PET 
because only mature IL-1β is imaged. Our results support further investigation into the use of 
imaging inducible and intracellularly processed immune mediators for detecting inflammation 
in IBD. Furthermore, immuno-PET using radiolabels with long half-lives, such as 89Zr, enables 
longitudinal imaging, which would provide valuable information on the temporal nature of 
immune responses in IBD.  
SPECT is a cost-effective technique for nuclear imaging but generally has reduced resolution 
relative to PET. Nonetheless, SPECT imaging of the neutrophil-attracting chemokine CXCL8, 
and CD4, has also shown potential in preclinical and human studies of IBD (11,12,30). 
Furthermore, whereas SPECT imaging of the TNF-α–neutralising antibody infliximab also 
demonstrated some efficacy in preclinical colitis, it was hindered by high background, the 
cause of which was likely its chimeric mouse–human properties (13). The most readily 
available alternative markers for immuno-PET imaging of IBD include antibodies that are 
currently used for treatment, including variations targeting TNF-α, α4β7 (vedolizumab), α4β1 
(natalizumab), and IL-12/23 (ustekinumab) (31). However, markers do not have to be limited 
to the immune system. Epithelial damage and increased epithelial barrier permeability are 
hallmarks of IBD and colitis, as we demonstrate in our model (32,33). The permeability of the 
epithelial monolayer to luminal contents is regulated by a large family of tight-junction 
proteins, many of which are reduced in degraded tissue in the inflamed intestine, impeding 
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their use as markers. Conversely, expression of some of these proteins promotes increased 
permeability and is increased during IBD, such as the pore-forming claudin-2 (34,35). Other 
potential markers include those associated with tissue remodeling associated with the 
resolution of inflammation (36). Matrix metalloproteases are involved in tissue remodeling 
and, interestingly, are thought to play a key role in promoting fibrosis. Although an ant body 
against matrix metalloprotease 9 was ultimately withdrawn from clinical trials on IBD, interest 
in this target remains and it may have more promise as a marker of fibrosis (37).  
 
The clinical utility of immuno-PET for IBD is currently limited by several issues. Primarily, 
antibodies are large molecules with molecular weights of about 150 kDa. This large size 
prolongs their half-life and reduces excretion, which is beneficial when used as treatments but 
is challenging for imaging because tissue penetration is reduced and excretion prolonged. 
Issues related to tissue penetration may be somewhat diminished in IBD because vascular 
permeability is increased in inflammation, aiding immune cell migration into inflammatory 
sites (38). However, increased leukocyte extravasation is unlikely to drastically reduce the 
time taken for systemically administered antibodies to reach inflammatory sites in IBD, and 
the current clinical paradigm would require dosing and imaging to occur at separate visits over 
several days. This requirement results in increased exposure to radiolabels, potentially 
increasing the risk of side effects. Promising alternatives to intact antibodies that potentially 
limit these concerns are in development (39). Notably, engineered small antibody fragments 
against anti-CD4 and β7 have already shown promise in preclinical colitis (9,10). A different 
strategy uses a 2-step process for pretargeting. The initial step comprises administration of 
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an antibody modified to incorporate a radiolabel capture site, which is allowed enough time 
to localize to its target. A few days later, the radiolabel is injected and binds to the antibody. 
This strategy has shown promise in cancer (40) but has yet to be applied to IBD and may prove 





We have demonstrated that radiolabelled antibodies against innate immune cells and 
mediators are suitable for immuno-PET of colitis. Our results provide further evidence of the 
clinical utility of immuno-PET for IBD diagnosis and monitoring. Development of these 
techniques would be of particular benefit to patients who are difficult to scope, including the 
paediatric population and those that have inflamed or fibrotic regions of the small intestine. 
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Chapter 6 Mechanisms underpinning intestinal fibrosis in IBD and 
current and future diagnostic imaging: a review  
 
6.1 Statement of authorship 
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6.2 Introduction  
 
Intestinal fibrosis is a major common complication of IBD and occurs after extended or 
recurrent periods of intestinal damage and healing, leading to an excessive deposition of 
extracellular matrix (ECM). The excessive deposition of ECM is driven by an imbalance 
between matrix metalloproteinases (MMPs) and tissue inhibitors of matrix 
metalloproteinases (TIMPs) during periods of tissue repair and the activation of ECM-
producing cells (1). This increased deposition of ECM and lack of normal tissue restructuring 
can lead to loss of function of the gastrointestinal tract. Complications of fibrostenotic disease 
such as fistulae, strictures and abscesses are the main indications for surgery in Crohn’s 
disease (CD). Within 5 years of being diagnosed with CD, 49% of patients are diagnosed with 
stricturing disease or penetrative complications, this increases to 53%-70% at 10 years post-
diagnosis (2, 3). The risk of intestinal fibrosis is lower in ulcerative colitis (UC) with 5% of 
patients developing strictures during the course of their disease (4). In patients with CD this 
leads to thickening of all layers of the gut from the mucosa and muscularis mucosa to the 
muscularis propria (5). This is associated with an infiltration of dense bands of collagen and 
collections of smooth muscle cells as well as an expansion of the muscularis mucosa (6). 
Thickening of the muscularis mucosae and the increased deposition of collagen in the colon 
leads to shortening and increased rigidity of the colon (7). 
Chapter 6 Mechanisms and imaging of intestinal fibrosis 
 146 
In CD, the degree of fibroblast accumulation correlates with the expression of ECM mediators 
and fibrotic cytokines (8). Intestinal fibrotic changes are associated with an increase in 
fibronectin, tenascin C and total collagen which is predominantly collagen III and V (9). 
Patients with UC or CD can also display fibro-muscular obliteration of the submucosa which 
usually occurs with thickening of the muscularis propria. Although the formation of intestinal 
fibrosis can be decreased by inhibiting inflammatory pathways, in conditions such as IBD, 
regulation of the intestinal inflammatory pathways can be difficult as therapies such as 
commonly used anti-TNF-α monoclonal antibodies can decrease in efficacy over time. 
Currently, apart from surgical intervention, there are no therapies to reverse the development 
of intestinal fibrosis, as such an increased understanding into the mechanisms underpinning 
intestinal fibrosis is urgently required. 
 
6.3 Clinical impact and significance 
 
The presence of internal penetrating disease in patients with CD is usually accompanied with 
strictures, with fistulae being highly predictive of the presence of associated strictures (10). 
As a result, it is often thought that strictures precede the development of fistulae and internal 
penetrating disease. Acute obstruction due to strictures can be removed by surgical resection, 
but in CD reoccurrence is possible. The formation of strictures seems to correlate with the 
location of inflammation with strictures most commonly occurring in the terminal ileum or 
ileocecal area. Currently there are no reliable clinical markers or predictors of intestinal 
fibrosis. Endoscopic, clinical and environmental risk factors have been identified, but most 
biomarkers only identified a complex course of CD which is not specific for fibrostenotic 
disease. 
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Risk factors for patients currently include under 40 years of age at time of diagnosis, perianal 
disease and early requirement of treatment with steroids (11, 12). The prediction and 
prevention of intestinal fibrosis and stricturing is crucial for the management of IBD. Studies 
have attempted to identify serologic and genetic markers that are associated with formation 
of strictures. Nucleotide-binding oligomerisation domain-containing protein 2 (NOD2) and 
MMP-3 were genes linked with fibrostenotic disease in CD (13).  In terms of serological 
markers, although TIMP-1 is increased in CD mucosa in areas of stricturing disease, there is no 
correlation between serum TIMP-1 and the fibrostenotic phenotype (14, 15). Fibronectin, an 
ECM protein, is decreased in CD patients relative to controls but is increased in the plasma of 
CD patients with stricturing disease (16, 17). Serum basic fibroblast growth factor (bFGF) 
activates wound healing and is increased in CD and correlates with thickness of the bowel wall 
and fibrostenotic disease (18, 19).  
 
6.4 Current treatments  
 
The prevention of fibrostenotic disease relies on the effective management and treatment of 
periods of inflammation and relapse in IBD. There are a few pharmacological therapies 
available which can slow the rate of fibrosis progression, but there are no therapies to reverse 
the progression of fibrosis, thus more effective therapies are needed.  Immunosuppressive 
therapies can slow or delay the progression of fibrosis, but surgery and endoscopic balloon 
dilation still remains the most common therapies for strictures in CD patients (20). Patients 
should be prescribed immunosuppressants such as anti-tumour necrosis factor (TNF) agents 
to reduce gut wall oedema, which may reduce bowel wall thickness and decrease obstructive 
symptoms (20). The reoccurrence rate after strictureplasty was found to be 23%, 10% of 
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patients had recurrence requiring reoperation at the previous site of strictureplasty, which 
may suggest that strictures can be reversible (21). Additionally, it has been found that there 
is no significant difference between recurrence rates following strictureplasty versus resection 
(21).  
 
6.5 Diagnosis of intestinal fibrosis and imaging techniques  
 
Intestinal fibrosis is a common IBD complication, however, patients initially present to the 
clinic due to an inflammatory phenotype, in the absence of complications such as fistulae or 
strictures (5). Currently, no validated and reliable diagnostic tools exist to detect intestinal 
fibrosis with a high specificity and sensitivity. Diagnosis of fibrotic strictures is particularly 
difficult in the setting of CD as inflammation often coexists. Differentiating between 
inflammation and fibrosis remains the largest challenge in antifibrotic therapies and diagnosis. 
Additionally, it may be beneficial to differentiate between established fibrosis and active 
disease (fibrogenesis). Cross-sectional imaging modalities such as magnetic resonance 
imaging (MRI) and computed tomography (CT) are currently the gold standard in 
differentiating intestinal inflammation from intestinal fibrosis. This relies on differing 
anatomical features. For example, on MRI intestinal inflammation in CD is associated with 
increased T2 hyperintensity, ulcerations and mucosal enhancement, in contrast to intestinal 
fibrosis which presents as abnormalities in contrast uptake; however, diffusion weighted MRI 
and magnetisation MRI have also shown potential for the quantification of fibrosis (13). In 
addition, magnetic resonance elastography, MRI-defined motility, T2* mapping and intravoxel 
incoherent motion DWI may also prove useful for the imaging of fibrosis. Ultrasound provides 
a non-invasive and radiation-free option to visualise fibrostenotic disease in some cases.
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Due to the many overlapping loops of the bowel and the depth of some segments, ultrasound 
cannot be used to visualise the entire gastrointestinal tract. The terminal ileum is well 
visualised with ultrasound, in contrast to the proximal ileum and jejunum which usually cannot 
be visualised. Patient body habitus may also impede ultrasound sensitivity. The diagnostic 
accuracy of ultrasound is also highly operator-dependant, when compared to MRI or CT. 
Ultrasound strain elastography is commonly used in fibrostenotic disease and can be used to 
estimate the stiffness of the tissue, which often correlates with fibrosis histopathological 
grade (22). Shear wave velocity ultrasound (SWE) is another technique used to estimate tissue 
stiffness through pulse waves generated by the ultrasound probe, in contrast to strain 
elastography which utilises direct pressure from the probe. In rat models SWE can successfully 
differentiate between fibrotic and acutely inflamed bowel (23). Contrast-enhanced 
ultrasound enhances the signal from blood cells and vessels, where fibrotic bowel will 
demonstrate a decreased blood flow and volume. A recent study has identified strain-
photoacoustic imaging as a potential modality for characterizing intestinal fibrosis (24). 
Increased haemoglobin and collagen content in fibrotic intestinal strictures were identified 
using spectroscopic photoacoustic imaging (25, 26). Parallel photoacoustic ultrasound is 
capable of visualising reduced blood content in intestinal strictures during the compression of 
the abdominal walls (24).  
  
Molecular imaging is at the forefront of medical imaging, providing non-invasive, quantitative 
technologies to visualise disease pathology at a cellular and subcellular level. This type of 
imaging will allow for the early detection, disease staging, assessment of disease activity and 
response to treatments. Molecular probes comprise of small molecules, peptides and 
antibodies that bind to specific mediators/targets involved in the disease pathology of 
interest.
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PET and single-photon emission computed tomography (SPECT) can be highly sensitive, 
detecting targets within picomolar concentrations and can provide quantification of the target 
(27). However, PET and SPECT also have lower spatial resolution and require radioactive probe 
production, thus making these options less suitable than non-ionising modalities for long term 
assessment.  In contrast to MRI which has a much higher resolution, no ionising radiation but 
much smaller range of biological contrasts are available. As such, PET and MRI can be 
combined to achieve highly sensitive target quantification with high resolution anatomical 
detail. As fibrogenic pathways share similarities between various fibrotic diseases, probes 
designed for one organ may also detect fibrosis in others.  Currently, there are over 25 
molecular probes available for imaging of fibrosis and fibrosis-associated pathways such as 
vascular leak and immune activation (see 27 for a thorough review). The ideal molecular probe 
for any disease should target a highly expressed molecular process which is unique to that 
disease and is in low levels or not present in areas not pathologically involved. Additionally, 
ideal probes will produce low background signals, which is achieved through low non-specific 
binding, rapid elimination and low binding to non-target areas. For probes designed for 
disease staging, uptake should increase linearly with an increase in disease.  Somatostatin 
receptors become upregulated on fibroblasts during fibrosis (28). Octresoscan is an FDA-
approved somatostatin peptide mimic, radiolabelled with 111In. It can successfully detect 
idiopathic pulmonary fibrosis, systemic sclerosis, sarcoidosis and idiopathic interstitial 
pneumonia. Somatostatin analogues such as 68Ga-DOTATATE (NETSPOT) can also detect 
idiopathic pulmonary fibrosis (29). However, proinflammatory M1 macrophages also express 
type 2 somatostatin receptors, thus may interfere with the true fibrosis signal (30). The 
deposition of ECM is one of the primary targets for the imaging of fibrosis and type 1 collagen 
is the most abundant of the collagens in the body (31).
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A peptide-based gadolinium probe (EP-3533) against type 1 collagen can successfully detect 
myocardial injury after infarction and liver and pulmonary fibrosis in preclinical models using 
MRI (32, 33). To date, no studies have attempted to use type 1 collagen probes to visualise 
intestinal fibrosis, although type 1 collagen deposition is significantly elevated in the gut 
during fibrosis. CM-101 is a more stable gadolinium probe, targeting type 1 collagen which 
has improved pharmacokinetic properties, compared with EP-3533 and has been used to 
detect liver fibrosis in rodents on MRI (34). CM-101 binding is increased in fibrotic animals and 
correlates well with hydroxyproline content. The same peptide probe used in CM-101 has also 
been optimised for PET of pulmonary fibrosis (35). Elastin has also previously been the target 
of molecular imaging probes for fibrosis and has been used to image atherosclerosis (36). 
However, elastin may not be a suitable target for intestinal fibrosis as it is often found to be 
decreased in the fibrotic gut (37). Immuno-PET relies on the use of radiolabelled antibodies or 
antibody fragments which will circulate throughout the body before binding to its target. The 
utility of this technique has been demonstrated in preclinical studies, imaging bowel 
inflammation in murine models of IBD, but also clinically in the imaging of various cancers (38-
40). 
 
6.6 Models of intestinal fibrosis 
 
Advances in this field can be restricted by accessibility to human biopsies and samples, as 
such, a number of well-characterised animal models of intestinal fibrosis have been 
developed. These models can be categorised into their modes of induction: spontaneous, 
genetically engineered, chemical, immune, bacteria, radiation-induced and post-operative 
(41, 42). 
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6.6.1. Chemically induced models 
 
Trinitrobenzene sulfonic acid  
Chemically induced models develop some of the immunological and histopathological 
features seen in human IBD. These models rely on repeated rounds of chemically induced 
gastrointestinal inflammation, followed by periods of healing and remission. However, many 
factors can influence the development of colitis in these models, therefore careful protocol 
standardisation is required to ensure translational value. Trinitrobenzene sulfonic acid (TNBS) 
is one of the most common compounds used to induce colitis in mice. Colitis is induced in 
susceptible strains by rectal administration of TNBS in ethanol. Ethanol is required to break 
the intestinal barrier, allowing TNBS to access the gut wall and haptenize gut proteins, 
initiating an immune response to colonic or microbiota-derived proteins, inducing an 
expansion and activation of CD4+ T cells. Consequently, the TNBS model of colitis is 
extensively used to investigate the role of CD4+ T cells in gut inflammation. The duration and 
intensity of TNBS colitis is dependent on multiple factors including, the dose of TNBS, 
concentration of ethanol, strain of mouse, genetic make-up of mice, time between treatments 
and the presence of certain T-cell activating microbiota. Typically, TNBS colitis results in TH1, 
TH2 and TH17 type responses (43). Histopathologically, in our experience, TNBS colitis results 
in much harsher intestinal damage. TNBS colitis classically induces transmural infiltration of 
macrophages, neutrophils and lymphocytes, loss of crypt architecture, blunted villi, thickening 
of the colon muscle wall and loss of goblet cells (44). Some of the immunological and 
histopathological features of TNBS colitis resemble CD and as such, is often used to study 
aspects of this disease. 
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Dextran Sodium Sulfate  
Dextran sodium sulfate (DSS) is dissolved in water and administered orally to induce self-
limiting colitis characterised by body weight loss, diarrhoea and bloody stools (45). DSS 
induces loss of epithelial cells, infiltration by neutrophils and ulcer formation, closely 
resembling some features of flare of UC (45). The colitogenic mechanism of DSS is not fully 
understood, but it thought to be directly toxic to the intestinal epithelial cells of the basal 
crypts. Breaking the intestinal barrier results in the translocation of luminal antigens into the 
mucosa and submucosa, causing a rapid and penetrating inflammatory response. As such, 
repeated DSS treatment can result in the development of intestinal fibrosis. Recent studies 
suggest that medium-chain fatty acids are required for the induction of DSS colitis and that 
the extent and severity of colitis is significantly impacted by various microbiota (46, 47). 
Additionally, short-chain fatty acids have been found to be protective in DSS colitis and have 
been identified as a possible therapeutic for IBD (48). DSS colitis incudes a TH2-like 
inflammatory response, leading to an increase of TNF-α, IL-6, IL-17 and KC in acute colitis and 
an increase in IL-4, IL-10 and decrease in TNF-α, IL-6, IL-17 and KC in chronic inflammation 
(43). Severe combined immunodeficiency (SCID) and Rag-/- mice can develop severe DSS 
colitis, suggesting that colitis can be induced without activation of the adaptive immune 
system (49, 50). As such, the DSS model of colitis is often used to study innate immune 
mechanisms in colitis. Recently, it has been shown that fibrogenesis in chronic DSS is not 
influenced by the neutralisation of TREG cells and the depletion of IL-13, IFN-γ and IL-17F (51). 
Inhibition of IL-17A slightly increased colonic collagen deposition without inducing any colonic 
or systemic inflammation. This may suggest that although increased in chronic DSS, TH1, TH2, 
TH17 cytokines and TREG cells are not crucial for the chronicity of inflammation and the 
development of fibrosis (51). 
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Peptidoglycan-polysaccharides  
Microbial models of intestinal fibrosis are becoming of greater interest as IBD GWAS studies 
continue to identify genes responsible for innate immunity, mucosal barrier integrity and 
bacterial sensing (52). Additionally, the microbiome of IBD patients differs from healthy 
controls.   A number of models attempt to alter the microbiome by utilising specific microbiota 
or microbial components to induce inflammation and intestinal fibrosis. Transmural injection 
of peptidoglycan-polysaccharides (PG-PS) into the distal colon, cecum or small bowel of 
genetically susceptible rats results in transmural enterocolitis (53, 54). Intramural injection of 
PG-PS results in an acute phase of inflammation 3 days after injection, followed by a 
spontaneous reactivation of colitis characterised by immune infiltration by macrophages, 
neutrophils and lymphocytes into the submucosa and muscularis propria at 3-4 weeks (54). 
Transmural administration of PG-PS into the gastrointestinal tract induces colonic thickening, 
adhesions, increased colonic permeability and increased myeloperoxidase activity, compared 
with controls. Granulomatous areas of intestine have an increased expression of collagen-α1 
(COL1A1), TGF-β1 and IL-6 (55). The areas surrounding the granulomas are fibrotic in nature 
and have an increased proportion of mesenchymal cells, particularly myofibroblasts. This 
technique is time-consuming, technically difficult and is limited by its poor reproducibility. 
Similar to the PG-PS model, intramural injection of rat faecal suspension into the colon bowel 
wall in rats can also induce intestinal fibrosis (56). 
 
Chronic Salmonella typhimurium infection  
As mentioned in this review, chronic infection with Salmonella typhimurium in antibiotic mice 
can cause colitis and subsequent fibrosis (57, 58). Mice pre-treated with streptomycin 24 
hours prior to oral administration of S. typhimurium leads to transmural inflammation and 
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mucosal ulcerations, accompanied by increased expression of TGF-β1, connective tissue 
growth factor, insulin-like growth factor 1 as well as an increased deposition of collagen in the 
caecal mucosa, submucosa and muscularis mucosa (58). Areas of fibrosis also had elevated 
levels of fibroblasts and myofibroblasts. In this study, fibrosis is evident by 7 days post-
infection, peaking at 21 days and persisting until 70 days. This model is easy to use and highly 
reproducible, as such is used extensively to research intestinal fibrosis.  
 
Chronic adherent-invasive Escherichia coli infection  
Chronic infection with adherent-invasive Escherichia coli (AIEC) leads to chronic inflammation 
and intestinal fibrosis (59).  Typically, AIEC dysbiosis is associated with human CD, however 
their role in CD immunopathology is unclear, due to a lack of suitable experimental models. 
Mice pre-treated with streptomycin receive oral administration of AIEC, inducing a TH1 and 
TH17-like immune response, resulting in increased levels of colonic IL-17, TNF-α, MCP-1, TGF-
β1, connective tissue growth factor, insulin-like growth factor and ECM deposition. Increased 
ECM deposition was visible as early as 7 days post-infection and was evident in the muscularis 
mucosa and lamina propria. Fibrosis persisted in the caecal wall of these mice 63 days post-
infection. Expression of Col1a2 and Col3a1 mRNA was increased in the caeca of AIEC-infected 
mice, compared with controls. The above changes in cytokines, growth factors and profibrotic 
mediators shows many similarities with the profiles seen in CD.  
 
6.6.2 Immune-mediated models  
 
T cell adoptive transfer 
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It is known that T cell abnormalities may indirectly modulate mesenchymal cells to exert 
profibrotic effects. Accordingly, T cell adoptive transfer may provide an immune-mediated 
model of intestinal fibrosis. Transfer of CD4+ CD45RBhigh T cells into b-17 SCID mice results 
in a lethal wasting disease with severe infiltration of mononuclear cells into the colon, and 
elevated IFN-γ mRNA (60-62). In contrast, transfer of CD4+ CD45RBlow or co-transfer of both 
T cell subsets did not result in colitis (61). Transfer of CD4+CD45RBhigh T cells resulted in 
diffuse inflammation from the caecum to the rectum, which was restricted to the lamina 
propria, but transmural in a few mice. This colitis resulted in mucin depletion, epithelial 
hyperplasia and mucosal thickening. The changes to the large intestine mirror those seen in 
UC and CD patients.  
 
6.6.3 Genetic models 
 
TGF-b1 induction 
TGF-β1 is a crucial mediator of fibrosis and mesenchymal cell proliferation, as such induction 
of the TGF-β1 gene in mice can lead to intestinal fibrosis (63). Transfection of spontaneously 
biologically active TGF-β1 recombinant gene via an adenovirus vector leads to increased TGF-
β1 levels in the colon, relative to uninfected mice. TGF-β1 gene transfer induces body weight 
loss, distension and hardening of the colon, as well as accumulation of faecal matter in the 
dilated region, indicative of severe fibrosis. Acute inflammation, mucosal ulceration and 
transmural immune infiltration was visible over the first 3 days post-infection, with 
inflammation and tissue injury resolving by day 14 post-infection. ECM deposition was seen 
in the submucosa of transfected mice and the serosa and subserosal region showed thickening 
in addition to increased cellularity. 14-28 days post-infection, more than 50% of 
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transfected mice developed colonic dilation and subsequent obstruction. These changes were 
associated with a thickening of the muscularis mucosa and muscularis externa. Masson’s 
trichome and Verhoeff’s elastic staining showed that the presence of fibrosis was not uniform 
throughout the colon but appeared as focal points, affecting regions 0.5 to 2 cm in length in 
the distal colon. In some instances, circumferential fibrosis was observed and, in some 
samples, only part of the tissue cross-section was fibrosed. Despite severe mucosal 
inflammation in the first week post-infection in transfected mice, at 14-28 days the colonic 
mucosa appeared similar to uninfected controls. However, the submucosa continued to show 
signs of fibrosis such as the accumulation of fibroblasts, granulocytes and monocytes and a 
significant deposition of collagen in the external muscle layers. Increased staining of α-smooth 
muscle actin (α-SMA) was observed in the heavily fibrotic serosal and subserosal areas of 
colon of transfected mice, but not in controls. Weak desmin staining within these sections 
confirmed that these α-SMA positive cells were in fact myofibroblasts and not smooth muscle 
cells. The TGF-b1 transfection model mimics many features of CD-induced fibrosis, especially 
the development of bowel obstructions. This model may be useful in the elucidation of 
mechanisms leading to intestinal fibrosis in CD.  
 
IL-10 deficiency  
IL-10 is a well characterised immunoregulatory and anti-inflammatory cytokine and genetic 
deficiency of the IL-10 receptor leads to severe IBD (64). As such, IL-10-/- mice show aberrant 
cytokine production and TH1-like responses, consequently leading to intestinal inflammation 
and fibrosis (65).  In 3-week old IL-10-/- mice, inflammatory changes initially occur in the 
caecum, ascending and transverse colon. As time progressed, lesions appeared in the 
remaining distal colon and rectum, with some mice developing inflammation in the small 
intestine.
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These changes seem to be driven by uncontrolled cytokine secretion by activated 
macrophages and CD4+ TH1-like T cells. TH1-like inflammatory mechanisms were reinforced 
by anti-IFN-γ antibody attenuation of intestinal inflammation in IL-10-/- mice. Treatments of 
infant mice with IL-10 also attenuated intestinal inflammation but did not alter disease 
progression. By 3 months of age, IL-10-/- mice developed multifocal lesions throughout the 
large intestine, including the caecum and rectum. The large intestine developed prominent 
epithelial hyperplasia, transmural inflammation predominantly of lymphocytes, plasma cells, 
macrophages and neutrophils and occasionally crypt abscesses were also present, signs 
consistent with human CD. Mice also showed signs of fibrosis in the absence of fissures, 
fistulae and ileal inflammation and as a result the authors suggest that IL-10-/- cannot be 
viewed as a true model of CD.  
 
Macrophage chemoattractant protein overexpression (MCP-1)  
Macrophage chemoattractant protein (MCP-1) is increased throughout the gastrointestinal 
tract in IBD. Increased levels of MCP-1 drives intestinal inflammation, however the exact role 
of MCP-1 in intestinal fibrosis is not known. Transfection of the MCP-1 gene significantly 
increased collagen, TGF-b1 and TIMP-1 production in the distal colon (66). Transmural 
collagen deposition was associated with an infiltration of T cells, macrophages and vimentin+ 
cells.  Collagen type I was most predominantly deposited in the muscularis mucosa and 
muscularis propria, whereas collagen type III in the submucosa and myenteric plexus. 
Overexpression of MCP-1 was unable to induce overproduced collagen in immunodeficient 
Rag2-/- mice. Overexpression of MCP-1 peaked on day 3 post-infection but persisted to day 42 
following administration of the recombinant gene. Collagen deposition was observed in the 
sub mucosa 3 days post-infection and the muscularis propria at later time points. MCP-1 
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overexpressing mice also had a significant increase in total collagen levels, relative to controls. 
Immunological assessment saw an increase in α-SMA+ fibroblasts within the muscularis 
propria. MCP-1 overexpressing mice showed a significant increase in colonic TGF-b1, TIMP-1 
and MMP-3 levels, relative to controls. This suggests that MCP-1 overexpression can be used 
a model for intestinal fibrosis and that MCP-1 may be a novel therapeutic target against 
intestinal fibrosis.  
 
TNF-like cytokine 1A overexpression  
Tumour necrosis factor-like cytokine (TL1A, TNFSF15) is involved in IBD pathogenesis, 
modulating the location and severity of intestinal inflammation and fibrosis (67). TL1A is 
overexpressed in the inflamed gut mucosa and regions of fibrostenosing disease in CD. 
Overexpression of TL1A in mice leads to spontaneous ileitis, proximal colitis and fibrosis. It has 
been demonstrated that the inflammatory effects driven by overexpression of TL1A can be 
ameliorated in the absence of resident microbiota. Reconstitution of germ-free Tl1a 
transgenic mice with specific pathogen free (SPF) mouse but not human microbiota resulted 
in increased fibroblast activation and collagen deposition. Fibroblast activation and migration 
was reduced in germ-free mice compared to native conditions, suggesting that intestinal 
fibrosis can be modulated by the gut microbiota.  WT mice showed no change in intestinal 
inflammation or collagen deposition when colonised with SPF or human flora. Tl1a transgenic 
mice colonised with SPF flora showed increased collagen deposition in the inflamed ileum and 
noninflamed caecum. Interestingly, Tl1a transgenic mice colonised with human flora showed 
no change in ileal or caecal collagen deposition or inflammation. This data suggests that Tl1a-
mediated intestinal inflammation requires the intestinal microbiota or microbial secreted 
products found in SPF mouse microbiota but not in human microbiota. 
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Fibroblasts express toll-like receptors and therefore can be activated by bacterial products 
(68). In the cecum of SPF-colonised mice which showed signs of fibrosis such as increased 
collagen deposition and fibroblasts activation, several microbes were found to correlate with 
fibrosis. The mucin-degrading bacteria M. schaedleri was found to correlate with fibrosis in 
the caecum, versus the decreased abundance of fibrosis in the colon or small intestine, in 
addition to Ruminococcus which are increased in CD and are associated with stricturing 
disease in paediatric CD (69). Additionally, Anaeroplasma was also increased in the fibrosed 
caecum of SPF-colonised mice. In contrast, members of Streptococcus and Lactobacillus 
correlated with fibrosis in the ileum. This is the first study to implicate the intestinal 
microbiome in intestinal fibrosis, suggesting that TL1A pathways and the microbiome may 
provide novel therapeutic targets against fibrostenosing CD.  
 
6.6.4 Spontaneous models  
 
SAMP mouse strain  
The SAMP1/YitFc (SAMP) mouse strain develops spontaneous chronic ileitis and subsequent 
ileal fibrosis and is a relatively new model of intestinal fibrosis. Although the exact 
pathogenetic mechanisms of this model are unknown, SAMP mice show TH1/TH2 immune 
activation, with TH1 responses predominating the acute phase, with a switch to TH2 in the 
chronic phase (70). This model highly mimics CD in regard to the disease location, histologic 
features, extra-intestinal manifestations and response to common therapeutics.  SAMP mice 
show signs of intestinal inflammation as early as 4 weeks of age, with an expansion of 
secretory epithelial cells such as goblet and Paneth cells, ileal hyperplasia of the muscularis 
propria, increased collagen deposition and stricture formation (71). Ileal mRNA expression of 
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COL1A1, COL3A, insulin-like growth factor-1 and connective tissue growth factor are all 
significantly increased in SAMP mice, relative to controls. Interestingly, neutralisation of IL-33 
mitigates ileitis and ileal fibrosis in SAMP mice when compared with vehicle controls (72). This 
model may allow for the consistent and reliable examination of fibrogenic pathways in CD at 
various timepoints.  
 
6.6.5 Human intestinal organoids  
 
Current in vitro models lack the ability to replicate the intricate architecture of the intestine -
intestinal organoids develop as 3D structures which resemble the intestine and are also 
comprised of a variety of specialised cell types, normally found in the gut. Intestinal organoids 
can be developed using human intestinal stem cells, thus provide a higher physiological 
resemblance to human disease, offering a more practical model for high-throughput screening 
(73). Generated from normal human pluripotent stem cells, intestinal organoids proceed 
through normal embryonic intestinal development and contain epithelium and mesenchyme, 
including myofibroblasts and as such is a feasible in vitro human model of intestinal fibrosis 
(74). Stimulation of human intestinal organoids with TGF-b1 results in upregulation of 
fibrogenic genes, including COL1A1, FN1, ACTA2, MYLK and MKL1 and a marked induction of 
α-SMA (75). Organoids can also be generated from the gastrointestinal tracts of mice, in 
particular the organoid-based epithelial to mesenchymal transition model may also be used 
as a novel model of intestinal fibrosis (76). Cells that contribute to fibrosis in CD can originate 
from intestinal epithelial cells via epithelial-to-mesenchymal transition (EMT) or from 
endothelial cells via endothelial-to-mesenchymal transition (77, 78). Recently, an EMT-
inducting transcription factor, ZNF281 is induced in HT29 cells when treated with 
inflammatory agents, cultured uninflamed colonic biopsies from patients with CD and in DSS-
treated mice (79).
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Expression of ZNF281 is found to correlate with disease severity in CD and UC and inhibition 
reduces proinflammatory and profibrogenic factors such as TIMP-1, fibronectin, α-SMA, IL-1β, 
IL-17 and IL-23. As with human intestinal organoids, mouse-derived intestinal organoids also 
respond to TGF-b1 in a concentration and time-dependent manner, causing disruption and 
death of organoids (76). Co-culture of intestinal epithelial organoids with macrophages 
significantly improves epithelial to mesenchymal transition, compared to organoids 
stimulated with TGF-b1 without co-culture. The authors suggest that this may be due to the 
increased concentration of TNF-α secreted by the LPS-activated macrophages.  
 
 Human intestinal organoids are ideal for testing responses to anti-fibrotic drugs, as such the 
authors assessed whether TGF-b1-mediated fibrogenic responses could be reversed by 
treatment with spironolactone, which is used as an anti-fibrotic agent in heart patients (75). 
Spironolactone suppressed TGF-b1-stimulated induction of COL1A1, FN1, ACTA2, MYLK and 
α-SMA protein expression. Accordingly, human intestinal organoids are highly effective for 
testing anti-fibrotic drugs and provide a more relevant disease state than in vivo animal 
models, as such they should be utilised when studying fibrogenic pathways and antifibrotic 
therapeutics. 
 
6.7 Cellular mediators of fibrosis 
 
Fibrosis occurs due to the excessive deposition of ECM by activated mesenchymal cells, 
predominantly myofibroblasts (13). Fibroblasts are essential for the synthesis of various ECM 
proteins, the main type being collagen. Matrix-secreting cells can be stimulated by a variety 
of signals including pathogen-associated molecular patterns and para- and autocrine signals 
(80).
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Both innate and adaptive immune responses can induce activation and differentiation of 
fibroblasts. Persistent, low-grade inflammation with multiple cycles of acute damage and 
wound healing leads to fibrosis. Consequently, the prevention of cyclic periods of tissue 
inflammation is a certain way to prevent the development of fibrosis. However, this may be 
difficult when the aetiology of the underlying inflammatory mechanism is unknown or poorly 
understood, such as in IBD. 
 
Stellate cells are a subset of mesenchymal cell precursors which can contribute towards 
fibrosis as they differentiate into myofibroblasts (81). Stellate cells from IBD tissues produce 
collagen sooner and in greater levels, when compared to cells from healthy controls and also 
differentiate in vitro into myofibroblasts at a higher rate than controls (82).  This suggests that 
stellate cells can be primed in vivo by inflammatory mediators, contributing towards a 
fibrogenic phenotype in IBD. Fibroblast expansion and activation occurs in response to 
inflammatory signals in the gastrointestinal tract. Fibroblast cell culture studies suggest 
altered responses to profibrogenic cytokines in IBD (83). Fibroblasts from UC and CD patients 
replicate faster than those from healthy controls, with no difference between CD and UC. 
Fibroblast collagen secretion, regardless of subtype, was increased IBD, relative to health. 
Additionally, platelet derived growth factor (PDGF), bFGF and TGF-b1-induced fibroblast 
secretion of collagen is increased from IBD fibroblasts. This activated subset of fibroblasts in 
both UC and CD are present in the tissue, regardless of the presence of intestinal fibrosis or 
inflammation. Fibroblasts can migrate along the intestine via concentration gradients of 
chemical signals involved in intestinal inflammation. Molecules which can induce chemotaxis 
include fibronectin, PDGF, IGF-I, EGF and TGF-b (when in the presence of fibronectin) (84-86). 
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TNF and IFN-γ have been found to repress fibroblast chemotaxis in vitro, possibly leading to 
the retention of fibroblasts in areas of inflammation.  
   
In the first stage of tissue repair, platelets are activated to induce coagulation, in turn releasing 
growth factors such as TGF-b1, which stimulates fibroblast-mediated ECM synthesis, in 
addition to platelet-derived growth factor which is a potent proinflammatory cell 
chemoattractant (87). As such, dysfunction within the coagulation cascade can lead to fibrosis 
(88). Damaged endothelial and epithelial cells also release a myriad of chemoattractant 
factors which can recruit inflammatory monocytes and neutrophils to sites of tissue damage. 
The persistent presence of neutrophils and macrophages can lead to the secretion of reactive 
oxygen and nitrogen compounds which can damage the surrounding tissues, leading to the 
formation of scars.  
 
6.8 Immune regulation of fibrosis 
 
The innate immune system is the first line of defence in the gastrointestinal tract, providing 
rapid and non-specific protection against pathogens.  Dysfunction or loss of innate immune 
regulation leading to dysregulated immune responses has been implicated in the 
pathogenesis of IBD. Innate immunity is largely driven through the interaction of immune cell 
pattern-recognition receptors (PRR) with pathogen associated molecular patterns (PAMP), 
which are pathogen-specific and crucial for their survival. PRRs are expressed on 
predominantly macrophages and dendritic cells and can identify a range of pathogens 
including bacteria, viruses, parasites, fungi and protozoa. Activation of PRR via the recognition 
of PAMPs leads to proinflammatory activation, particularly stimulation of phagocytic cells 
such as macrophages, neutrophils and dendritic cells, leading to the secretion of 
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proinflammatory cytokines such as TNF-α, IL-1β and IL-6 and chemokines such as CCL5. 
Furthermore, dysfunction of PRRs such as toll-like receptors (TLR) and NOD-like receptors 
(NLR) have been found to be implicated in the pathogenesis of IBD.  
 
In contrast, the adaptive immune system provides a highly powerful and pathogen specific 
response which takes days to develop. Adaptive immunity is reliant on the recognition of 
specific antigens by T or B cells, resulting in the activation of TH lymphocytes (TH1, TH2, TH17 
and TH22 cells). Cells such as macrophages and dendritic cells bridge innate and adaptive 
immunity through the presentation of antigens to T cells via major histocompatibility 
complexes (MHC) in lymphoid tissue.  Activated T cells proliferate and differentiate into 
memory or effector T cells which migrate towards the site of inflammation via the circulatory 
system. The migration of T cells is mediated by adhesion molecules such as integrins and 
selectins found on the cell surface. In IBD inflammation, T cells are directed to the lamina 
propria via expression of gut homing integrin α4β7 and the mucosal addressin-cell adhesion 
molecule 1 (MAdCAM-1). TH1 immune responses are predominantly against intracellular 
pathogens such as bacterial, viruses and fungi, leading to the secretion of IFN-γ, IL-12 and TNF-
α, via activation of STAT1 (89). In contrast, TH2 responses are targeted against extracellular 
pathogens through the secretion of IL-4, IL-5, IL-13, IL-21 and IL-25, which leads to the 
activation of STAT6 and GATA-3 (89). Classically, CD has been considered to be a TH1-driven 
disease, whilst UC was TH2-mediated, however recent studies show overlap with multiple 
subsets of T lymphocytes (90, 91). Additionally, TH17 pathways are activated by IL-6, IL-23 and 
TGF-b1 via STAT3 in the absence of IL-4 and IL-12 and leads to the increased 
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secretion of IL-22, IL-13, TNF-α and fibroblast growth factor. Accordingly, TH17 lymphocytes 
have been implicated in the pathogenies of intestinal fibrosis.  
 
Innate immune regulation of fibrosis 
Innate immune cells such as monocytes, neutrophils and mast cells produce proinflammatory 
and profibrotic mediators such as interleukins, tumour necrosis factor, TGF-b1 and PDGF, 
promoting myofibroblast differentiation. As such, innate immune pathways contribute 
towards the cellular activation of fibrosis.  Monocyte-derived cells such as macrophages and 
dendritic cells can regulate activated myofibroblasts and their progenitors by acting directly 
on the matrix (92). Activated M1 macrophages are induced by IFN-γ, TNF-α or bacterial 
productions which act via MyD88 and NF-κB which lead to further tissue damage and 
increased myofibroblast resistance to apoptosis. M2 macrophages are key inducers of wound 
healing and have been implicated in the development of fibrosis. They are produced following 
the secretion of IL-4 or IL-13 through STAT6 activation. It has been shown that M2 cells 
compete with TH2 cells and fibroblasts for L-arginine and L-proline which are crucial for 
regulating cell growth and collagen synthesis, respectively (93). M2 cells are also powerful 
inducers of anti-inflammatory effects by TREG cells, leading to the suppression of fibrosis. As 
such, M2 macrophages, through multiple mechanisms, contribute towards the inhibition of 
ECM synthesis by myofibroblasts. Additionally, M2 macrophages produce profibrotic factors 
such as TGF-b1, connective tissue growth factor, PDGF, fibrosis growth factor and insulin-like 
growth factor (94). 
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During epithelial injury, neutrophils are recruited to exterminate invading pathogens but to 
also remove tissue debris. Prolonged neutrophil activation can exacerbate tissue damage and 
promote the activation of myofibroblasts through the secretion of fibrotic cytokines, 
chemokines and reactive oxygen and nitrogen species (94). Neutrophils are also one of the 
main sources of MMP-9 during intestinal inflammation which is degranulated upon 
stimulation (95). Furthermore, proline-glycine-proline is a product of collagen breakdown by 
MMPs and propyl endopeptidase and has been found to be a chemoattractant for neutrophil 
(96). Recently this has been suggested as a mechanism for MMP-induced neutrophil 
infiltration in IBD. Neutralisation of proline-glycine-proline leads to reduced neutrophil 
infiltration and subsequent intestinal inflammation (97). Mast cells and eosinophils can 
promote fibrosis through their secretion of TGF-b1 and IL-13 and activation of 
proinflammatory lymphocytes.  
 
Adaptive immune regulation of fibrosis  
The TH17-secreted cytokine IL-17a has been implicated in the pathogenesis of fibrosis, 
particularly in lungs, heart and liver (98, 99). IL-17a secretion induces amplified neutrophil 
recruitment, leading to tissue damage and tissue fibrosis. Additionally, IL-17a directly induces 
the expression of MMP-1 in human cardiac fibroblasts, suggesting that IL-17a regulates 
fibrosis by inducing inflammatory responses and regulating the downstream activation of 
fibroblasts (93). TH2 cytokines such as IL-4, IL-5 and IL-13 have all been shown to be involved 
in profibrogenic mechanisms (100, 101). IL-13 is crucial for fibrotic tissue remodelling and has 
been implicated in lung, skin, gut and liver fibrosis and stimulates the production of TGF-b1 
(102-105). IL-13-induced fibrosis is regulated by the abundance of IL-13Ra1 signalling receptor 
and IL-13Ra2 decoy receptor expressed on cells such as myofibroblasts (106, 107). Low or 
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absent IL-13 binding to the decoy receptor exacerbates fibrosis (108). TH1 immune activation 
such as IFN-γ, can have antifibrotic activity, partially by antagonising TGF-b1 (109). IFN-γ also 
directly dampens fibroblasts proliferation, TGF-b1-induced expression of procollagen I and 
procollagen III and collagen deposition by myofibroblasts (93, 110). Additionally, IFN-γ can 
also prevent TH2-cytokine-induced differentiation of peripheral blood monocytes into 
fibrocytes, of which are believed to participate in fibrogenic pathways (93, 111). 
 
6.9 Profibrotic mediators of fibrosis 
 
The gastrointestinal microbiota and microbial-secreted products, as well as growth factors 
and cytokines secreted from immune and non-immune cells promote the differentiation and 
activation of mesenchymal cells which drives intestinal fibrosis (13). TGF-b1 is undeniably the 
key inducer of fibrosis and has been shown to have both anti-inflammatory and profibrotic 
effects. Increased TGF-b1 secretion correlates with the development of liver, lung, kidney, skin 
and cardiac fibrosis and inhibition of this signalling pathway reduces the progression of fibrosis 
in experimental models (93). TGF-b1 can directly induce the differentiation and activation of 
fibroblasts in collagen-secreting myofibroblasts. It has been suggested that the source of TGF-
b1 secretion can dictate its activity (112). TGF-b1 secreted from macrophages generally causes 
wound-healing leading to profibrotic activity and secretion from TREG cells leads to anti-
inflammatory and antifibrotic affects (112).  
 
 Interestingly, mouse models do not develop fibrosis in absence of microbiota (41). It has been 
shown that persistent infection with Salmonella enterica Serovar Typhimurium can induce 
protease expression during intestinal fibrosis (113). Mice develop severe and persistent 
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intestinal fibrosis in response to chronic S. Typhimurium infections, closely resembling the 
phenotype of human disease. MMPs, serine proteases, cysteine proteases and protease 
inhibitors were among the proteins which had differential regulation in fibrosis.  Of the 96 
significantly regulated proteases and inhibitors, 56 were upregulated and 40 were 
downregulated in fibrotic caecal tissue, when compared to control ceca from mock-infected 
mice. Some of the most strongly upregulated proteases in fibrotic caecal tissue included MMP-
3, MMP-7, MMP-8, MMP-10 and MMP-13. Expression of MMP-2 remained unchanged during 
infection. The epithelial barrier-promoting metalloprotease meprin-b (Mep1b) and the 
glandular kallikreins Klk1b5, Klk1b8 and Klk1b22 and tryptase-g (Tpsg1) were amongst some 
of the proteins which were significantly downregulated in fibrotic tissue. It was also found that 
S. Typhimurium infection can directly stimulate protease expression in macrophages and 
epithelial cells but not in fibroblasts. Several cathepsins (Ctsc, Ctsd, Ctsk), protease inhibitors 
Serpina3m and stefinA1 (Stfa1) and TIMP-1 were upregulated in S. Typhimurium-induced 
intestinal fibrosis, overall showing upregulated expression of MMPs and impairment of serine 
protease expression. The epithelium of noninflamed controls also stained positive for MMP-
3 and MMP-8, in contrast to the epithelia of CD and UC patients, where MMP-3 and MMP-8-
positive inflammatory cells were only identified in the lamina propria. Additionally, MMP-7, 
MMP-10 and granzyme K were not detected in control tissue, but a small subset of UC and CD 
crypt epithelial cells stained strongly for MMP-7. Epithelial and inflammatory cells from IBD 
patients stained positive for MMP-10 and granzyme K. Staining of cathepsin C, cathepsin D 
and cystatin A was decreased in the lamina propria of healthy control tissue, when compared 
to tissue from both UC and CD patients. Overall, there were no changes in protease staining 
between UC and CD intestinal tissue, which were both significantly changed when compared 
to noninflamed controls. Additionally, protease changes that were observed in 
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intestinal mouse tissues were largely reflected in human IBD tissues. This study suggests that 
the specific inhibition of some proteases could be a novel target in the treatment of chronic 
inflammation and subsequent fibrosis in IBD.  
 
TGF-b is highly produced in CD and has been shown to drive pro-fibrogenic action in CD by 
stimulating TIMP-1 and reducing MMP-12 activity. In contrast, TGF-b neutralising is also 
upregulated in segments of fibrostenotic bowel, stimulating the production of collagen, TIMP-
1, MMP-3 and MMP-12 (114).  Mucosal and submucosal biopsies from IBD patients have 
higher collagen content, including type VI collagen, compared to control tissue (115). In tissues 
from CD patients with fibrostenotic disease, levels of IL-36A were significantly increased and 
correlated with high numbers of activated fibroblasts that were positive for a-SMA. IL-36R 
stimulation of mouse and human fibroblasts leads to upregulation of genes required for tissue 
remodelling and fibrosis, as well as an increased expression of collagen VI. Il1rl2-/- mice and 
mice administered antibodies against IL-36R developed less severe DSS and TNBS colitis and 
fibrosis. Administration of IL-36R neutralising antibodies significantly reduced established 
fibrosis in mice with chronic intestinal inflammation. As such, antagonising or blocking IL-36R 
signalling may be beneficial for the prevention and treatment of intestinal fibrosis in IBD.  
 
6.10 Antifibrotic mediators of fibrosis 
 
IFN-γ and IL-12 are two of the main mediators which work to supress fibrosis (116). IFN-γ 
directly inhibits fibroblast proliferation as well as the TGF-b1 dependent expression of 
procollagens I and III and collagen in activated myofibroblasts (110). Additionally, IFN-γ 
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interferes with fibroblast migration by modulating the cellular distribution of fibronectin and 
the cytoskeleton (117). Despite showing therapeutic potential, clinical studies investigating 
IFN-γ in idiopathic pulmonary fibrosis have been discouraging (118). IL-12 also induces 
antifibrotic mechanisms through its stimulation of natural killer and TH1 cells and subsequent 
IFN-γ secretion.  
 
The induction of autophagy in CX3CR1+ mononuclear cells limits intestinal fibrosis through 
modulation of the IL-23/IL-22 axis (119). MTOR inhibition by rapamycin or mTOR deletion in 
CX3CR1+ mononuclear phagocytes inhibits the expression of IL-23 and is accompanied by 
reduced intestinal production of IL-22 which improves TNBS-induced fibrosis in mice. 
Decreased IL-23 expression results in increased autophagy activity. Suppression of the 
autophagy gene Atg7 results in the increased expression of IL-23 and the subsequent 
expression of IL-22 and increased intestinal fibrosis. This induction of IL-22 and intestinal 
fibrosis can occur in RAG-/- mice and depletion of innate lymphoid cells attenuates 
fibrogenesis, suggesting that this process is independent of T and B cells. IL-22 stimulates the 
differentiation of fibroblasts to myofibroblasts. Neutralisation of IL-22 or IL-23 suppresses 
fibrogenesis. This study shows that altered mTOR/autophagy in CX3CR1+ mononuclear 
phagocytes stimulates the IL-23/IL-22 axis, causing a disproportionate fibrotic response. This 
suggests that this signalling cascade may provide novel targets for the treatment of fibrosis in 
CD. 




In contrast to other organs such as the lungs and liver, intestinal fibrosis is understudied, 
despite being one of the most common complications of IBD. Dysregulated and uncontrolled 
periods of inflammation drive the development of fibrosis and the promotion of fibroblast 
activation and alteration of the normal ECM. Although fibrogenic mechanisms are conserved 
between various organs, fibrosis in the setting of IBD is complicated by the myriad of 
inflammatory mechanisms underpinning gastrointestinal inflammation. Although fibrosis can 
be prevented by reducing inflammatory processes, there are no current pharmacological 
therapies to reverse already established fibrosis. Treatment of this complex complication will 
require a multifactorial approach, consisting of anti-inflammatory, anti-fibrotic and epigenetic 
elements. The emergence of more clinically relevant models such as human intestinal 
organoids will allow for a more accurate replication of fibrotic diseases. In addition to poor 
pharmacological treatments, diagnostic imaging of fibrosis of any organ, but particularly the 
gastrointestinal tract is lacking and requires attention. Molecular imaging and immuno-PET 
may provide the sensitivity and quantification of the entire gastrointestinal tract that is 
required for improved patient care and outcomes.  
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7.2 Abstract  
 
Intestinal fibrosis is a common complication of inflammatory bowel disease (IBD) but remains 
difficult to detect and treat. Matrix metalloproteases (MMPs) and tissue inhibitors of matrix 
metalloproteases (TIMPs) have key roles in fibrosis and are therefore potential targets for 
detection of fibrosis by immuno-PET, however it remains unclear whether they differ between 
inflamed and fibrotic states. Here we aimed to determine whether immuno-PET of F(ab’)2 
antibody fragments targeting MMPs can detect DSS colitis induced colonic fibrosis. Methods: 
Mice were administered 2% DSS treated water for 1 cycle (inflamed) or 3 cycles (fibrotic) or 
were untreated (control). Colonic and kidney collagen, innate cytokine, MMPs, TIMP-1 and 
faecal MPO concentrations were analysed by multiplex / ELISA. α-pro-MMP-9 F(ab’)2 
fragments were engineered, conjugated to 89Zr and administered i.v. prior to PET imaging. Ex-
vivo analysis was determined by Cherenkov imaging (IVIS spectrum) and biodistribution by γ-
counts. Results: Colonic innate cytokine concentrations were increased in inflamed mice but 
not fibrotic mice. Colonic collagen concentrations were increased in fibrotic mice. MMPs were 
increased in inflamed mice, but only pro-MMP-9 remained increased in fibrotic mice. 89Zr-pro-
MMP-9 F(ab’)2 uptake was increased in the intestine but also in the kidney of fibrotic mice, 
where collagen and pro-MMP-9 concentrations were increased. Conclusion: 89Zr-pro-MMP-9 
F(ab’)2 detects colitis induced intestinal fibrosis and associated kidney fibrosis. This is the first 
immuno-PET study of fibrosis and highlights the utility of combining antibody specificity with 
PET sensitivity for detecting disease targets in tissues that are distant to the disease origin.  
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7.3 Introduction  
 
Inflammatory bowel disease (IBD), incorporating Crohn’s disease and ulcerative colitis, is 
characterised by remitting and relapsing inflammation of the lower gastrointestinal (GI) tract 
(1). Intestinal fibrosis is one of the most common IBD related complications, with severe 
fibrosis leading to stricture and stenosis in ~30% of IBD patients (2-4). Intestinal fibrosis is not 
currently treatable and can become life threatening, leaving endoscopic mechanical 
manipulation or surgical resection as the only options (5, 6). Importantly, no validated 
diagnostic tools or biomarkers currently exist for detecting or staging intestinal fibrosis (5, 6).  
 
Fibrosis is characterised by the excessive deposition of extracellular matrix (ECM) proteins 
including collagen by persistently activated fibroblasts (7-9). Fibrosis typically occurs in a 
progressive manner following repeated episodes of inflammatory damage and remission, or 
healing, such as occurs in IBD and in the dextran sodium sulphate (DSS) preclinical model of 
intestinal fibrosis (8, 10, 11). Matrix metalloproteinases (MMPs) regulate fibrosis by degrading 
the ECM that is normally laid down as the tissue renews (7, 12). MMP function is tightly 
regulated by tissue inhibitors of matrix metalloproteinases (TIMPs), which inhibit MMP 
activity in a 1:1 ratio. MMP-2, -3, -8 and -9, and TIMP-1 are altered to varying extents in fibrotic 
tissue resected from IBD patients and in preclinical models of intestinal fibrosis (10, 11, 13-
15). 
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However, MMPs and TIMPs are also increased in inflamed intestinal tissue and it remains 
unclear how their expression is altered in inflamed relative to fibrotic tissue.  
 
Diagnostic tools are ideally sensitive, quantitative and selective for their pathology, non-
invasive to the patient, provide information rapidly and do not influence the disease process 
(5, 16). Stricture can be detected by endoscopy, however endoscopy is limited to imaging only 
the mucosal surface and not the deeper layers of the colon wall where fibrosis develops (17). 
Molecular imaging approaches including positron emission tomography (PET) have superior 
sensitivity and provide quantitative information (16, 18). Immuno-PET combines the superior 
target selectivity provided by antibodies with the sensitivity of PET and we, amongst others, 
have previously demonstrated that immuno-PET strategies effectively detect intestinal 
inflammation (16, 19-21). However, the use of intact antibodies as molecular imaging probes 
is challenging as their relatively high molecular weight results in long half-lives, potentially 
translating into increased patient exposure to ionising radiation, and it may also impede the 
penetration of fibrotic tissue (22). Engineering F(ab’)2 antibody fragments from intact 
antibodies by cleaving the effector FC region retains the target specificity of the antibody 
whilst reducing its molecular weight, thereby increasing excretion and promoting tissue 
penetration.  
 
Here we aimed to undertake the first immuno-PET study of fibrosis in any tissue, preclinical 
or clinical, to determine whether immuno-PET of F(ab’)2 antibody fragments targeting MMPs 
can detect DSS colitis induced colonic fibrosis. 
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7.4 Materials and methods  
 
All experiments were approved by the Animal Ethics Committee of the South Australian Health 
and Medical Research Institute (SAHMRI) and The University of Adelaide.  
 
Mice  
Male C57BL/6jSah mice aged 10-14 weeks (20-30g) were bred and group housed in a specific 
pathogen-free environment at the South Australian Health and Medical Research Institute 
(SAHMRI). Animals had ad libitum access to food and water. Experiments were conducted 
with only male mice to eliminate the potential confounding effects of the oestrous cycle. Mice 
were humanely euthanised via CO2 inhalation and cervical dislocation to remove tissues.  
 
DSS Colitis Model  
Colonic inflammation was induced by the addition of 2% (w/v) dextran sodium sulphate (DSS) 
(molecular mass 40–50 kDa, Alfa Aesar, Lancashire, United Kingdom) for 5 days followed by 
an additional 3 days of normal drinking water for inflamed mice (d8 inflamed) (20), while 
fibrosis was induced by repeating 3 cycles of 5 days DSS treatment followed by 9 days of 
normal drinking water. Mice were assessed daily for signs of colitis including body weight and 
diarrhoea. Healthy mice were age and weight matched. Colon length was measured from the 
tip of the anus to the distal end of the colon.
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Hydroxyproline assay  
Hydroxyproline concentrations were determined essentially as described in the 
manufacturer’s protocol (Abcam, Cambridge, UK). Briefly, ~1cm sections of distal colon or 
kidney were excised free of surrounding fat and blood vessels and homogenised in 100µL 
dH2O / 10mg tissue before being hydrolysed in 10N NaOH (Sigma, Sydney, Australia) for 1 hr. 
at 120°C, then neutralised with 10N HCl (Chem Supply, Gillman, Australia) and the 
supernatant collected after centrifugation. Samples and standards were evaporated on a 96 
well flat bottom plate, oxidised (Chloramine-T for 20 minutes), and absorbance measured at 
560nm after 4-(Dimethylamino)benzaldehyde incubation for 45 minutes at 65°C. 
Hydroxyproline concentrations were determined based on their relationship with standards 
of known concentration and normalised to tissue weight.  
 
Histology 
1cm sections of distal colon were excised with surrounding fat, stored in 4% formalin at 4°C 
and mounted in paraffin blocks. 10x4 µm sections of formalin fixed (4°C overnight) paraffin 
embedded sections were stained with Masson’s Trichome and processed for image capture 
(Nanozoomer (Hamamatsu, Japan)).  
 
Innate cytokine and matrix metalloprotease concentrations 
Proteins were extracted from a 1cm section of distal colon or kidney as previously described 
(20, 23-25). Concentrations of the innate cytokines IL-1α, IL-1β, IL-6, IL-10 and TNF-α (Merck 
Millipore, Massachusetts, USA) and matrix metalloproteases (MMP) MMP-2, MMP-3, MMP-8 
and Pro-MMP9 (Merck Millipore) were determined by multiplex assay, while TIMP-1 
concentrations were determined by ELISA (R&D systems, Minnesota, USA). Kidney pro-
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MMP-9 concentrations were determined by ELISA (R&D systems). Concentrations were 
normalised to total protein concentration as determined by a BCA assay (Abcam, UK) as 
previously described (20, 24, 25).  
 
MPO ELISA  
Luminal faecal pellets were removed and homogenised for MPO processing and supernatants 
collected as previously described (20, 23). MPO concentrations were determined by ELISA 
essentially as per manufacturer’s instructions (ThermoFisher Scientific, Waltham, MA, USA), 
with MPO concentrations determined based on a relationship to standards of known 
concentration and results standardised to faecal wet weight. The limit of sensitivity was 
<14ng/ml.  
 
F(ab’)2 generation, conjugation and radiolabelling 
Rat α-mouse pro-MMP-9 IgG2A (R&D Systems Clone # 116134) F(ab’)2 fragments were 
generated by digesting on an immobilised pepsin agarose resin for 4 hours. at 37°C, followed 
by purification on a protein A column essentially as per manufacturer’s instructions 
(ThermoFisher Scientific). Intact and fragmented antibodies were collected and analysed by 
SEC-HPLC (LC-20, Shimadzu, Kyoto, Japan) with an AdvanceBio SEC 300 column (7.8x300 mm, 
2.7µm, Agilent Technologies, Foster City, USA) under isocratic conditions, with peaks detected 
at 280nM. Mass was calculated from a 15-600kDa protein standard mix (Sigma). 89Zirconium 
(89Zr) production and antibody radiolabelling and conjugation was performed essentially as 
previously described (20). Briefly, 89Zr-oxalate was produced via proton irradiation of an 89Y 
target on a PETtrace 880 cyclotron (GE Healthcare, Illinois, USA) and purified on the ALECO 
solid target processing system (Comecer, Italy). 
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NCS-Bz-DFO (Macrocyclics, Texas, USA) was conjugated to a-pro-MMP-9 F(ab’)2 fragments 
and radiolabelled with 89Zr. Purity was confirmed by SEC-HPLC as described above. Specificity 
was determined by shift assay (SEC-HPLC) following incubation of recombinant pro-MMP-9 
(R&D systems, 5mg/mL) in the presence or absence of a-pro-MMP9 F(ab’)2 in 1:10 ratio for 
2hours. at room temperature.  
 
MRI-PET  
1-2 MBq of 89Zr-a-pro-MMP-9 F(ab’)2 (71µg) in 100-200µL of normal saline was administered 
intravenously (tail vein) 18 hours. prior to imaging and PET scans performed 18 hours later 
over 30 minutes using a submillimeteric-resolution (0.7mm) (Albira PET-SPECT small animal 
scanner, Bruker Biospin GmbH) as previously described (20). Manually drawn volumes of 
interest (VOI) were analysed as previously described (20).  
 
Ex vivo analysis  
Organs were dissected immediately after PET imaging, weighed and intestinal 89Zr 
accumulation counted by Cherenkov luminescence imaging performed with an optimal 
imager (IVIS Lumina, Perkin Elmer USA) equipped with a CCD camera (exposure time 600sec., 
binning factor 8, field of view 23cm, in open filter mode), with counts background corrected. 
89Zr biodistribution was determined in organs using a Hidex g-counter (Hidex, Finland) with 
counts background and decay-corrected as previously described (20). 
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Statistical Analysis  
Data are expressed as mean±SEM in all cases. The significance of results were determined by 
unpaired t test or one-way ANOVA with Tukey’s post-hoc test. Differences with P<0.05 were 
considered statistically significant.  
 
7.5 Results  
 
Repeated cycles of DSS induces colonic fibrosis 
Colon length was reduced in d8 inflamed mice, however colonic shortening did not occur in 
fibrotic mice to the same extent as inflamed mice (Figure 1a). Collagen deposition was 
increased in the colons of fibrotic mice relative to inflamed mice and controls as indicated by 
hydroxyproline content and Masson’s trichrome staining (Figure 1B). 



















Figure 1. Colonic collagen content increases in inflamed (1 DSS cycle) and fibrotic (3 DSS cycles) 
mice. (A) Colon length did not shorten to the same extent in fibrotic mice as in inflamed mice. 
(B) Repeated DSS cycles increased the colonic collagen content as indicated by hydroxyproline 
concentration (left) and Masson’s trichrome staining (right) **P<0.01, ***P<0.001. 
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Innate cytokines are not altered in fibrotic mice 
The colonic concentrations of innate cytokines IL-1α (Figure 2a), IL-1β (Figure 2b), IL-6 (Figure 
2c) and TNF-α (Figure 2d), and faecal MPO (Figure 2f) were substantially increased in inflamed 
mice relative to controls. However, the colonic concentrations of IL-1α, IL-1β, IL-6 and TNF-α 
and faecal MPO did not differ between controls and fibrotic mice. IL-10 intestinal 
concentrations did not differ between d8 inflamed, d42 fibrotic and control mice (Figure 2e). 
These results indicate that the key innate immune mediators of intestinal inflammation are 













Figure 2. Innate immune mediators are not altered in colonic fibrosis. A) Colonic 
concentrations of A) IL-1α, B) IL-1β, C) IL-6 and D) TNF-α were increased in inflamed but not 
fibrotic colons, as are F) faecal MPO concentrations, while E) IL-10 concentrations were not 
altered in inflamed or fibrotic mice. *P<0.05, **P<0.01. 
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Pro-MMP9 remains increased in the fibrotic colon.  
The colonic concentrations of the MMP members MMP-2 (Figure 3a), MMP-3 (Figure 3b), 
MMP-8 (Figure 3c), Pro-MMP-9 (Figure 3d) and TIMP-1 (Figure 3e) were substantially 
increased in inflamed mice relative to control mice. However, while the colonic concentrations 
of MMP-3, MMP-8 and TIMP-1 were higher in fibrotic mice than controls, they were 
substantially reduced compared to inflamed mice. MMP-2 concentrations did not differ in d42 
fibrotic mice relative to control mice. Importantly, only pro-MMP-9 concentrations remained 













Figure 3. Pro-MMP-9 concentrations remain increased in fibrosis. (A) MMP-2, (B) MMP-3, (C) 
MMP-8, (D) pro-MMP-9 and (E) TIMP-1 were increased in inflamed and fibrotic mice, but only 
pro-MMP-9 remained as high in fibrotic colons as in inflamed colons. *P<0.05, **P<0.01, 
***P<0.001. 
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89Zr-Pro-MMP-9 F(ab’)2 immuno-PET Detects Intestinal fibrosis  
a-pro-MMP9 F(ab’)2 fragments had a retention time of 10.24 minutes. and a molecular weight 
of 103kDa, while the intact pro-MMP-9 antibody had a retention time of 9.82 minutes and a 
molecular weight of 138kDa (Figure 4a). The specificity of our tracer was confirmed by the 
reduction in pro-MMP-9 signal in samples co-incubated with a-pro-MMP9 F(ab’)2 (Figure 4b). 
PET imaging revealed intestinal uptake of 89Zr-Pro-MMP-9 F(ab’)2 was increased in the colon 
(Figure 5a), but, unexpectedly, also in the kidney (Figure 5b) relative to controls (See online 
resource video 1 (control) and 2 (fibrotic)). These findings were confirmed by ex-vivo analysis 
that demonstrated that 89Zr-α-pro-MMP-9 F(ab’)2 uptake was increased in the large intestine 
and kidney in d42 fibrotic mice relative to controls by analysis of Cherenkov luminescence 
(Figure 6a) and g-counts (Figure 6b). 89Zr-α-pro-MMP-9 F(ab’)2 uptake was not observed in 
other gastrointestinal sites including the small intestine and caecum but was increased the 
spleen and liver (Figure 6b). Uptake was similar between DSS treated and control mice in all 
other tissues investigated.  
 
Figure 4. A) α-pro-MMP-9 F(ab’)2 fragments had a longer retention time than intact antibody 
and B) specifically bound pro-MMP-9. 





















Figure  5. 89Zr-α-pro-MMP-9 F(ab’)2 PET detection of A) colonic and B) kidney fibrosis. Volume 
of interest (VOI) analysis with representative PET image (coronal and sagittal) of control and 
fibrotic mice. Ki=kidney. **P <0.01, ***P <0.001. 
Chapter 7 Immuno-PET of intestinal fibrosis 
 207 
Repeated DSS cycles induce kidney fibrosis 
Hydroxyproline (Figure 7a) and pro-MMP-9 (Figure 7b) concentrations were increased in the 
kidney of fibrotic mice relative to inflamed mice and controls.  
 
 
Figure 6. Ex vivo A) Cherenkov luminescence analysis and B) biodistribution of 89Zr-α-Pro-









Figure 7. Repeated DSS cycles increased A) hydroxyproline and B) pro-MMP-9 concentrations 
in the kidney *P<0.05, **P<0.01, ***P<0.001. 




Fibrosis is a common and serious complication of IBD but remains difficult to detect and treat. 
We conducted the first immuno-PET study of fibrosis to demonstrate that 89Zr labelled F(ab’)2 
antibody fragments directed against pro-MMP-9 reliably detects colonic fibrosis in the 
absence of inflammation. We demonstrate that the pro-MMP-9 signal in the colon co-exists 
with a strong signal in the kidney, which we also reveal becomes fibrotic in this model. These 
findings highlight the utility of immuno-PET for detecting changes in specific mediators of 
fibrosis in the organ of interest and also in organs that are distant from the initially affected 
site.  
 
We compared MMP, TIMP and innate immune cytokine concentrations in inflamed and 
fibrotic intestines and demonstrate that pro-MMP-9 selectively remains as high in fibrotic 
tissue as in inflamed tissue. Our findings of increased MMP-2, -3, -9 and TIMP-1 in fibrotic 
intestinal tissue confirm previous findings in preclinical models of intestinal fibrosis (10, 11, 
26). However MMP and TIMP expression in fibrotic intestinal resections from IBD patients 
remains controversial; MMP-2, -3, -9 and TIMP-1 are reportedly increased to a similar extent 
in fibrotic and inflamed intestinal tissue relative to tissue from healthy subjects (14, 15), while 
others observed that TIMP-1 is increased but MMP-3 is reduced in intestinal fibrosis relative 
to nearby unstrictured tissue (13). Furthermore, MMPs and TIMPs are typically also 
upregulated in inflamed regions of IBD patients, and some have suggested that serum MMP 
concentrations may be suitable as biomarkers of intestinal inflammation (14, 27-31). These 
observations highlight the difficulty in identifying unique markers of fibrosis as inflammation 
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and fibrosis can co-exist (6), highlighting the importance of comparing inflamed and fibrotic 
tissue. We found that of all the MMPs and innate cytokines investigated, only pro-MMP-9 
remained as high in fibrotic tissue as in inflamed tissue indicating that pro-MMP-9 
concentrations remain high in the absence of inflammation. Our findings related to MPO are 
particularly important as MPO is closely related to calprotectin in humans and faecal 
calprotectin content is a clinically useful marker of intestinal inflammation. Therefore, our 
study demonstrates that high pro-MMP-9 is a biomarker of intestinal fibrosis in the absence 
of inflammation and would potentially be of use in IBD patients experiencing symptoms of 
fibrosis that are concomitant with low faecal calprotectin levels. The focus of this study was 
to image and compare intestinal fibrosis with healthy, non-fibrotic mice, as such we did not 
perform imaging experiments on d8 inflamed mice. As such, this may limit some of the 
conclusions that can be drawn from this study. 
 
There are no validated diagnostic tests for intestinal fibrosis, highlighting a major unmet need 
as early intervention is prevented. Furthermore, there are no endorsed endpoints for clinical 
trials of urgently needed therapeutics. Endoscopy has long been the backbone tool for 
diagnosis of intestinal disease, but is only useful for detecting fibrosis in its later stages when 
stricture and stenosis manifest, and the jejunum and proximal ileum are normally difficult to 
access by endoscopy (17, 32). Additionally, there is no accepted histopathological scoring 
system for grading the severity of intestinal fibrosis in biopsies obtained from endoscopy. 
Recent developments in MRI, CT and intestinal ultrasound have provided some promise for 
imaging intestinal fibrosis (5), however their sensitivity is typically lower than PET and 
generating quantifiable data can be difficult (18). Additionally, these technologies typically 
focus on discrete body regions and therefore potentially miss concurrent disease in other 
organs, as we observed in the kidney in the current study. Only one study to date has assessed 
Chapter 7 Immuno-PET of intestinal fibrosis 
 210 
 PET/SPECT approaches for detecting fibrosis in IBD patients, demonstrating that PET 
combined with MR enterography could differentiate fibrotic strictures from inflammation 
while PET/CT did not perform as well (17, 33). However, the metabolic marker 18F-FDG was 
used as the probe in this study and discriminating the changes in metabolism that are induced 
in fibrosis from those that are related to inflammation involved changes is likely to be difficult. 
Advances in the molecular imaging of fibrosis have been made in other tissues, and 
clinical/preclinical studies have now identified useful probes targeting the stomatostatin 
receptor, ECM constituents including collagen and fibrin, cathepsins and integrins involved in 
TGF-β activation (18). However, these are yet to be applied to intestinal fibrosis in clinical or 
preclinical studies, and, to the best of our knowledge, our study is the first immuno-PET based 
approach to identify fibrosis in any tissue.  
 
Immuno-PET directed against immune cells or mediators has demonstrated efficacy for 
detecting colonic inflammation in preclinical models (16, 19-21). We recently demonstrated 
that targeting inflammation induced immune mediators such as IL-1β results in a substantially 
more localised bio-distribution than targeting immune cells, presumably as while immune 
cells migrate to inflamed sites they are also widely distributed throughout the body (20). 
These findings prompted our examination of inducible mediators of fibrosis as opposed to 
markers on the surface of fibroblasts or constitutively secreted mediators such as TGF-β1. 
Here, using the same model of colonic inflammation as our previous study, we confirmed that 
IL-1β is the most favourable innate immune cytokine for detecting intestinal inflammation as 
it had the highest fold increase. While there was also a substantial increase in colonic IL-6 
concentrations during inflammation, targeting IL-6 for imaging is complicated by its 
constitutive secretion from a range of non-immune cell types including muscle, its relatively 
high serum concentration, and its known variability in human disease states (34). 
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Enthusiasm for developing antibody-based probes for PET imaging has been tempered by 
concerns related to the use of ionising radiation, which are amplified by the high molecular 
weight of antibodies, and the potential for the probe to interfere with the disease process (5). 
Our use of engineered antibody fragments to detect fibrosis extends from studies employing 
antibody fragments against the THELPER immune cell surface marker CD4 and the gut homing 
immune cell integrin β7 to detect colonic inflammation in preclinical models (19, 21). F(ab’)2 
antibody fragments have a substantially reduced size compared to intact antibodies which 
promotes tissue penetration and increases clearance, thereby reducing patient exposure to 
ionising radiation (16, 22). Furthermore, F(ab’)2 antibody fragments retain target specificity 
and removal of the effector FC region effectively renders the antibody inert as FC mediated 
activation of innate immune cells and the complement cascade is eliminated. F(ab’)2 
fragments may theoretically influence the disease process by neutralising their target, 
however this effect is improbable as the antibody dose for their use as probes for immuno-
PET is much lower than when they are used as conventional drugs (18). The dose of ionising 
radiation we used in our current study was similar to that used in these previous studies and 
much lower than the dose we previously used with conjugated intact antibodies to detect 
colonic inflammation (20), reducing exposure to radiation (19, 21). Furthermore, it should be 
noted that the ionising radiation dose for whole body 18F-FDG PET scans is much lower than 
typically used for abdominal pelvic CT scans, but much more information regarding distant 
organs can be obtained (16, 35, 36). Importantly, immuno-PET offers the potential for both 
early detection and theranostic treatment which are critically needed for treatment in the 
intestine and other fibrotic tissues. 
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We observed that the increased pro-MMP-9 signal in the fibrotic colon occurred concurrently 
with increased signal in the kidney, which we demonstrate for the first time develops fibrosis 
in this model. IBD is frequently associated with extra-intestinal manifestations. Nephritis and 
nephrolithiasis, or stone formation, is the most frequently experienced renal diseases in IBD 
patients, and is particularly prevalent in those with long standing disease (37). MMP-9 
expression is increased in nephritis and nephrolithiasis has been linked to MMP-9 
polymorphisms, however in relation to IBD it remains difficult to determine whether these 
diseases result from immune mechanisms that are shared or distinct to those in the intestine, 
or whether they result from drug toxicity (37, 38). Kidney injury and increased inflammatory 
mediator content has previously been demonstrated in DSS induced colitis (39). However, our 
study is the first to investigate the kidney in a model of intestinal fibrosis. The mechanisms 




We performed the first immuno-PET study in any organ, clinical or preclinical, and 
demonstrated that pro-MMP-9 F(ab’)2 fragments detected inflammation induced intestinal 
fibrosis after inflammation had resolved. Furthermore, we also established that the kidney 
becomes fibrotic in this model, underscoring the benefit of PET for detecting disease in organs 
that are distant from the original disease site and are therefore potentially ignored. As the 
mechanisms underlying fibrosis are broadly similar across all organs, and ~45% of all natural 
deaths in the western world can be attributed to fibroproliferative disease (8), we propose 
that immuno-PET of pro-MMP-9 antibody fragments are a valuable addition to the detection 
of fibrosis in all tissues. 
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IBD is a chronic, debilitating disease that currently lacks efficient and long-term therapeutics 
and sensitive, quantitative diagnostic imaging that can visualise the entire gastrointestinal 
tract. I analysed the underlying mechanisms of DSS colitis and how dietary emulsifiers can 
modulate these mechanisms, this study provided targets for immuno-PET of gastrointestinal 
inflammation. I designed and validated two immuno-PET tracers against innate immune 
mediators and compared tracer efficacy between targeting immune cells and inducible 
cytokines, in a preclinical model of acute IBD. Furthermore, I designed and validated an 
antibody fragment immuno-PET tracer against intestinal fibrosis in a preclinical model of 
chronic IBD, which to our knowledge is the first immuno-PET study of fibrosis in any tissue.  
8.2 Dietary emulsifiers exacerbate DSS colitis  
 
To be able to image certain disease processes, there must be an understanding of the 
underlying mechanisms. As such, I elucidated the inflammatory mechanisms involved in 
murine DSS colitis but also how the dietary emulsifier CMC affects gastrointestinal 
homeostasis, as the increased consumption of a Westernised diet has been linked with the 
increasing incidence of IBD. In the past decade, there has been an increased awareness of 
healthy eating habits and reducing our consumption of processed foods. This has been 
followed by a number of studies examining the effects of dietary emulsifiers such as CMC or 
P80 on the gastrointestinal tract. Our results support the current literature, suggesting that 
CMC can disrupt gastrointestinal homeostasis and exacerbate murine chemically induced 
colitis. 
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 8.3 Immuno-PET of innate immune markers 
 
Following the identification of tracer targets, I visualised and compared immuno-PET directed 
against a key innate immune cytokine IL-1β and cell marker CD11b. My results showed that 
immuno-PET targeting cell secreted immune mediators provided a higher colonic uptake with 
decreased uptake in non-target organs, in contrast to targeting immune cells. These findings 
correlate to the underlying immunologic mechanisms involved in colitis. When activated, 
innate immune cells migrate from induction sites in the lymphatic vessels through the 
bloodstream to sites of inflammation, where they mature and secrete cytokine such as IL-1β, 
before clearing from the area. Innate cells such as macrophages, dendritic cells and 
neutrophils express CD11b, regardless of their maturity or state of activation and thus imaging 
of CD11b will highlight areas of inflammation but also show migration throughout the blood 
and lymph, which may help explain the uptake distribution that we saw. In contrast, IL-1β is 
inducible and is only secreted by activated cells located in inflammatory loci. Additionally, 
proteolytic manipulation of IL-1β into its mature form occurs within the cell and it is secreted 
in its functional form. My results also supported the current literature in the use of FDG-PET 
for the detection of inflammatory lesions in colitis, however, as previously mentioned, FDG 
uptake is based on the tissue metabolism of glucose. As such, the specificity, sensitivity and 
clinical utility of PET in the setting of IBD can be improved through the direct targeting of 
inflammatory markers. Additionally, in some cases it has been found that FDG-PET is unable 
to differentiate between pathologic findings and adjacent regular intestinal segments (1). It is 
also unclear in which context FDG-PET in IBD would prove clinically useful and provide a 
change in management.   
 
Imaging modalities are ideally sensitive, quantitative and selective for their pathology and are 
non-invasive to the patient, in contrast to the current gold standard of endoscopies which are 
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highly invasive and require thorough bowel preparation. Molecular imaging techniques such 
as immuno-PET provide superior sensitivity in comparison to traditional methods such as MRI 
or CT through the combination of the high target selectivity of antibodies with the sensitivity 
of PET. Typically, PET images are combined with CT or MR to provide anatomical mapping. 
Immuno-PET provides whole body imaging of disease processes, which is useful for IBD as 
patients often experience extra-intestinal manifestations such as arthritis. Additionally, in 
contrast to endoscopic techniques, immuno-PET can detect inflammation below the mucosal 
surface and the deeper layers of the colon. Our study supports further investigation into the 
use of targeting inducible, intracellularly processed immune mediators for immuno-PET of 
intestinal inflammation.  
 
8.4 Immuno-PET of intestinal fibrosis 
 
Intestinal fibrosis is one of the most common complications of IBD and lacks an efficient 
imaging modality. As such, I developed a murine model of fibrosis that is stimulated by chronic 
chemically induced colitis. I assessed the changes in fibrotic mediators such as TIMP, MMPs 
and immune cytokines and chemokines and found that pro-MMP-9 was suitable for immuno-
PET due to its persistent induction, in the absence of inflammation. As expected, innate and 
adaptive immune activation decreased in chronic DSS colitis, in contrast to acute DSS colitis. 
Concurrently, there was an increase in markers such as MMP-3, MMP-8, pro-MMP-9 and 
TIMP-1, in chronic DSS, however only pro-MMP-9 remained as high in fibrotic colons as in 
inflamed colons.  
 
The use of intact IgG antibodies as imaging probes leads to an increased half-life and retention 
in non-target organs, potentially leading to an increase in the exposure of ionising radiation. 
Radiation exposure from PET tracers is much less than that of an abdominal CT study. As such, 
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if the patient receives improved care, prognosis and quality of life as a result of the PET study, 
the radiation dose can be justified. The Fc portion of intact antibodies can be cleaved to form 
a F(ab’)2 fragment which results in decreased molecular weight and non-specific binding, 
whilst retaining the target specificity of the antibody. The use of antibody fragments decreases 
the antibody half-life as well as its circulation time and binding to non-target organs, 
increasing excretion and promoting tissue penetration. Consequently, the patient’s radiation 
dose is reduced. Targeting intestinal fibrosis using anti-pro-MMP-9 antibody fragments 
provided visualisation of fibrotic segments of the colon. This study suggests that targeting 
MMPs may be suitable for the visualisation of intestinal fibrosis.  
 
It is imperative to select tracer targets that will not influence the mechanism or disease 
pathway that is being imaged – this may lead to decreased accuracy. Targets like TGF-β, 
although critical for fibrogenesis would not be suitable immuno-PET targets as they are 
constitutively secreted and involved in many other disease mechanisms and may influence 
the very mechanisms that are going to be visualised. However, this effect is typically 
minimalised as the dose used for imaging is much less than what is used therapeutically. 
Furthermore, proteins such as collagen, although increased in fibrotic tissue would not be 
suitable for immuno-PET targeting due to a high basal expression throughout the body in 
health. Interestingly, our results showed for the first time that chronic DSS colitis leads to 
fibrosis of the kidneys in addition to the large intestine. Interestingly, I observed mediators of 
fibrosis such as collagen and pro-MMP-9 were also elevated in the kidneys in the absence of 
inflammation, indicative of fibrosis. As this is the first description of fibrotic kidneys in this 
model, the mechanisms underlying these effects require further study. However, patients 
with IBD have been shown to develop kidney pathologies such as nephritis or nephrolithiasis, 
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particularly in longstanding disease. To our knowledge, this is the first study to demonstrate 
immuno-PET of fibrosis in any tissue in a preclinical or clinical setting.  
 
8.5 Discussion of combined results 
 
Elucidation of immune mechanisms underlying DSS colitis and emulsifier-induced 
exacerbation of colitis showed strong innate immune activation, particularly a large increase 
in colonic IL-1β and CD11b+ immune cells, suggesting possible targets for visualisation of 
intestinal inflammation with immuno-PET. Consequently, radiolabelling of monoclonal 
antibodies against IL-1β and CD11b provided visualisation of gastrointestinal inflammation in 
acute DSS colitis. Targeting of IL-1β proved to be superior due to its localised secretion in areas 
of inflammation, in contrast to targeting CD11b+ immune cells which migrate throughout the 
body. This study suggests that future immuno-PET studies of inflammatory changes should 
ideally target inducible cytokines or mediators to achieve the best visualisation of disease 
changes. For the fibrosis immuno-PET study this prompted us to target inducible mediators 
such as MMPs when detecting intestinal fibrosis, in contrast to cells such as fibroblasts.  
 
Chronic administration of DSS colitis resulted in the induction of MMPs, particularly pro-MMP-
9 which was persistently elevated in the absence of inflammation. Targeting of pro-MMP-9 
provided visualisation of intestinal fibrosis in chronic DSS colitis but also showed uptake in the 
kidneys which was shown to be due to fibrotic changes and not tracer excretion. As expected, 
F(ab’)2 fragment tracer resulted in an altered biodistribution, showing decreased uptake in 
nontarget areas, in contrast to our innate immune marker study which utilised intact 
antibodies. The use of antibodies of less than 60 kDa favours the renal route of excretion, in 
contrast to larger proteins which are hepatically cleared. The results from the intestinal 
fibrosis immuno-PET study highlighted the superior use of immuno-PET for inflammatory 
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diseases, as pathological changes can be detected in organs other than the original disease 
site, which may be potentially missed when using conventional techniques such as 
colonoscopies.  Further optimisation of anti-IL-1β and anti-pro-MMP-9 F(ab’)2 immuno-PET is 
required which may lead to clinical trials.  
 
8.6 Future studies 
 
The use of humanised immune system (HIS) mice may bridge the gap between murine models 
of colitis and clinical trials, improving bench-to-bedside translation. HIS mice provide a more 
immunologically relevant mouse model of IBD, relying on the implantation of human 
hematopoietic stem cells or peripheral blood mononuclear cells (PBMC) into immuno-
deficient NOD/scid-IL2rγ−/− or NSG mice. Recently a novel model of chemically induced IBD in 
human PBMC NSG mice has been described (2). Briefly, these mice were implanted with 
human PBMCs from UC patients and were later sensitised via dermal application, and then 
intrarectally challenged. Histopathological assessment showed mice developed signs 
intestinal inflammation as seen in IBD such as oedema, fibrosis and the infiltration of T cells 
into the lamina propria. The development of these murine models may offer a more 
immunologically relevant model for the preclinical testing of immuno-PET tracers. 
Furthermore, although there have been previous studies using repeated doses of 89Zr tracers 
in humans the radiation burden to patients must always considered. Pretargeting imaging 
approaches can mitigate some of the disadvantages associated with conventional antibody 
imaging such as further decreasing radiation doses. This involves injection of the antibody, 
uptake period (days), followed by injection of a clearing agent which will remove excess 
antibody tags and then injection of the radioactive tag which takes minutes to hours to bind 
to the previously injected antibody agent. This technique removes the dilemma of having to 
match long half-life antibodies with long half-life radioisotopes, as such, shorter-lived isotopes
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 such as fluorine-18 (110 minutes), carbon-11 (20 minutes) and gallium-68 (70 minutes) can 
be used. However, the logistics of these tracers may be challenging as the radiopharmacy unit 
must be in close proximity to the clinic where the imaging will be performed. Additionally, PET 
cameras have a greater sensitivity and higher spatial and temporal resolution than SPECT 




IBD is a debilitating chronic condition that currently lacks effective therapeutics and non-
invasive imaging modalities. Unravelling the pathogenesis of IBD does not only provide novel 
therapeutic targets, but also targets for immuno-PET. Molecular imaging is a rapidly 
expanding field at the forefront of diagnostic imaging, which may satisfy the unmet need of 
highly sensitive, quantitative and non-invasive imaging of IBD. We have shown that immuno-
PET of innate immune markers, particularly inducible cytokines, can be used to successfully 
visualise intestinal inflammation in a preclinical model of IBD and for the first time, that 
targeting pro-MMP-9 allows for the visualisation of intestinal fibrosis in a preclinical model of 
chronic IBD. Further research into these techniques is required as they show clinical potential. 
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